bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
camazepam and temazepam is a Intervention_Pharmacological, placebo is a Intervention_Control, sleep parameters is a Outcome_Physical, percent duration of stage II is a Outcome_Physical, sleep efficiency is a Outcome_Other, Camazepam shows modification is a Outcome_Other	78284_task1	Sentence: Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern . Instructions: please typing these entity words according to sentence: camazepam and temazepam, placebo, sleep parameters, percent duration of stage II, sleep efficiency, Camazepam shows modification Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern .	[ "Comparison", "between", "the", "central", "effects", "of", "camazepam", "and", "temazepam", ".", "Computerized", "analysis", "of", "sleep", "recordings", ".", "The", "effects", "of", "acute", "administration", "per", "os", "of", "30", "mg", "camazepam", "and", "the", "same", "dose", "of", "temazepam", ",", "were", "compared", "with", "placebo", "in", "8", "young", "male", "volunteers", ",", "fully", "adapted", "to", "the", "laboratory", "environment", "by", "6", "nights", "of", "adaptation", ".", "The", "study", "was", "double", "-", "blind", ",", "in", "a", "random", "order", ",", "10", "days", "separating", "each", "session", ".", "Spectral", "analysis", "was", "performed", "on", "the", "all", "-", "night", "records", "(", "1-min", "epochs", ")", ",", "and", "the", "relative", "power", "of", "six", "frequency", "bands", "calculated", ".", "Concerning", "sleep", "parameters", ",", "temazepam", "induces", "a", "statistically", "significant", "reduction", "of", ":", "phase", "shifts", ";", "number", "of", "awakenings", ";", "percent", "duration", "of", "sleep", "stages", "I", "and", "IV", ".", "A", "significant", "increase", "of", "the", "percent", "duration", "of", "stage", "II", "and", "sleep", "efficiency", "was", "also", "found", ".", "Camazepam", "shows", "modification", ",", "with", "the", "same", "trend", ",", "but", "not", "reaching", "statistical", "significance", ".", "Concerning", "spectral", "analysis", ",", "temazepam", "induces", "a", "light", "increase", "of", "the", "relative", "power", "of", "the", "slowest", "frequencies", ",", "paralleled", "by", "an", "increase", "of", "the", "fast", "bands", ",", "while", "major", "effects", "are", "found", "on", "the", "characteristic", "periodicity", "of", "delta", "activities", ",", "which", "appear", "disrupted", "by", "the", "drug", ".", "These", "effects", "are", "not", "evident", "with", "camazepam", ",", "which", "does", "not", "seem", "to", "distort", "the", "normal", "sleep", "pattern", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
camazepam and temazepam, placebo, sleep parameters, percent duration of stage II, sleep efficiency, Camazepam shows modification	78284_task2	Sentence: Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern .	[ "Comparison", "between", "the", "central", "effects", "of", "camazepam", "and", "temazepam", ".", "Computerized", "analysis", "of", "sleep", "recordings", ".", "The", "effects", "of", "acute", "administration", "per", "os", "of", "30", "mg", "camazepam", "and", "the", "same", "dose", "of", "temazepam", ",", "were", "compared", "with", "placebo", "in", "8", "young", "male", "volunteers", ",", "fully", "adapted", "to", "the", "laboratory", "environment", "by", "6", "nights", "of", "adaptation", ".", "The", "study", "was", "double", "-", "blind", ",", "in", "a", "random", "order", ",", "10", "days", "separating", "each", "session", ".", "Spectral", "analysis", "was", "performed", "on", "the", "all", "-", "night", "records", "(", "1-min", "epochs", ")", ",", "and", "the", "relative", "power", "of", "six", "frequency", "bands", "calculated", ".", "Concerning", "sleep", "parameters", ",", "temazepam", "induces", "a", "statistically", "significant", "reduction", "of", ":", "phase", "shifts", ";", "number", "of", "awakenings", ";", "percent", "duration", "of", "sleep", "stages", "I", "and", "IV", ".", "A", "significant", "increase", "of", "the", "percent", "duration", "of", "stage", "II", "and", "sleep", "efficiency", "was", "also", "found", ".", "Camazepam", "shows", "modification", ",", "with", "the", "same", "trend", ",", "but", "not", "reaching", "statistical", "significance", ".", "Concerning", "spectral", "analysis", ",", "temazepam", "induces", "a", "light", "increase", "of", "the", "relative", "power", "of", "the", "slowest", "frequencies", ",", "paralleled", "by", "an", "increase", "of", "the", "fast", "bands", ",", "while", "major", "effects", "are", "found", "on", "the", "characteristic", "periodicity", "of", "delta", "activities", ",", "which", "appear", "disrupted", "by", "the", "drug", ".", "These", "effects", "are", "not", "evident", "with", "camazepam", ",", "which", "does", "not", "seem", "to", "distort", "the", "normal", "sleep", "pattern", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
Wiederherstellung is an umlsterm, Anatomie is an umlsterm, Mehrfachrezidivhernien is an umlsterm, Wiederherstellung is an umlsterm	DerChirurg.70680488.ger.abstr_task0	Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .	[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]	[ "umlsterm" ]
Wiederherstellung is an umlsterm, Anatomie is an umlsterm, Mehrfachrezidivhernien is an umlsterm, Wiederherstellung is an umlsterm	DerChirurg.70680488.ger.abstr_task1	Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please typing these entity words according to sentence: Wiederherstellung, Anatomie, Mehrfachrezidivhernien, Wiederherstellung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .	[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]	[ "umlsterm" ]
Wiederherstellung, Anatomie, Mehrfachrezidivhernien, Wiederherstellung	DerChirurg.70680488.ger.abstr_task2	Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .	[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]	[ "umlsterm" ]
Alterspatienten is an umlsterm, Demenzerkrankungen is an umlsterm, Menschen is an umlsterm, Neuroleptika is an umlsterm, Patienten is an umlsterm, Neuroleptika is an umlsterm, Benzodiazepine is an umlsterm, Altenpflegeheimen is an umlsterm, Psychopharmaka is an umlsterm, Schlafstoerungen is an umlsterm	DerNervenarzt.80690999.ger.abstr_task0	Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .	[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]	[ "umlsterm" ]
Alterspatienten is an umlsterm, Demenzerkrankungen is an umlsterm, Menschen is an umlsterm, Neuroleptika is an umlsterm, Patienten is an umlsterm, Neuroleptika is an umlsterm, Benzodiazepine is an umlsterm, Altenpflegeheimen is an umlsterm, Psychopharmaka is an umlsterm, Schlafstoerungen is an umlsterm	DerNervenarzt.80690999.ger.abstr_task1	Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please typing these entity words according to sentence: Alterspatienten, Demenzerkrankungen, Menschen, Neuroleptika, Patienten, Neuroleptika, Benzodiazepine, Altenpflegeheimen, Psychopharmaka, Schlafstoerungen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .	[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]	[ "umlsterm" ]
Alterspatienten, Demenzerkrankungen, Menschen, Neuroleptika, Patienten, Neuroleptika, Benzodiazepine, Altenpflegeheimen, Psychopharmaka, Schlafstoerungen	DerNervenarzt.80690999.ger.abstr_task2	Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .	[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]	[ "umlsterm" ]
lymphangioleiomyomatosis is an umlsterm, woman is an umlsterm, pneumothorax is an umlsterm, evaluation is an umlsterm, lung is an umlsterm, biopsy is an umlsterm, video - thoracoscopy is an umlsterm, tumour is an umlsterm, right is an umlsterm, kidney is an umlsterm, angiomyolipoma is an umlsterm, actin is an umlsterm, tissue is an umlsterm, angiomyolipoma is an umlsterm, pathologic is an umlsterm, lung is an umlsterm, tissue is an umlsterm, tumour is an umlsterm, frontal lobe is an umlsterm, brain is an umlsterm, tumours is an umlsterm, classification is an umlsterm, tuberous sclerosis is an umlsterm	DerPathologe.40150354.eng.abstr_task0	Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]	Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .	[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]	[ "umlsterm" ]
lymphangioleiomyomatosis is an umlsterm, woman is an umlsterm, pneumothorax is an umlsterm, evaluation is an umlsterm, lung is an umlsterm, biopsy is an umlsterm, video - thoracoscopy is an umlsterm, tumour is an umlsterm, right is an umlsterm, kidney is an umlsterm, angiomyolipoma is an umlsterm, actin is an umlsterm, tissue is an umlsterm, angiomyolipoma is an umlsterm, pathologic is an umlsterm, lung is an umlsterm, tissue is an umlsterm, tumour is an umlsterm, frontal lobe is an umlsterm, brain is an umlsterm, tumours is an umlsterm, classification is an umlsterm, tuberous sclerosis is an umlsterm	DerPathologe.40150354.eng.abstr_task1	Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please typing these entity words according to sentence: lymphangioleiomyomatosis, woman, pneumothorax, evaluation, lung, biopsy, video - thoracoscopy, tumour, right, kidney, angiomyolipoma, actin, tissue, angiomyolipoma, pathologic, lung, tissue, tumour, frontal lobe, brain, tumours, classification, tuberous sclerosis Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]	Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .	[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]	[ "umlsterm" ]
lymphangioleiomyomatosis, woman, pneumothorax, evaluation, lung, biopsy, video - thoracoscopy, tumour, right, kidney, angiomyolipoma, actin, tissue, angiomyolipoma, pathologic, lung, tissue, tumour, frontal lobe, brain, tumours, classification, tuberous sclerosis	DerPathologe.40150354.eng.abstr_task2	Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]	Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .	[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]	[ "umlsterm" ]
Cytokine - modulating activity is an other_name, tepoxalin is an other_organic_compound, antirheumatic is an other_name	99288_task0	Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]	Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.	[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]	[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]
Cytokine - modulating activity is an other_name, tepoxalin is an other_organic_compound, antirheumatic is an other_name	99288_task1	Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please typing these entity words according to sentence: Cytokine - modulating activity, tepoxalin, antirheumatic Options: other_organic_compound, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]	Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.	[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]	[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]
Cytokine - modulating activity, tepoxalin, antirheumatic	99288_task2	Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]	Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.	[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]	[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]
oil with medium- and long - chain fatty acids is a Intervention_Pharmacological, body fat is a Outcome_Physical, blood lipid profiles is a Outcome_Physical, male is a Participant_Sex, hypertriglyceridemic is a Participant_Condition, oil with medium- and long - chain triglyceride ( MLCT ) is a Intervention_Pharmacological, One - hundred - and - twelve is a Participant_Sample-size, Anthropometric and blood biochemical parameters is a Outcome_Physical, 50 is a Participant_Sample-size, 34 is a Participant_Sample-size, men is a Participant_Sex, 16 is a Participant_Sample-size, women is a Participant_Sex, 51 is a Participant_Sample-size, 33 is a Participant_Sample-size, 18 is a Participant_Sample-size, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E is a Outcome_Physical	42032_task0	Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .	[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]
oil with medium- and long - chain fatty acids is a Intervention_Pharmacological, body fat is a Outcome_Physical, blood lipid profiles is a Outcome_Physical, male is a Participant_Sex, hypertriglyceridemic is a Participant_Condition, oil with medium- and long - chain triglyceride ( MLCT ) is a Intervention_Pharmacological, One - hundred - and - twelve is a Participant_Sample-size, Anthropometric and blood biochemical parameters is a Outcome_Physical, 50 is a Participant_Sample-size, 34 is a Participant_Sample-size, men is a Participant_Sex, 16 is a Participant_Sample-size, women is a Participant_Sex, 51 is a Participant_Sample-size, 33 is a Participant_Sample-size, 18 is a Participant_Sample-size, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E is a Outcome_Physical	42032_task1	Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please typing these entity words according to sentence: oil with medium- and long - chain fatty acids, body fat, blood lipid profiles, male, hypertriglyceridemic, oil with medium- and long - chain triglyceride ( MLCT ), One - hundred - and - twelve, Anthropometric and blood biochemical parameters, 50, 34, men, 16, women, 51, 33, 18, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E Options: Intervention_Pharmacological, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .	[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]
oil with medium- and long - chain fatty acids, body fat, blood lipid profiles, male, hypertriglyceridemic, oil with medium- and long - chain triglyceride ( MLCT ), One - hundred - and - twelve, Anthropometric and blood biochemical parameters, 50, 34, men, 16, women, 51, 33, 18, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E	42032_task2	Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .	[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]
akutes Abdomen is an umlsterm, Nekrosen is an umlsterm, Fettgewebes is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Verdachtsdiagnose is an umlsterm, Methoden is an umlsterm, Schmerzen is an umlsterm, Ultraschall is an umlsterm, Tumors is an umlsterm, Computertomographie is an umlsterm, Laparoskopie is an umlsterm, Magenantrum is an umlsterm, Fettgewebsnekrose is an umlsterm, Netzinfarkt is an umlsterm, Laparoskopie is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Beschwerdefreiheit is an umlsterm, Komplikationen is an umlsterm, Superinfektion is an umlsterm, Blutungen is an umlsterm	DerChirurg.00710225.ger.abstr_task0	Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .	[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]	[ "umlsterm" ]
akutes Abdomen is an umlsterm, Nekrosen is an umlsterm, Fettgewebes is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Verdachtsdiagnose is an umlsterm, Methoden is an umlsterm, Schmerzen is an umlsterm, Ultraschall is an umlsterm, Tumors is an umlsterm, Computertomographie is an umlsterm, Laparoskopie is an umlsterm, Magenantrum is an umlsterm, Fettgewebsnekrose is an umlsterm, Netzinfarkt is an umlsterm, Laparoskopie is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Beschwerdefreiheit is an umlsterm, Komplikationen is an umlsterm, Superinfektion is an umlsterm, Blutungen is an umlsterm	DerChirurg.00710225.ger.abstr_task1	Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please typing these entity words according to sentence: akutes Abdomen, Nekrosen, Fettgewebes, Diagnose, Patienten, Verdachtsdiagnose, Methoden, Schmerzen, Ultraschall, Tumors, Computertomographie, Laparoskopie, Magenantrum, Fettgewebsnekrose, Netzinfarkt, Laparoskopie, Diagnostik, Therapie, Beschwerdefreiheit, Komplikationen, Superinfektion, Blutungen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .	[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]	[ "umlsterm" ]
akutes Abdomen, Nekrosen, Fettgewebes, Diagnose, Patienten, Verdachtsdiagnose, Methoden, Schmerzen, Ultraschall, Tumors, Computertomographie, Laparoskopie, Magenantrum, Fettgewebsnekrose, Netzinfarkt, Laparoskopie, Diagnostik, Therapie, Beschwerdefreiheit, Komplikationen, Superinfektion, Blutungen	DerChirurg.00710225.ger.abstr_task2	Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .	[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]	[ "umlsterm" ]
age is a Person, > 18 y.o is a Value, American Society of Anesthesiologists Physical Status Classification is a Measurement, ASA is a Measurement, 1 - 2 is a Value	NCT03070847_inc_task0	Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Person, Measurement, Value	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators	[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]	[ "Measurement", "Value", "Person" ]
age is a Person, > 18 y.o is a Value, American Society of Anesthesiologists Physical Status Classification is a Measurement, ASA is a Measurement, 1 - 2 is a Value	NCT03070847_inc_task1	Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please typing these entity words according to sentence: age, > 18 y.o, American Society of Anesthesiologists Physical Status Classification, ASA, 1 - 2 Options: Person, Measurement, Value	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators	[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]	[ "Measurement", "Value", "Person" ]
age, > 18 y.o, American Society of Anesthesiologists Physical Status Classification, ASA, 1 - 2	NCT03070847_inc_task2	Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please extract entity words from the input sentence	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators	[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]	[ "Measurement", "Value", "Person" ]
1,5-diarylpyrrole nitrooxyalkyl ethers is a CHEMICAL, cyclooxygenase-2 is a GENE-Y, nitric oxide is a CHEMICAL, 3-substituted 1,5-diarylpyrroles is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, pyrrole is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, esters is a CHEMICAL, carbonates is a CHEMICAL, ethers is a CHEMICAL, COX-2 is a GENE-Y, NO is a CHEMICAL, nitrooxyalkyl ethers is a CHEMICAL, alcohols is a CHEMICAL, Nitrooxy is a CHEMICAL, NO is a CHEMICAL, COX-2 is a GENE-Y, interleukin-1β is a GENE-Y, IL-1β is a GENE-Y, ( 13)C is a CHEMICAL, nitrooxyalkyl ester and ether is a CHEMICAL, COX-2 is a GENE-Y	30108_task0	Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.	[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]	[ "CHEMICAL", "GENE-Y" ]
1,5-diarylpyrrole nitrooxyalkyl ethers is a CHEMICAL, cyclooxygenase-2 is a GENE-Y, nitric oxide is a CHEMICAL, 3-substituted 1,5-diarylpyrroles is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, pyrrole is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, esters is a CHEMICAL, carbonates is a CHEMICAL, ethers is a CHEMICAL, COX-2 is a GENE-Y, NO is a CHEMICAL, nitrooxyalkyl ethers is a CHEMICAL, alcohols is a CHEMICAL, Nitrooxy is a CHEMICAL, NO is a CHEMICAL, COX-2 is a GENE-Y, interleukin-1β is a GENE-Y, IL-1β is a GENE-Y, ( 13)C is a CHEMICAL, nitrooxyalkyl ester and ether is a CHEMICAL, COX-2 is a GENE-Y	30108_task1	Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please typing these entity words according to sentence: 1,5-diarylpyrrole nitrooxyalkyl ethers, cyclooxygenase-2, nitric oxide, 3-substituted 1,5-diarylpyrroles, nitrooxyalkyl, pyrrole, nitrooxyalkyl, esters, carbonates, ethers, COX-2, NO, nitrooxyalkyl ethers, alcohols, Nitrooxy, NO, COX-2, interleukin-1β, IL-1β, ( 13)C, nitrooxyalkyl ester and ether, COX-2 Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.	[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]	[ "CHEMICAL", "GENE-Y" ]
1,5-diarylpyrrole nitrooxyalkyl ethers, cyclooxygenase-2, nitric oxide, 3-substituted 1,5-diarylpyrroles, nitrooxyalkyl, pyrrole, nitrooxyalkyl, esters, carbonates, ethers, COX-2, NO, nitrooxyalkyl ethers, alcohols, Nitrooxy, NO, COX-2, interleukin-1β, IL-1β, ( 13)C, nitrooxyalkyl ester and ether, COX-2	30108_task2	Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.	[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]	[ "CHEMICAL", "GENE-Y" ]
Hauttumoren is an umlsterm, Blutgefaesse is an umlsterm, Auge is an umlsterm, tumorspezifische is an umlsterm, Element is an umlsterm, Hauttumoren is an umlsterm, Diagnose is an umlsterm, Melanome is an umlsterm, Beurteilung is an umlsterm, Hauttumoren is an umlsterm	DerHautarzt.60470264.ger.abstr_task0	Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .	[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]	[ "umlsterm" ]
Hauttumoren is an umlsterm, Blutgefaesse is an umlsterm, Auge is an umlsterm, tumorspezifische is an umlsterm, Element is an umlsterm, Hauttumoren is an umlsterm, Diagnose is an umlsterm, Melanome is an umlsterm, Beurteilung is an umlsterm, Hauttumoren is an umlsterm	DerHautarzt.60470264.ger.abstr_task1	Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please typing these entity words according to sentence: Hauttumoren, Blutgefaesse, Auge, tumorspezifische, Element, Hauttumoren, Diagnose, Melanome, Beurteilung, Hauttumoren Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .	[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]	[ "umlsterm" ]
Hauttumoren, Blutgefaesse, Auge, tumorspezifische, Element, Hauttumoren, Diagnose, Melanome, Beurteilung, Hauttumoren	DerHautarzt.60470264.ger.abstr_task2	Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .	[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]	[ "umlsterm" ]
Partial mole is a Condition, treatment is a Procedure, molar pregnancy is a Condition, evacuation or chemotherapy is a Scope, Women is a Person, hysterectomy is a Procedure, H Mole is a Condition	NCT01630954_exc_task0	Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition, Procedure	[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]	Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole	[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]	[ "Scope", "Condition", "Procedure", "Person" ]
Partial mole is a Condition, treatment is a Procedure, molar pregnancy is a Condition, evacuation or chemotherapy is a Scope, Women is a Person, hysterectomy is a Procedure, H Mole is a Condition	NCT01630954_exc_task1	Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please typing these entity words according to sentence: Partial mole, treatment, molar pregnancy, evacuation or chemotherapy, Women, hysterectomy, H Mole Options: Scope, Person, Condition, Procedure	[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]	Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole	[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]	[ "Scope", "Condition", "Procedure", "Person" ]
Partial mole, treatment, molar pregnancy, evacuation or chemotherapy, Women, hysterectomy, H Mole	NCT01630954_exc_task2	Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please extract entity words from the input sentence	[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]	Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole	[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]	[ "Scope", "Condition", "Procedure", "Person" ]
STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein	146_task0	Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.	[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]	[ "Protein" ]
STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein	146_task1	Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please typing these entity words according to sentence: STAT1, STAT1, STAT1, STAT1, STAT1, STAT1, STAT1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.	[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]	[ "Protein" ]
STAT1, STAT1, STAT1, STAT1, STAT1, STAT1, STAT1	146_task2	Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.	[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]	[ "Protein" ]
P. aeruginosa is a Organism, P. aeruginosa is a Organism	35_task0	Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.	[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]	[ "Organism" ]
P. aeruginosa is a Organism, P. aeruginosa is a Organism	35_task1	Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please typing these entity words according to sentence: P. aeruginosa, P. aeruginosa Options: Organism	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.	[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]	[ "Organism" ]
P. aeruginosa, P. aeruginosa	35_task2	Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.	[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]	[ "Organism" ]
klinische Forschung is an umlsterm, Entscheidungsfindung is an umlsterm, Chirurgie is an umlsterm, Industrieunterstuetzung is an umlsterm, Deutschland is an umlsterm, Oesophagus is an umlsterm, Pankreas is an umlsterm, Darmerkrankungen is an umlsterm	DerChirurg.00710626.ger.abstr_task0	Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .	[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]	[ "umlsterm" ]
klinische Forschung is an umlsterm, Entscheidungsfindung is an umlsterm, Chirurgie is an umlsterm, Industrieunterstuetzung is an umlsterm, Deutschland is an umlsterm, Oesophagus is an umlsterm, Pankreas is an umlsterm, Darmerkrankungen is an umlsterm	DerChirurg.00710626.ger.abstr_task1	Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please typing these entity words according to sentence: klinische Forschung, Entscheidungsfindung, Chirurgie, Industrieunterstuetzung, Deutschland, Oesophagus, Pankreas, Darmerkrankungen Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .	[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]	[ "umlsterm" ]
klinische Forschung, Entscheidungsfindung, Chirurgie, Industrieunterstuetzung, Deutschland, Oesophagus, Pankreas, Darmerkrankungen	DerChirurg.00710626.ger.abstr_task2	Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .	[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]	[ "umlsterm" ]
muscle actin is a Individual_protein, profilin is a Individual_protein	607_task0	Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]	Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.	[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]	[ "Individual_protein" ]
muscle actin is a Individual_protein, profilin is a Individual_protein	607_task1	Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please typing these entity words according to sentence: muscle actin, profilin Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]	Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.	[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]	[ "Individual_protein" ]
muscle actin, profilin	607_task2	Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]	Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.	[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]	[ "Individual_protein" ]
therapy is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, platelet is an umlsterm, coronary artery disease is an umlsterm, antiplatelet drugs is an umlsterm, anticoagulation is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, aspirin is an umlsterm, drug is an umlsterm, choice is an umlsterm, treatment is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, contrast is an umlsterm, anticoagulation is an umlsterm, patients is an umlsterm, risk is an umlsterm, thrombosis is an umlsterm, urokinase is an umlsterm, therapy is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, angina pectoris is an umlsterm, leads is an umlsterm, symptoms is an umlsterm, platelet membrane glycoprotein is an umlsterm, clinical trials is an umlsterm, weight is an umlsterm, heparins is an umlsterm, syndromes is an umlsterm, future is an umlsterm	ZfuerKardiologie.8087s145.eng.abstr_task0	Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .	[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]	[ "umlsterm" ]
therapy is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, platelet is an umlsterm, coronary artery disease is an umlsterm, antiplatelet drugs is an umlsterm, anticoagulation is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, aspirin is an umlsterm, drug is an umlsterm, choice is an umlsterm, treatment is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, contrast is an umlsterm, anticoagulation is an umlsterm, patients is an umlsterm, risk is an umlsterm, thrombosis is an umlsterm, urokinase is an umlsterm, therapy is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, angina pectoris is an umlsterm, leads is an umlsterm, symptoms is an umlsterm, platelet membrane glycoprotein is an umlsterm, clinical trials is an umlsterm, weight is an umlsterm, heparins is an umlsterm, syndromes is an umlsterm, future is an umlsterm	ZfuerKardiologie.8087s145.eng.abstr_task1	Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please typing these entity words according to sentence: therapy, treatment, syndromes, platelet, coronary artery disease, antiplatelet drugs, anticoagulation, treatment, syndromes, aspirin, drug, choice, treatment, patients, coronary artery disease, contrast, anticoagulation, patients, risk, thrombosis, urokinase, therapy, patients, coronary artery disease, angina pectoris, leads, symptoms, platelet membrane glycoprotein, clinical trials, weight, heparins, syndromes, future Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .	[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]	[ "umlsterm" ]
therapy, treatment, syndromes, platelet, coronary artery disease, antiplatelet drugs, anticoagulation, treatment, syndromes, aspirin, drug, choice, treatment, patients, coronary artery disease, contrast, anticoagulation, patients, risk, thrombosis, urokinase, therapy, patients, coronary artery disease, angina pectoris, leads, symptoms, platelet membrane glycoprotein, clinical trials, weight, heparins, syndromes, future	ZfuerKardiologie.8087s145.eng.abstr_task2	Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .	[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]	[ "umlsterm" ]
objective is an umlsterm, stent is an umlsterm, Stent is an umlsterm, technology is an umlsterm, Polymers is an umlsterm, high temperature is an umlsterm, pressure is an umlsterm, derivatives is an umlsterm, lactic acid is an umlsterm, glycolic acid is an umlsterm, hydroxyethylene - methacrylate is an umlsterm, HEMA is an umlsterm, cell adhesion is an umlsterm, Methacrylates is an umlsterm, protein is an umlsterm, cell adhesion is an umlsterm, degradation is an umlsterm, polymers is an umlsterm, cell adhesion is an umlsterm, HEMA is an umlsterm, grafting is an umlsterm, stent is an umlsterm, HEMA is an umlsterm, stents is an umlsterm, female is an umlsterm, sheep is an umlsterm, blood is an umlsterm, urine analysis is an umlsterm, ultrasound is an umlsterm, autopsy is an umlsterm, findings is an umlsterm, Histopathological is an umlsterm, analysis is an umlsterm, epithelium is an umlsterm, stent is an umlsterm, regeneration is an umlsterm	DerUrologeA.00390557.eng.abstr_task0	Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .	[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]	[ "umlsterm" ]
objective is an umlsterm, stent is an umlsterm, Stent is an umlsterm, technology is an umlsterm, Polymers is an umlsterm, high temperature is an umlsterm, pressure is an umlsterm, derivatives is an umlsterm, lactic acid is an umlsterm, glycolic acid is an umlsterm, hydroxyethylene - methacrylate is an umlsterm, HEMA is an umlsterm, cell adhesion is an umlsterm, Methacrylates is an umlsterm, protein is an umlsterm, cell adhesion is an umlsterm, degradation is an umlsterm, polymers is an umlsterm, cell adhesion is an umlsterm, HEMA is an umlsterm, grafting is an umlsterm, stent is an umlsterm, HEMA is an umlsterm, stents is an umlsterm, female is an umlsterm, sheep is an umlsterm, blood is an umlsterm, urine analysis is an umlsterm, ultrasound is an umlsterm, autopsy is an umlsterm, findings is an umlsterm, Histopathological is an umlsterm, analysis is an umlsterm, epithelium is an umlsterm, stent is an umlsterm, regeneration is an umlsterm	DerUrologeA.00390557.eng.abstr_task1	Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please typing these entity words according to sentence: objective, stent, Stent, technology, Polymers, high temperature, pressure, derivatives, lactic acid, glycolic acid, hydroxyethylene - methacrylate, HEMA, cell adhesion, Methacrylates, protein, cell adhesion, degradation, polymers, cell adhesion, HEMA, grafting, stent, HEMA, stents, female, sheep, blood, urine analysis, ultrasound, autopsy, findings, Histopathological, analysis, epithelium, stent, regeneration Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .	[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]	[ "umlsterm" ]
objective, stent, Stent, technology, Polymers, high temperature, pressure, derivatives, lactic acid, glycolic acid, hydroxyethylene - methacrylate, HEMA, cell adhesion, Methacrylates, protein, cell adhesion, degradation, polymers, cell adhesion, HEMA, grafting, stent, HEMA, stents, female, sheep, blood, urine analysis, ultrasound, autopsy, findings, Histopathological, analysis, epithelium, stent, regeneration	DerUrologeA.00390557.eng.abstr_task2	Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .	[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]	[ "umlsterm" ]
IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, CD3 is a Protein, CD28 is a Protein, MEK is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, IL-10 is a Protein, MEK is a Protein, p38 MAPK is a Protein, GSK-3beta is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein	39_task0	Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.	[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]	[ "Protein" ]
IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, CD3 is a Protein, CD28 is a Protein, MEK is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, IL-10 is a Protein, MEK is a Protein, p38 MAPK is a Protein, GSK-3beta is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein	39_task1	Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please typing these entity words according to sentence: IL-10, ERK1, ERK2, IL-10, ERK1, ERK2, CD3, CD28, MEK, ERK1, ERK2, IL-10, IL-10, MEK, p38 MAPK, GSK-3beta, IL-10, ERK1, ERK2, IL-10 Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.	[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]	[ "Protein" ]
IL-10, ERK1, ERK2, IL-10, ERK1, ERK2, CD3, CD28, MEK, ERK1, ERK2, IL-10, IL-10, MEK, p38 MAPK, GSK-3beta, IL-10, ERK1, ERK2, IL-10	39_task2	Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.	[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]	[ "Protein" ]
SULT1E1 is a protein, beta - estradiol is a compound	DS.d1448_task0	Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]	SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.	[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]	[ "compound", "protein" ]
SULT1E1 is a protein, beta - estradiol is a compound	DS.d1448_task1	Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please typing these entity words according to sentence: SULT1E1, beta - estradiol Options: compound, protein	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]	SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.	[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]	[ "compound", "protein" ]
SULT1E1, beta - estradiol	DS.d1448_task2	Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please extract entity words from the input sentence	[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]	SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.	[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]	[ "compound", "protein" ]
motorischen Endplatte is an umlsterm, Parese is an umlsterm, Behandlung is an umlsterm, Kiefergelenkluxationen is an umlsterm, Mundoeffnung is an umlsterm, Luxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Patienten is an umlsterm, Kiefergelenkluxationen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Luxationen is an umlsterm, Erstbehandlung is an umlsterm, Luxation is an umlsterm, Behandlungen is an umlsterm, Luxationen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, Patienten is an umlsterm, Mundoeffnung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, kieferoeffnenden is an umlsterm, Therapie is an umlsterm, Kiefergelenkluxationen is an umlsterm	MundKieferGesichtschirurgie.8002s125.ger.abstr_task0	Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .	[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]	[ "umlsterm" ]
motorischen Endplatte is an umlsterm, Parese is an umlsterm, Behandlung is an umlsterm, Kiefergelenkluxationen is an umlsterm, Mundoeffnung is an umlsterm, Luxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Patienten is an umlsterm, Kiefergelenkluxationen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Luxationen is an umlsterm, Erstbehandlung is an umlsterm, Luxation is an umlsterm, Behandlungen is an umlsterm, Luxationen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, Patienten is an umlsterm, Mundoeffnung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, kieferoeffnenden is an umlsterm, Therapie is an umlsterm, Kiefergelenkluxationen is an umlsterm	MundKieferGesichtschirurgie.8002s125.ger.abstr_task1	Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please typing these entity words according to sentence: motorischen Endplatte, Parese, Behandlung, Kiefergelenkluxationen, Mundoeffnung, Luxationen, Kiefergelenkluxationen, Kiefergelenkluxationen, Patienten, Kiefergelenkluxationen, Behandlung, Patienten, Luxationen, Erstbehandlung, Luxation, Behandlungen, Luxationen, Patienten, Behandlung, Rezidiven, Patienten, Mundoeffnung, Patienten, Patienten, Behandlung, Rezidiven, kieferoeffnenden, Therapie, Kiefergelenkluxationen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .	[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]	[ "umlsterm" ]
motorischen Endplatte, Parese, Behandlung, Kiefergelenkluxationen, Mundoeffnung, Luxationen, Kiefergelenkluxationen, Kiefergelenkluxationen, Patienten, Kiefergelenkluxationen, Behandlung, Patienten, Luxationen, Erstbehandlung, Luxation, Behandlungen, Luxationen, Patienten, Behandlung, Rezidiven, Patienten, Mundoeffnung, Patienten, Patienten, Behandlung, Rezidiven, kieferoeffnenden, Therapie, Kiefergelenkluxationen	MundKieferGesichtschirurgie.8002s125.ger.abstr_task2	Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .	[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]	[ "umlsterm" ]
Aminoglutethimide is a DRUG, Aminoglutethimide is a DRUG, corticosteroids is a GROUP, Amphotericin B is a DRUG, corticosteroids is a GROUP, amphotericin B is a DRUG, diuretics is a GROUP, amphotericin B is a DRUG, hydrocortisone is a DRUG, Antibiotics is a GROUP, Macrolide antibiotics is a GROUP, corticosteroid is a GROUP, Anticholinesterases is a GROUP, anticholinesterase agents is a GROUP, corticosteroids is a GROUP, anticholinesterase agents is a GROUP, corticosteroid is a GROUP, Anticoagulants is a GROUP, corticosteroids is a GROUP, warfarin is a DRUG, warfarin is a DRUG, Antidiabetics is a GROUP, corticosteroids is a GROUP, antidiabetic agents is a GROUP, isoniazid is a DRUG, Cholestyramine is a DRUG, Cholestyramine is a DRUG, corticosteroids is a GROUP, Cyclosporine is a DRUG, cyclosporine is a DRUG, corticosteroids is a GROUP, indomethacin is a DRUG, Digitalis glycosides is a GROUP, digitalis glycosides is a GROUP, Ephedrine is a DRUG, Ephedrine is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, Estrogens is a GROUP, contraceptives is a GROUP, Estrogens is a GROUP, corticosteroids is a GROUP, barbiturates is a GROUP, phenytoin is a DRUG, carbamazepine is a DRUG, rifampin is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, macrolide antibiotics is a GROUP, erythromycin is a DRUG, corticosteroids is a GROUP, Dexamethasone is a DRUG, indinavir is a DRUG, erythromycin is a DRUG, Ketoconazole is a DRUG, Ketoconazole is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, corticosteroid is a DRUG, Nonsteroidal anti - inflammatory agents is a GROUP, NSAIDS is a GROUP, aspirin is a BRAND, nonsteroidal antiinflammatory agents is a GROUP, corticosteroids is a GROUP, Aspirin is a BRAND, corticosteroids is a GROUP, salicylates is a GROUP, corticosteroids is a GROUP, Phenytoin is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, Corticosteroids is a GROUP, Thalidomide is a DRUG, thalidomide is a DRUG, Vaccines is a GROUP, corticosteroid is a GROUP, live is a GROUP, inactivated vaccines is a GROUP, Corticosteroids is a GROUP, live attenuated vaccines is a GROUP, vaccines is a GROUP, corticosteroid is a GROUP	Dexamethasone_ddi_task0	Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, BRAND, DRUG	[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.	[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]	[ "GROUP", "DRUG", "BRAND" ]
Aminoglutethimide is a DRUG, Aminoglutethimide is a DRUG, corticosteroids is a GROUP, Amphotericin B is a DRUG, corticosteroids is a GROUP, amphotericin B is a DRUG, diuretics is a GROUP, amphotericin B is a DRUG, hydrocortisone is a DRUG, Antibiotics is a GROUP, Macrolide antibiotics is a GROUP, corticosteroid is a GROUP, Anticholinesterases is a GROUP, anticholinesterase agents is a GROUP, corticosteroids is a GROUP, anticholinesterase agents is a GROUP, corticosteroid is a GROUP, Anticoagulants is a GROUP, corticosteroids is a GROUP, warfarin is a DRUG, warfarin is a DRUG, Antidiabetics is a GROUP, corticosteroids is a GROUP, antidiabetic agents is a GROUP, isoniazid is a DRUG, Cholestyramine is a DRUG, Cholestyramine is a DRUG, corticosteroids is a GROUP, Cyclosporine is a DRUG, cyclosporine is a DRUG, corticosteroids is a GROUP, indomethacin is a DRUG, Digitalis glycosides is a GROUP, digitalis glycosides is a GROUP, Ephedrine is a DRUG, Ephedrine is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, Estrogens is a GROUP, contraceptives is a GROUP, Estrogens is a GROUP, corticosteroids is a GROUP, barbiturates is a GROUP, phenytoin is a DRUG, carbamazepine is a DRUG, rifampin is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, macrolide antibiotics is a GROUP, erythromycin is a DRUG, corticosteroids is a GROUP, Dexamethasone is a DRUG, indinavir is a DRUG, erythromycin is a DRUG, Ketoconazole is a DRUG, Ketoconazole is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, corticosteroid is a DRUG, Nonsteroidal anti - inflammatory agents is a GROUP, NSAIDS is a GROUP, aspirin is a BRAND, nonsteroidal antiinflammatory agents is a GROUP, corticosteroids is a GROUP, Aspirin is a BRAND, corticosteroids is a GROUP, salicylates is a GROUP, corticosteroids is a GROUP, Phenytoin is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, Corticosteroids is a GROUP, Thalidomide is a DRUG, thalidomide is a DRUG, Vaccines is a GROUP, corticosteroid is a GROUP, live is a GROUP, inactivated vaccines is a GROUP, Corticosteroids is a GROUP, live attenuated vaccines is a GROUP, vaccines is a GROUP, corticosteroid is a GROUP	Dexamethasone_ddi_task1	Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please typing these entity words according to sentence: Aminoglutethimide, Aminoglutethimide, corticosteroids, Amphotericin B, corticosteroids, amphotericin B, diuretics, amphotericin B, hydrocortisone, Antibiotics, Macrolide antibiotics, corticosteroid, Anticholinesterases, anticholinesterase agents, corticosteroids, anticholinesterase agents, corticosteroid, Anticoagulants, corticosteroids, warfarin, warfarin, Antidiabetics, corticosteroids, antidiabetic agents, isoniazid, Cholestyramine, Cholestyramine, corticosteroids, Cyclosporine, cyclosporine, corticosteroids, indomethacin, Digitalis glycosides, digitalis glycosides, Ephedrine, Ephedrine, corticosteroids, corticosteroid, Estrogens, contraceptives, Estrogens, corticosteroids, barbiturates, phenytoin, carbamazepine, rifampin, corticosteroids, corticosteroid, ketoconazole, macrolide antibiotics, erythromycin, corticosteroids, Dexamethasone, indinavir, erythromycin, Ketoconazole, Ketoconazole, corticosteroids, corticosteroid, ketoconazole, corticosteroid, Nonsteroidal anti - inflammatory agents, NSAIDS, aspirin, nonsteroidal antiinflammatory agents, corticosteroids, Aspirin, corticosteroids, salicylates, corticosteroids, Phenytoin, phenytoin, dexamethasone, Corticosteroids, Thalidomide, thalidomide, Vaccines, corticosteroid, live, inactivated vaccines, Corticosteroids, live attenuated vaccines, vaccines, corticosteroid Options: GROUP, BRAND, DRUG	[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.	[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]	[ "GROUP", "DRUG", "BRAND" ]
Aminoglutethimide, Aminoglutethimide, corticosteroids, Amphotericin B, corticosteroids, amphotericin B, diuretics, amphotericin B, hydrocortisone, Antibiotics, Macrolide antibiotics, corticosteroid, Anticholinesterases, anticholinesterase agents, corticosteroids, anticholinesterase agents, corticosteroid, Anticoagulants, corticosteroids, warfarin, warfarin, Antidiabetics, corticosteroids, antidiabetic agents, isoniazid, Cholestyramine, Cholestyramine, corticosteroids, Cyclosporine, cyclosporine, corticosteroids, indomethacin, Digitalis glycosides, digitalis glycosides, Ephedrine, Ephedrine, corticosteroids, corticosteroid, Estrogens, contraceptives, Estrogens, corticosteroids, barbiturates, phenytoin, carbamazepine, rifampin, corticosteroids, corticosteroid, ketoconazole, macrolide antibiotics, erythromycin, corticosteroids, Dexamethasone, indinavir, erythromycin, Ketoconazole, Ketoconazole, corticosteroids, corticosteroid, ketoconazole, corticosteroid, Nonsteroidal anti - inflammatory agents, NSAIDS, aspirin, nonsteroidal antiinflammatory agents, corticosteroids, Aspirin, corticosteroids, salicylates, corticosteroids, Phenytoin, phenytoin, dexamethasone, Corticosteroids, Thalidomide, thalidomide, Vaccines, corticosteroid, live, inactivated vaccines, Corticosteroids, live attenuated vaccines, vaccines, corticosteroid	Dexamethasone_ddi_task2	Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please extract entity words from the input sentence	[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]	Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.	[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]	[ "GROUP", "DRUG", "BRAND" ]
DOSTINEX is a BRAND, phenothiazines is a GROUP, butyrophenones is a GROUP, thioxanthines is a GROUP, metoclopramide is a DRUG	Cabergoline_ddi_task0	Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND	[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.	[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]	[ "GROUP", "DRUG", "BRAND" ]
DOSTINEX is a BRAND, phenothiazines is a GROUP, butyrophenones is a GROUP, thioxanthines is a GROUP, metoclopramide is a DRUG	Cabergoline_ddi_task1	Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please typing these entity words according to sentence: DOSTINEX, phenothiazines, butyrophenones, thioxanthines, metoclopramide Options: GROUP, DRUG, BRAND	[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.	[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]	[ "GROUP", "DRUG", "BRAND" ]
DOSTINEX, phenothiazines, butyrophenones, thioxanthines, metoclopramide	Cabergoline_ddi_task2	Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please extract entity words from the input sentence	[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]	DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.	[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]	[ "GROUP", "DRUG", "BRAND" ]
diagnostic is an umlsterm, axes is an umlsterm, axis is an umlsterm, psychiatric diagnoses is an umlsterm, Guidelines is an umlsterm, Diagnostic is an umlsterm, Criteria is an umlsterm, Research is an umlsterm, Axis is an umlsterm, Diagnostic is an umlsterm, Scale is an umlsterm, DDS is an umlsterm, axis is an umlsterm, lifestyle is an umlsterm, axis is an umlsterm, axis is an umlsterm, Assessment is an umlsterm, Scale is an umlsterm, case histories is an umlsterm, axis is an umlsterm, axis is an umlsterm, axis is an umlsterm, assessment is an umlsterm, axis is an umlsterm, variation is an umlsterm, axis is an umlsterm, value is an umlsterm	DerNervenarzt.70680231.eng.abstr_task0	Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .	[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]	[ "umlsterm" ]
diagnostic is an umlsterm, axes is an umlsterm, axis is an umlsterm, psychiatric diagnoses is an umlsterm, Guidelines is an umlsterm, Diagnostic is an umlsterm, Criteria is an umlsterm, Research is an umlsterm, Axis is an umlsterm, Diagnostic is an umlsterm, Scale is an umlsterm, DDS is an umlsterm, axis is an umlsterm, lifestyle is an umlsterm, axis is an umlsterm, axis is an umlsterm, Assessment is an umlsterm, Scale is an umlsterm, case histories is an umlsterm, axis is an umlsterm, axis is an umlsterm, axis is an umlsterm, assessment is an umlsterm, axis is an umlsterm, variation is an umlsterm, axis is an umlsterm, value is an umlsterm	DerNervenarzt.70680231.eng.abstr_task1	Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please typing these entity words according to sentence: diagnostic, axes, axis, psychiatric diagnoses, Guidelines, Diagnostic, Criteria, Research, Axis, Diagnostic, Scale, DDS, axis, lifestyle, axis, axis, Assessment, Scale, case histories, axis, axis, axis, assessment, axis, variation, axis, value Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .	[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]	[ "umlsterm" ]
diagnostic, axes, axis, psychiatric diagnoses, Guidelines, Diagnostic, Criteria, Research, Axis, Diagnostic, Scale, DDS, axis, lifestyle, axis, axis, Assessment, Scale, case histories, axis, axis, axis, assessment, axis, variation, axis, value	DerNervenarzt.70680231.eng.abstr_task2	Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .	[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]	[ "umlsterm" ]
serum is a Organism_substance	PMID-2607031_task0	Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.	[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]	[ "Organism_substance" ]
serum is a Organism_substance	PMID-2607031_task1	Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please typing these entity words according to sentence: serum Options: Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.	[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]	[ "Organism_substance" ]
serum	PMID-2607031_task2	Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.	[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]	[ "Organism_substance" ]
perfusion is an umlsterm, shock is an umlsterm, mucosa is an umlsterm, oxygen is an umlsterm, vessels is an umlsterm, mucosa is an umlsterm, tip is an umlsterm, risk is an umlsterm, ischemia is an umlsterm, dysfunction is an umlsterm, bacteria is an umlsterm, toxins is an umlsterm, leukocytes is an umlsterm, cytokine is an umlsterm, syndrome is an umlsterm, role is an umlsterm, shock is an umlsterm, dysfunction is an umlsterm	DerAnaesthesist.00490446.eng.abstr_task0	Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .	[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]	[ "umlsterm" ]
perfusion is an umlsterm, shock is an umlsterm, mucosa is an umlsterm, oxygen is an umlsterm, vessels is an umlsterm, mucosa is an umlsterm, tip is an umlsterm, risk is an umlsterm, ischemia is an umlsterm, dysfunction is an umlsterm, bacteria is an umlsterm, toxins is an umlsterm, leukocytes is an umlsterm, cytokine is an umlsterm, syndrome is an umlsterm, role is an umlsterm, shock is an umlsterm, dysfunction is an umlsterm	DerAnaesthesist.00490446.eng.abstr_task1	Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please typing these entity words according to sentence: perfusion, shock, mucosa, oxygen, vessels, mucosa, tip, risk, ischemia, dysfunction, bacteria, toxins, leukocytes, cytokine, syndrome, role, shock, dysfunction Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .	[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]	[ "umlsterm" ]
perfusion, shock, mucosa, oxygen, vessels, mucosa, tip, risk, ischemia, dysfunction, bacteria, toxins, leukocytes, cytokine, syndrome, role, shock, dysfunction	DerAnaesthesist.00490446.eng.abstr_task2	Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .	[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]	[ "umlsterm" ]
p53 is a protein, bioflavonoid is a compound, apigenin is a compound, RNA - binding protein is a protein	DS.d696_task0	Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]	Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.	[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]	[ "protein", "compound" ]
p53 is a protein, bioflavonoid is a compound, apigenin is a compound, RNA - binding protein is a protein	DS.d696_task1	Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please typing these entity words according to sentence: p53, bioflavonoid, apigenin, RNA - binding protein Options: compound, protein	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]	Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.	[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]	[ "protein", "compound" ]
p53, bioflavonoid, apigenin, RNA - binding protein	DS.d696_task2	Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]	Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.	[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]	[ "protein", "compound" ]
Hand is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Schweden is an umlsterm, Genereal is an umlsterm, Wisconsin is an umlsterm, USA is an umlsterm, Schmerz is an umlsterm, Biopsieergebnisse is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Biopsiepositionen is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Ohnmacht is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Patientenaufklaerung is an umlsterm, Biopsie is an umlsterm, Biopsiepositionen is an umlsterm, Patienten is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Biopsieposition is an umlsterm	DerRadiologe.70370629.ger.abstr_task0	Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .	[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]	[ "umlsterm" ]
Hand is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Schweden is an umlsterm, Genereal is an umlsterm, Wisconsin is an umlsterm, USA is an umlsterm, Schmerz is an umlsterm, Biopsieergebnisse is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Biopsiepositionen is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Ohnmacht is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Patientenaufklaerung is an umlsterm, Biopsie is an umlsterm, Biopsiepositionen is an umlsterm, Patienten is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Biopsieposition is an umlsterm	DerRadiologe.70370629.ger.abstr_task1	Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please typing these entity words according to sentence: Hand, Brustbiopsie, Biopsie, Schweden, Genereal, Wisconsin, USA, Schmerz, Biopsieergebnisse, Spezifitaet, Biopsiepositionen, Biopsiepositionen, Biopsie, Biopsie, Ohnmacht, Spezifitaet, Biopsiepositionen, Patientenaufklaerung, Biopsie, Biopsiepositionen, Patienten, Brustbiopsie, Biopsie, Biopsieposition Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .	[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]	[ "umlsterm" ]
Hand, Brustbiopsie, Biopsie, Schweden, Genereal, Wisconsin, USA, Schmerz, Biopsieergebnisse, Spezifitaet, Biopsiepositionen, Biopsiepositionen, Biopsie, Biopsie, Ohnmacht, Spezifitaet, Biopsiepositionen, Patientenaufklaerung, Biopsie, Biopsiepositionen, Patienten, Brustbiopsie, Biopsie, Biopsieposition	DerRadiologe.70370629.ger.abstr_task2	Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .	[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]	[ "umlsterm" ]
Antikonvulsiva is an umlsterm, Schmerzen is an umlsterm, Kopfschmerzsyndromen is an umlsterm, Schmerzen is an umlsterm	DerSchmerz.70110411.ger.abstr_task0	Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .	[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]	[ "umlsterm" ]
Antikonvulsiva is an umlsterm, Schmerzen is an umlsterm, Kopfschmerzsyndromen is an umlsterm, Schmerzen is an umlsterm	DerSchmerz.70110411.ger.abstr_task1	Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please typing these entity words according to sentence: Antikonvulsiva, Schmerzen, Kopfschmerzsyndromen, Schmerzen Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .	[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]	[ "umlsterm" ]
Antikonvulsiva, Schmerzen, Kopfschmerzsyndromen, Schmerzen	DerSchmerz.70110411.ger.abstr_task2	Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .	[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]	[ "umlsterm" ]
JA is an intervention, SP is an intervention, young children with autism is a participant	1258_task0	Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, participant	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]	These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .	[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]	[ "participant", "intervention" ]
JA is an intervention, SP is an intervention, young children with autism is a participant	1258_task1	Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please typing these entity words according to sentence: JA, SP, young children with autism Options: intervention, participant	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]	These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .	[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]	[ "participant", "intervention" ]
JA, SP, young children with autism	1258_task2	Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]	These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .	[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]	[ "participant", "intervention" ]
Hydroxy - Methyl - Peroxy is a CHEMICAL	23641685_task0	Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]	Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.	[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]	[ "CHEMICAL" ]
Hydroxy - Methyl - Peroxy is a CHEMICAL	23641685_task1	Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please typing these entity words according to sentence: Hydroxy - Methyl - Peroxy Options: CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]	Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.	[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]	[ "CHEMICAL" ]
Hydroxy - Methyl - Peroxy	23641685_task2	Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]	Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.	[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]	[ "CHEMICAL" ]
AML1 is a Protein, CBF beta is a Protein, c - Myb is a Protein, MZF-1 is a Protein	766_task0	Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.	[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]	[ "Protein" ]
AML1 is a Protein, CBF beta is a Protein, c - Myb is a Protein, MZF-1 is a Protein	766_task1	Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please typing these entity words according to sentence: AML1, CBF beta, c - Myb, MZF-1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.	[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]	[ "Protein" ]
AML1, CBF beta, c - Myb, MZF-1	766_task2	Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.	[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]	[ "Protein" ]
methylmalonate semialdehyde dehydrogenase is a GENE-Y	1898092_task0	Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.	[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
methylmalonate semialdehyde dehydrogenase is a GENE-Y	1898092_task1	Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please typing these entity words according to sentence: methylmalonate semialdehyde dehydrogenase Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.	[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
methylmalonate semialdehyde dehydrogenase	1898092_task2	Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.	[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
interleukin-4 receptor alpha chain is a protein_subunit, p47phox is an other_organic_compound, phagocyte NADPH oxidase is a protein_molecule, B cells is a cell_type	38652_task0	Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_type, protein_molecule, protein_subunit	[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.	[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]	[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]
interleukin-4 receptor alpha chain is a protein_subunit, p47phox is an other_organic_compound, phagocyte NADPH oxidase is a protein_molecule, B cells is a cell_type	38652_task1	Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please typing these entity words according to sentence: interleukin-4 receptor alpha chain, p47phox, phagocyte NADPH oxidase, B cells Options: other_organic_compound, cell_type, protein_molecule, protein_subunit	[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.	[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]	[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]
interleukin-4 receptor alpha chain, p47phox, phagocyte NADPH oxidase, B cells	38652_task2	Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.	[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]	[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]
Chromosomale is an umlsterm, Spontanaborten is an umlsterm, Paraffin - eingebetteten is an umlsterm, Gewebe is an umlsterm, Aborte is an umlsterm, Metaphasen is an umlsterm, Zentromer - spezifischen is an umlsterm, DNA - Sonden is an umlsterm, Chromosomen is an umlsterm, Kernsuspensionen is an umlsterm, Chromosomenaberrationen is an umlsterm, Kernsuspensionen is an umlsterm, Paraffin - eingebettetem is an umlsterm, Abortmaterial is an umlsterm, genetischen Beratung is an umlsterm, Eltern is an umlsterm	DerPathologe.80190120.ger.abstr_task0	Sentence: Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant .	[ "Chromosomale", "Aberrationen", "sind", "eine", "wichtige", "Ursache", "von", "Spontanaborten", ".", "Zum", "Nachweis", "genetischer", "Stoerungen", "im", "Paraffin", "-", "eingebetteten", "Gewebe", "wurden", "26", "Aborte", "mit", "bekanntem", "zytogenetischem", "Befund", "an", "Metaphasen", "(", "konventionelle", "Zytogenetik", "/", "KZG", ";", "25", "numerische", "und", "eine", "strukturelle", "Aberration", ")", "retrospektiv", "mit", "der", "sog", ".", "Interphasezytogenetik", "(", "IZG", ")", "mit", "Zentromer", "-", "spezifischen", "DNA", "-", "Sonden", "(", "fuer", "#", "X", ",", "#", "Y", ",", "#", "10", "#", "18", "und", "#", "13/#21", ")", ",", "analysiert", ".", "Durch", "Zuordnung", "der", "IZG", "-", "Signalverteilungen", "(", "Chromosomen", "#", "X", ",", "#", "Y", "und", "#", "18", ")", "zu", "den", "KZG", "-", "Befunden", "wurden", "Grenzwerte", "fuer", "die", "IZG", "-", "Diagnose", "von", "Aneusomien", "ermittelt", "(", "fuer", "Zugewinn", ">", "=", "15", "%", "Kerne", "mit", "+1", "Signal", ";", "fuer", "Deletion", ">", "=", "40", "%", "der", "Kerne", "mit", "-1", "Signal", ")", ".", "Die", "Ergebnisse", "in", "Schnittpraeparaten", "(", "6", "µm", "dick", ")", "und", "parallel", "untersuchten", "Kernsuspensionen", "korrelierten", "statistisch", "hoch", "signifikant", "(", "p", "0,0001", ")", ".", "KZG-", "und", "IZG", "-", "Diagnosen", "stimmten", "in", "18", "von", "20", "auswertbaren", "Faellen", "ueberein", "(", "90", "%", ";", "kein", "falsch", "-", "positiver", "Befund", ")", ".", "Korrelationen", "zwischen", "zytogenetischen", "und", "histomorphologischen", "Befunden", "fanden", "sich", "nicht", ".", "Mit", "der", "IZG", "lassen", "sich", "numerische", "Chromosomenaberrationen", "an", "Schnitten", "und", "Kernsuspensionen", "von", "Paraffin", "-", "eingebettetem", "Abortmaterial", "zuverlaessig", "nachweisen", ",", "was", "die", "Moeglichkeit", "zur", "genetischen", "Beratung", "der", "Eltern", "eroeffnet", ".", "Die", "ermittelten", "Grenzwerte", "fuer", "den", "Nachweis", "von", "Aneusomien", "sind", "auch", "fuer", "tumorzytogenetische", "Untersuchungen", "mit", "der", "IZG", "-", "Technik", "relevant", "." ]	[ "umlsterm" ]
Chromosomale is an umlsterm, Spontanaborten is an umlsterm, Paraffin - eingebetteten is an umlsterm, Gewebe is an umlsterm, Aborte is an umlsterm, Metaphasen is an umlsterm, Zentromer - spezifischen is an umlsterm, DNA - Sonden is an umlsterm, Chromosomen is an umlsterm, Kernsuspensionen is an umlsterm, Chromosomenaberrationen is an umlsterm, Kernsuspensionen is an umlsterm, Paraffin - eingebettetem is an umlsterm, Abortmaterial is an umlsterm, genetischen Beratung is an umlsterm, Eltern is an umlsterm	DerPathologe.80190120.ger.abstr_task1	Sentence: Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant . Instructions: please typing these entity words according to sentence: Chromosomale, Spontanaborten, Paraffin - eingebetteten, Gewebe, Aborte, Metaphasen, Zentromer - spezifischen, DNA - Sonden, Chromosomen, Kernsuspensionen, Chromosomenaberrationen, Kernsuspensionen, Paraffin - eingebettetem, Abortmaterial, genetischen Beratung, Eltern Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant .	[ "Chromosomale", "Aberrationen", "sind", "eine", "wichtige", "Ursache", "von", "Spontanaborten", ".", "Zum", "Nachweis", "genetischer", "Stoerungen", "im", "Paraffin", "-", "eingebetteten", "Gewebe", "wurden", "26", "Aborte", "mit", "bekanntem", "zytogenetischem", "Befund", "an", "Metaphasen", "(", "konventionelle", "Zytogenetik", "/", "KZG", ";", "25", "numerische", "und", "eine", "strukturelle", "Aberration", ")", "retrospektiv", "mit", "der", "sog", ".", "Interphasezytogenetik", "(", "IZG", ")", "mit", "Zentromer", "-", "spezifischen", "DNA", "-", "Sonden", "(", "fuer", "#", "X", ",", "#", "Y", ",", "#", "10", "#", "18", "und", "#", "13/#21", ")", ",", "analysiert", ".", "Durch", "Zuordnung", "der", "IZG", "-", "Signalverteilungen", "(", "Chromosomen", "#", "X", ",", "#", "Y", "und", "#", "18", ")", "zu", "den", "KZG", "-", "Befunden", "wurden", "Grenzwerte", "fuer", "die", "IZG", "-", "Diagnose", "von", "Aneusomien", "ermittelt", "(", "fuer", "Zugewinn", ">", "=", "15", "%", "Kerne", "mit", "+1", "Signal", ";", "fuer", "Deletion", ">", "=", "40", "%", "der", "Kerne", "mit", "-1", "Signal", ")", ".", "Die", "Ergebnisse", "in", "Schnittpraeparaten", "(", "6", "µm", "dick", ")", "und", "parallel", "untersuchten", "Kernsuspensionen", "korrelierten", "statistisch", "hoch", "signifikant", "(", "p", "0,0001", ")", ".", "KZG-", "und", "IZG", "-", "Diagnosen", "stimmten", "in", "18", "von", "20", "auswertbaren", "Faellen", "ueberein", "(", "90", "%", ";", "kein", "falsch", "-", "positiver", "Befund", ")", ".", "Korrelationen", "zwischen", "zytogenetischen", "und", "histomorphologischen", "Befunden", "fanden", "sich", "nicht", ".", "Mit", "der", "IZG", "lassen", "sich", "numerische", "Chromosomenaberrationen", "an", "Schnitten", "und", "Kernsuspensionen", "von", "Paraffin", "-", "eingebettetem", "Abortmaterial", "zuverlaessig", "nachweisen", ",", "was", "die", "Moeglichkeit", "zur", "genetischen", "Beratung", "der", "Eltern", "eroeffnet", ".", "Die", "ermittelten", "Grenzwerte", "fuer", "den", "Nachweis", "von", "Aneusomien", "sind", "auch", "fuer", "tumorzytogenetische", "Untersuchungen", "mit", "der", "IZG", "-", "Technik", "relevant", "." ]	[ "umlsterm" ]

camazepam and temazepam is a Intervention_Pharmacological, placebo is a Intervention_Control, sleep parameters is a Outcome_Physical, percent duration of stage II is a Outcome_Physical, sleep efficiency is a Outcome_Other, Camazepam shows modification is a Outcome_Other

78284_task1

Sentence: Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern . Instructions: please typing these entity words according to sentence: camazepam and temazepam, placebo, sleep parameters, percent duration of stage II, sleep efficiency, Camazepam shows modification Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern .

[ "Comparison", "between", "the", "central", "effects", "of", "camazepam", "and", "temazepam", ".", "Computerized", "analysis", "of", "sleep", "recordings", ".", "The", "effects", "of", "acute", "administration", "per", "os", "of", "30", "mg", "camazepam", "and", "the", "same", "dose", "of", "temazepam", ",", "were", "compared", "with", "placebo", "in", "8", "young", "male", "volunteers", ",", "fully", "adapted", "to", "the", "laboratory", "environment", "by", "6", "nights", "of", "adaptation", ".", "The", "study", "was", "double", "-", "blind", ",", "in", "a", "random", "order", ",", "10", "days", "separating", "each", "session", ".", "Spectral", "analysis", "was", "performed", "on", "the", "all", "-", "night", "records", "(", "1-min", "epochs", ")", ",", "and", "the", "relative", "power", "of", "six", "frequency", "bands", "calculated", ".", "Concerning", "sleep", "parameters", ",", "temazepam", "induces", "a", "statistically", "significant", "reduction", "of", ":", "phase", "shifts", ";", "number", "of", "awakenings", ";", "percent", "duration", "of", "sleep", "stages", "I", "and", "IV", ".", "A", "significant", "increase", "of", "the", "percent", "duration", "of", "stage", "II", "and", "sleep", "efficiency", "was", "also", "found", ".", "Camazepam", "shows", "modification", ",", "with", "the", "same", "trend", ",", "but", "not", "reaching", "statistical", "significance", ".", "Concerning", "spectral", "analysis", ",", "temazepam", "induces", "a", "light", "increase", "of", "the", "relative", "power", "of", "the", "slowest", "frequencies", ",", "paralleled", "by", "an", "increase", "of", "the", "fast", "bands", ",", "while", "major", "effects", "are", "found", "on", "the", "characteristic", "periodicity", "of", "delta", "activities", ",", "which", "appear", "disrupted", "by", "the", "drug", ".", "These", "effects", "are", "not", "evident", "with", "camazepam", ",", "which", "does", "not", "seem", "to", "distort", "the", "normal", "sleep", "pattern", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]

camazepam and temazepam, placebo, sleep parameters, percent duration of stage II, sleep efficiency, Camazepam shows modification

78284_task2

Sentence: Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison between the central effects of camazepam and temazepam . Computerized analysis of sleep recordings . The effects of acute administration per os of 30 mg camazepam and the same dose of temazepam , were compared with placebo in 8 young male volunteers , fully adapted to the laboratory environment by 6 nights of adaptation . The study was double-blind , in a random order , 10 days separating each session . Spectral analysis was performed on the all-night records ( 1-min epochs ) , and the relative power of six frequency bands calculated . Concerning sleep parameters , temazepam induces a statistically significant reduction of : phase shifts ; number of awakenings ; percent duration of sleep stages I and IV . A significant increase of the percent duration of stage II and sleep efficiency was also found . Camazepam shows modification , with the same trend , but not reaching statistical significance . Concerning spectral analysis , temazepam induces a light increase of the relative power of the slowest frequencies , paralleled by an increase of the fast bands , while major effects are found on the characteristic periodicity of delta activities , which appear disrupted by the drug . These effects are not evident with camazepam , which does not seem to distort the normal sleep pattern .

[ "Comparison", "between", "the", "central", "effects", "of", "camazepam", "and", "temazepam", ".", "Computerized", "analysis", "of", "sleep", "recordings", ".", "The", "effects", "of", "acute", "administration", "per", "os", "of", "30", "mg", "camazepam", "and", "the", "same", "dose", "of", "temazepam", ",", "were", "compared", "with", "placebo", "in", "8", "young", "male", "volunteers", ",", "fully", "adapted", "to", "the", "laboratory", "environment", "by", "6", "nights", "of", "adaptation", ".", "The", "study", "was", "double", "-", "blind", ",", "in", "a", "random", "order", ",", "10", "days", "separating", "each", "session", ".", "Spectral", "analysis", "was", "performed", "on", "the", "all", "-", "night", "records", "(", "1-min", "epochs", ")", ",", "and", "the", "relative", "power", "of", "six", "frequency", "bands", "calculated", ".", "Concerning", "sleep", "parameters", ",", "temazepam", "induces", "a", "statistically", "significant", "reduction", "of", ":", "phase", "shifts", ";", "number", "of", "awakenings", ";", "percent", "duration", "of", "sleep", "stages", "I", "and", "IV", ".", "A", "significant", "increase", "of", "the", "percent", "duration", "of", "stage", "II", "and", "sleep", "efficiency", "was", "also", "found", ".", "Camazepam", "shows", "modification", ",", "with", "the", "same", "trend", ",", "but", "not", "reaching", "statistical", "significance", ".", "Concerning", "spectral", "analysis", ",", "temazepam", "induces", "a", "light", "increase", "of", "the", "relative", "power", "of", "the", "slowest", "frequencies", ",", "paralleled", "by", "an", "increase", "of", "the", "fast", "bands", ",", "while", "major", "effects", "are", "found", "on", "the", "characteristic", "periodicity", "of", "delta", "activities", ",", "which", "appear", "disrupted", "by", "the", "drug", ".", "These", "effects", "are", "not", "evident", "with", "camazepam", ",", "which", "does", "not", "seem", "to", "distort", "the", "normal", "sleep", "pattern", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]

Wiederherstellung is an umlsterm, Anatomie is an umlsterm, Mehrfachrezidivhernien is an umlsterm, Wiederherstellung is an umlsterm

DerChirurg.70680488.ger.abstr_task0

Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .

[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]

[ "umlsterm" ]

Wiederherstellung is an umlsterm, Anatomie is an umlsterm, Mehrfachrezidivhernien is an umlsterm, Wiederherstellung is an umlsterm

DerChirurg.70680488.ger.abstr_task1

Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please typing these entity words according to sentence: Wiederherstellung, Anatomie, Mehrfachrezidivhernien, Wiederherstellung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .

[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]

[ "umlsterm" ]

Wiederherstellung, Anatomie, Mehrfachrezidivhernien, Wiederherstellung

DerChirurg.70680488.ger.abstr_task2

Sentence: Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Jeder rekonstruktive Eingriff an der Bauchdecke hat die Wiederherstellung der funktionellen Stabilitaet und adaequate Weichteilbedeckung zum Ziel . Es werden Anatomie und Hebung des gestielten myofascialen M. -tensor-fasciae-latae-Lappens und des freien mikrovasculaer angeschlossenen musculocutanen M. -latissimus-dorsi-Lappens beschrieben und klinisch vorgestellt . Die gestielte M. -tensor-fasciae-latae-Einheit gewaehrleistet bei ausgedehntesten Fasciendefekten bei Mehrfachrezidivhernien ohne anatomisch fassbare Bruchpforte eine starke und zugleich dynamische funktionelle Wiederherstellung der Fascienkontinuitaet zur Praevention eines neuerlichen Bruchs . Der innervierte mikrochirurgisch anastomosierte M. -latissimus-dorsi-Lappen stellt die optimale funktionelle und aesthetische Rekonstruktion ausgedehnter Bauchwanddefekte , die alle anatomischen Schichten betreffen , dar .

[ "Zusammenfassung", ".", "Jeder", "rekonstruktive", "Eingriff", "an", "der", "Bauchdecke", "hat", "die", "Wiederherstellung", "der", "funktionellen", "Stabilitaet", "und", "adaequate", "Weichteilbedeckung", "zum", "Ziel", ".", "Es", "werden", "Anatomie", "und", "Hebung", "des", "gestielten", "myofascialen", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Lappens", "und", "des", "freien", "mikrovasculaer", "angeschlossenen", "musculocutanen", "M.", "-latissimus", "-", "dorsi", "-", "Lappens", "beschrieben", "und", "klinisch", "vorgestellt", ".", "Die", "gestielte", "M.", "-tensor", "-", "fasciae", "-", "latae", "-", "Einheit", "gewaehrleistet", "bei", "ausgedehntesten", "Fasciendefekten", "bei", "Mehrfachrezidivhernien", "ohne", "anatomisch", "fassbare", "Bruchpforte", "eine", "starke", "und", "zugleich", "dynamische", "funktionelle", "Wiederherstellung", "der", "Fascienkontinuitaet", "zur", "Praevention", "eines", "neuerlichen", "Bruchs", ".", "Der", "innervierte", "mikrochirurgisch", "anastomosierte", "M.", "-latissimus", "-", "dorsi", "-", "Lappen", "stellt", "die", "optimale", "funktionelle", "und", "aesthetische", "Rekonstruktion", "ausgedehnter", "Bauchwanddefekte", ",", "die", "alle", "anatomischen", "Schichten", "betreffen", ",", "dar", "." ]

[ "umlsterm" ]

Alterspatienten is an umlsterm, Demenzerkrankungen is an umlsterm, Menschen is an umlsterm, Neuroleptika is an umlsterm, Patienten is an umlsterm, Neuroleptika is an umlsterm, Benzodiazepine is an umlsterm, Altenpflegeheimen is an umlsterm, Psychopharmaka is an umlsterm, Schlafstoerungen is an umlsterm

DerNervenarzt.80690999.ger.abstr_task0

Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .

[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]

[ "umlsterm" ]

Alterspatienten is an umlsterm, Demenzerkrankungen is an umlsterm, Menschen is an umlsterm, Neuroleptika is an umlsterm, Patienten is an umlsterm, Neuroleptika is an umlsterm, Benzodiazepine is an umlsterm, Altenpflegeheimen is an umlsterm, Psychopharmaka is an umlsterm, Schlafstoerungen is an umlsterm

DerNervenarzt.80690999.ger.abstr_task1

Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please typing these entity words according to sentence: Alterspatienten, Demenzerkrankungen, Menschen, Neuroleptika, Patienten, Neuroleptika, Benzodiazepine, Altenpflegeheimen, Psychopharmaka, Schlafstoerungen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .

[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]

[ "umlsterm" ]

Alterspatienten, Demenzerkrankungen, Menschen, Neuroleptika, Patienten, Neuroleptika, Benzodiazepine, Altenpflegeheimen, Psychopharmaka, Schlafstoerungen

DerNervenarzt.80690999.ger.abstr_task2

Sentence: Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der vorliegende Beitrag stellt eine Untersuchung zur psychopharmakologischen Behandlungspraxis bei Alterspatienten mit Demenzerkrankungen vor , die 1992 und 1993 gerontopsychiatrisch-stationaer behandelt und nachfolgend in Altenheime entlassen worden waren ( n=49). Trotz des erhoehten Nebenwirkungsrisikos werden aelteren dementen Menschen , sehr haeufig Psychoparmaka , am haeufigsten Neuroleptika , verschrieben . Es zeigte sich , dass die untersuchten Patienten in den Altenheimen signifikant haeufiger Neuroleptika erhielten als bei Klinikentlassung ( p=0,0001). Benzodiazepine wurden in den Heimen etwa doppelt so oft verordnet , Clomethiazol dagegen seltener . In den Altenpflegeheimen waren Dauerverordnungen die Regel . In den meisten Faellen wurden Psychopharmaka dort aufgrund von Unruhe " , Schlafstoerungen oder Aggressivitaet " verordnet . Besonders hohe Neuroleptikadosierungen erhielten erstaunlicherweise diejenigen Heimbewohner , deren psychiatrische Begleitsymptomatik durch diese Substanzen nicht wesentlich positiv beeinflusst werden konnte .

[ "Der", "vorliegende", "Beitrag", "stellt", "eine", "Untersuchung", "zur", "psychopharmakologischen", "Behandlungspraxis", "bei", "Alterspatienten", "mit", "Demenzerkrankungen", "vor", ",", "die", "1992", "und", "1993", "gerontopsychiatrisch", "-", "stationaer", "behandelt", "und", "nachfolgend", "in", "Altenheime", "entlassen", "worden", "waren", "(", "n=49", ")", ".", "Trotz", "des", "erhoehten", "Nebenwirkungsrisikos", "werden", "aelteren", "dementen", "Menschen", ",", "sehr", "haeufig", "Psychoparmaka", ",", "am", "haeufigsten", "Neuroleptika", ",", "verschrieben", ".", "Es", "zeigte", "sich", ",", "dass", "die", "untersuchten", "Patienten", "in", "den", "Altenheimen", "signifikant", "haeufiger", "Neuroleptika", "erhielten", "als", "bei", "Klinikentlassung", "(", "p=0,0001", ")", ".", "Benzodiazepine", "wurden", "in", "den", "Heimen", "etwa", "doppelt", "so", "oft", "verordnet", ",", "Clomethiazol", "dagegen", "seltener", ".", "In", "den", "Altenpflegeheimen", "waren", "Dauerverordnungen", "die", "Regel", ".", "In", "den", "meisten", "Faellen", "wurden", "Psychopharmaka", "dort", "aufgrund", "von", "Unruhe", "\"", ",", "Schlafstoerungen", "oder", "Aggressivitaet", "\"", "verordnet", ".", "Besonders", "hohe", "Neuroleptikadosierungen", "erhielten", "erstaunlicherweise", "diejenigen", "Heimbewohner", ",", "deren", "psychiatrische", "Begleitsymptomatik", "durch", "diese", "Substanzen", "nicht", "wesentlich", "positiv", "beeinflusst", "werden", "konnte", "." ]

[ "umlsterm" ]

lymphangioleiomyomatosis is an umlsterm, woman is an umlsterm, pneumothorax is an umlsterm, evaluation is an umlsterm, lung is an umlsterm, biopsy is an umlsterm, video - thoracoscopy is an umlsterm, tumour is an umlsterm, right is an umlsterm, kidney is an umlsterm, angiomyolipoma is an umlsterm, actin is an umlsterm, tissue is an umlsterm, angiomyolipoma is an umlsterm, pathologic is an umlsterm, lung is an umlsterm, tissue is an umlsterm, tumour is an umlsterm, frontal lobe is an umlsterm, brain is an umlsterm, tumours is an umlsterm, classification is an umlsterm, tuberous sclerosis is an umlsterm

DerPathologe.40150354.eng.abstr_task0

Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]

Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .

[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]

[ "umlsterm" ]

lymphangioleiomyomatosis is an umlsterm, woman is an umlsterm, pneumothorax is an umlsterm, evaluation is an umlsterm, lung is an umlsterm, biopsy is an umlsterm, video - thoracoscopy is an umlsterm, tumour is an umlsterm, right is an umlsterm, kidney is an umlsterm, angiomyolipoma is an umlsterm, actin is an umlsterm, tissue is an umlsterm, angiomyolipoma is an umlsterm, pathologic is an umlsterm, lung is an umlsterm, tissue is an umlsterm, tumour is an umlsterm, frontal lobe is an umlsterm, brain is an umlsterm, tumours is an umlsterm, classification is an umlsterm, tuberous sclerosis is an umlsterm

DerPathologe.40150354.eng.abstr_task1

Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please typing these entity words according to sentence: lymphangioleiomyomatosis, woman, pneumothorax, evaluation, lung, biopsy, video - thoracoscopy, tumour, right, kidney, angiomyolipoma, actin, tissue, angiomyolipoma, pathologic, lung, tissue, tumour, frontal lobe, brain, tumours, classification, tuberous sclerosis Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]

Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .

[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]

[ "umlsterm" ]

lymphangioleiomyomatosis, woman, pneumothorax, evaluation, lung, biopsy, video - thoracoscopy, tumour, right, kidney, angiomyolipoma, actin, tissue, angiomyolipoma, pathologic, lung, tissue, tumour, frontal lobe, brain, tumours, classification, tuberous sclerosis

DerPathologe.40150354.eng.abstr_task2

Sentence: Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O" ]

Pulmonary lymphangioleiomyomatosis was diagnosed in a 26-year-old woman with recurrent pneumothorax by histological evaluation of a lung biopsy obtained during video-thoracoscopy . A tumour of the right kidney had been removed 2 years previously ; the histological picture was that of an angiomyolipoma . Immunohistochemical staining for anti-smooth mucle actin gave a strongly positive reaction in the tissue of the renal angiomyolipoma and in the pathologic lung tissue . Additional investigations showed an asymptomatic intracerebral tumour 5 cm in diameter in the left frontal lobe ( brain scan ) . This multilocal renal , pulmonary and cerebral manifestation of benign mesenchymal proliferating tumours supports the classification of this case in the tuberous sclerosis complex .

[ "Pulmonary", "lymphangioleiomyomatosis", "was", "diagnosed", "in", "a", "26-year", "-", "old", "woman", "with", "recurrent", "pneumothorax", "by", "histological", "evaluation", "of", "a", "lung", "biopsy", "obtained", "during", "video", "-", "thoracoscopy", ".", "A", "tumour", "of", "the", "right", "kidney", "had", "been", "removed", "2", "years", "previously", ";", "the", "histological", "picture", "was", "that", "of", "an", "angiomyolipoma", ".", "Immunohistochemical", "staining", "for", "anti", "-", "smooth", "mucle", "actin", "gave", "a", "strongly", "positive", "reaction", "in", "the", "tissue", "of", "the", "renal", "angiomyolipoma", "and", "in", "the", "pathologic", "lung", "tissue", ".", "Additional", "investigations", "showed", "an", "asymptomatic", "intracerebral", "tumour", "5", "cm", "in", "diameter", "in", "the", "left", "frontal", "lobe", "(", "brain", "scan", ")", ".", "This", "multilocal", "renal", ",", "pulmonary", "and", "cerebral", "manifestation", "of", "benign", "mesenchymal", "proliferating", "tumours", "supports", "the", "classification", "of", "this", "case", "in", "the", "tuberous", "sclerosis", "complex", "." ]

[ "umlsterm" ]

Cytokine - modulating activity is an other_name, tepoxalin is an other_organic_compound, antirheumatic is an other_name

99288_task0

Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.

[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]

[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]

Cytokine - modulating activity is an other_name, tepoxalin is an other_organic_compound, antirheumatic is an other_name

99288_task1

Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please typing these entity words according to sentence: Cytokine - modulating activity, tepoxalin, antirheumatic Options: other_organic_compound, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.

[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]

[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]

Cytokine - modulating activity, tepoxalin, antirheumatic

99288_task2

Sentence: Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_organic_compound", "O", "O", "O", "O", "B-other_name", "O" ]

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.

[ "Cytokine", "-", "modulating", "activity", "of", "tepoxalin", ",", "a", "new", "potential", "antirheumatic", "." ]

[ "other_organic_compound", "cell_type", "other_name", "(OR inorganic inorganic)", "protein_family_or_group", "DNA_family_or_group", "multi_cell", "inorganic", "protein_molecule", "", "atom" ]

oil with medium- and long - chain fatty acids is a Intervention_Pharmacological, body fat is a Outcome_Physical, blood lipid profiles is a Outcome_Physical, male is a Participant_Sex, hypertriglyceridemic is a Participant_Condition, oil with medium- and long - chain triglyceride ( MLCT ) is a Intervention_Pharmacological, One - hundred - and - twelve is a Participant_Sample-size, Anthropometric and blood biochemical parameters is a Outcome_Physical, 50 is a Participant_Sample-size, 34 is a Participant_Sample-size, men is a Participant_Sex, 16 is a Participant_Sample-size, women is a Participant_Sex, 51 is a Participant_Sample-size, 33 is a Participant_Sample-size, 18 is a Participant_Sample-size, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E is a Outcome_Physical

42032_task0

Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .

[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]

oil with medium- and long - chain fatty acids is a Intervention_Pharmacological, body fat is a Outcome_Physical, blood lipid profiles is a Outcome_Physical, male is a Participant_Sex, hypertriglyceridemic is a Participant_Condition, oil with medium- and long - chain triglyceride ( MLCT ) is a Intervention_Pharmacological, One - hundred - and - twelve is a Participant_Sample-size, Anthropometric and blood biochemical parameters is a Outcome_Physical, 50 is a Participant_Sample-size, 34 is a Participant_Sample-size, men is a Participant_Sex, 16 is a Participant_Sample-size, women is a Participant_Sex, 51 is a Participant_Sample-size, 33 is a Participant_Sample-size, 18 is a Participant_Sample-size, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E is a Outcome_Physical

42032_task1

Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please typing these entity words according to sentence: oil with medium- and long - chain fatty acids, body fat, blood lipid profiles, male, hypertriglyceridemic, oil with medium- and long - chain triglyceride ( MLCT ), One - hundred - and - twelve, Anthropometric and blood biochemical parameters, 50, 34, men, 16, women, 51, 33, 18, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E Options: Intervention_Pharmacological, Participant_Condition, Participant_Sex, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .

[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]

oil with medium- and long - chain fatty acids, body fat, blood lipid profiles, male, hypertriglyceridemic, oil with medium- and long - chain triglyceride ( MLCT ), One - hundred - and - twelve, Anthropometric and blood biochemical parameters, 50, 34, men, 16, women, 51, 33, 18, body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low - density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E

42032_task2

Sentence: A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sex", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects . A double blind clinical trial was carried out to clarify the effects of oil with medium- and long-chain triglyceride ( MLCT ) on body fat and blood lipid profiles in hypertriglyceridemic subjects . One-hundred-and-twelve subjects were enrolled and divided into two groups ; those that consumed MLCT oil and those that consumed long-chain triglyceride ( LCT ) oil for 8 weeks . All subjects were requested to consume 25-30 g of the oils daily and maintain a fixed level of energy intake and exercise . Anthropometric and blood biochemical parameters were measured when the study was initiated and completed . The LCT group consisted of 50 subjects ( 34 men and 16 women ) , while the MLCT group consisted of 51 subjects ( 33 men and 18 women ) who completed the study . Larger decreases in body weight , body mass index , waist circumference , body fat , total fat area and subcutaneous fat area in the abdomen and serum triglycerides , low-density lipoprotein cholesterol , apolipoprotein B , C2 , C3 and E were observed in male subjects in the MLCT group than those in the LCT group . However , no significant differences in these parameters between the female subjects in the two groups were observed . Data from this study indicate that consumption of medium-and long-chain triglycerides can reduce body weight and body fat and improve blood lipid profiles in male hypertriglyceridemic subjects .

[ "A", "good", "response", "to", "oil", "with", "medium-", "and", "long", "-", "chain", "fatty", "acids", "in", "body", "fat", "and", "blood", "lipid", "profiles", "of", "male", "hypertriglyceridemic", "subjects", ".", "A", "double", "blind", "clinical", "trial", "was", "carried", "out", "to", "clarify", "the", "effects", "of", "oil", "with", "medium-", "and", "long", "-", "chain", "triglyceride", "(", "MLCT", ")", "on", "body", "fat", "and", "blood", "lipid", "profiles", "in", "hypertriglyceridemic", "subjects", ".", "One", "-", "hundred", "-", "and", "-", "twelve", "subjects", "were", "enrolled", "and", "divided", "into", "two", "groups", ";", "those", "that", "consumed", "MLCT", "oil", "and", "those", "that", "consumed", "long", "-", "chain", "triglyceride", "(", "LCT", ")", "oil", "for", "8", "weeks", ".", "All", "subjects", "were", "requested", "to", "consume", "25", "-", "30", "g", "of", "the", "oils", "daily", "and", "maintain", "a", "fixed", "level", "of", "energy", "intake", "and", "exercise", ".", "Anthropometric", "and", "blood", "biochemical", "parameters", "were", "measured", "when", "the", "study", "was", "initiated", "and", "completed", ".", "The", "LCT", "group", "consisted", "of", "50", "subjects", "(", "34", "men", "and", "16", "women", ")", ",", "while", "the", "MLCT", "group", "consisted", "of", "51", "subjects", "(", "33", "men", "and", "18", "women", ")", "who", "completed", "the", "study", ".", "Larger", "decreases", "in", "body", "weight", ",", "body", "mass", "index", ",", "waist", "circumference", ",", "body", "fat", ",", "total", "fat", "area", "and", "subcutaneous", "fat", "area", "in", "the", "abdomen", "and", "serum", "triglycerides", ",", "low", "-", "density", "lipoprotein", "cholesterol", ",", "apolipoprotein", "B", ",", "C2", ",", "C3", "and", "E", "were", "observed", "in", "male", "subjects", "in", "the", "MLCT", "group", "than", "those", "in", "the", "LCT", "group", ".", "However", ",", "no", "significant", "differences", "in", "these", "parameters", "between", "the", "female", "subjects", "in", "the", "two", "groups", "were", "observed", ".", "Data", "from", "this", "study", "indicate", "that", "consumption", "of", "medium", "-", "and", "long", "-", "chain", "triglycerides", "can", "reduce", "body", "weight", "and", "body", "fat", "and", "improve", "blood", "lipid", "profiles", "in", "male", "hypertriglyceridemic", "subjects", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Condition", "Participant_Sex" ]

akutes Abdomen is an umlsterm, Nekrosen is an umlsterm, Fettgewebes is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Verdachtsdiagnose is an umlsterm, Methoden is an umlsterm, Schmerzen is an umlsterm, Ultraschall is an umlsterm, Tumors is an umlsterm, Computertomographie is an umlsterm, Laparoskopie is an umlsterm, Magenantrum is an umlsterm, Fettgewebsnekrose is an umlsterm, Netzinfarkt is an umlsterm, Laparoskopie is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Beschwerdefreiheit is an umlsterm, Komplikationen is an umlsterm, Superinfektion is an umlsterm, Blutungen is an umlsterm

DerChirurg.00710225.ger.abstr_task0

Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .

[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]

[ "umlsterm" ]

akutes Abdomen is an umlsterm, Nekrosen is an umlsterm, Fettgewebes is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Verdachtsdiagnose is an umlsterm, Methoden is an umlsterm, Schmerzen is an umlsterm, Ultraschall is an umlsterm, Tumors is an umlsterm, Computertomographie is an umlsterm, Laparoskopie is an umlsterm, Magenantrum is an umlsterm, Fettgewebsnekrose is an umlsterm, Netzinfarkt is an umlsterm, Laparoskopie is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Beschwerdefreiheit is an umlsterm, Komplikationen is an umlsterm, Superinfektion is an umlsterm, Blutungen is an umlsterm

DerChirurg.00710225.ger.abstr_task1

Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please typing these entity words according to sentence: akutes Abdomen, Nekrosen, Fettgewebes, Diagnose, Patienten, Verdachtsdiagnose, Methoden, Schmerzen, Ultraschall, Tumors, Computertomographie, Laparoskopie, Magenantrum, Fettgewebsnekrose, Netzinfarkt, Laparoskopie, Diagnostik, Therapie, Beschwerdefreiheit, Komplikationen, Superinfektion, Blutungen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .

[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]

[ "umlsterm" ]

akutes Abdomen, Nekrosen, Fettgewebes, Diagnose, Patienten, Verdachtsdiagnose, Methoden, Schmerzen, Ultraschall, Tumors, Computertomographie, Laparoskopie, Magenantrum, Fettgewebsnekrose, Netzinfarkt, Laparoskopie, Diagnostik, Therapie, Beschwerdefreiheit, Komplikationen, Superinfektion, Blutungen

DerChirurg.00710225.ger.abstr_task2

Sentence: Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Einleitung : Seltene Ursachen fuer ein akutes Abdomen sind idiopathische Nekrosen intraabdominal gelegenen peritonealisierten Fettgewebes . Die Diagnose wird kaum je praeoperativ gestellt und die Patienten werden meist unter der Verdachtsdiagnose einer Appendicitis oder Cholecystitis operiert . Methoden : Wir berichten ueber eine 32 jaehrige Patientin , die uns aufgrund von Schmerzen im rechten Oberbauch , welche bereits 2 Tage andauerten , zugewiesen wurde . Die Klinik suggerierte eine akute Cholecystitis , Labor und Ultraschall waren indes unauffaellig . Wegen eines deutlich palpablen und stark druckdolenten , epigastrischen Tumors von 2 x 3 x 3 cm Groesse wurde eine Computertomographie ( CT ) durchgefuehrt , die einen gut abgrenzbaren , entzuendlich infiltrierten Anteil des auffaellig fetthaltigen Lig . teres hepatis nachwies . Mittels Laparoskopie wurde der mit dem Magenantrum verklebte nekrotische Fettzipfel reseziert . Die Patientin war 24 Std. postoperativ nahezu beschwerdefrei und verliess das Spital nach 2 Tagen . Die anschliessend histologisch bestaetigte haemorrhagische Fettgewebsnekrose erinnert an die Befunde , wie sie beim segmentalen Netzinfarkt und die Appendicitis epiploica beobachtet werden koennen . Schlussfolgerungen : Die Laparoskopie bietet neben der erweiterten Diagnostik die Moeglichkeit zur Therapie . Die Resektion fuehrt zu rascher Beschwerdefreiheit und verhindert Komplikationen wie die bakterielle Superinfektion mit Abscessbildung oder spontane intraabdominelle Blutungen .

[ "Zusammenfassung", ".", "Einleitung", ":", "Seltene", "Ursachen", "fuer", "ein", "akutes", "Abdomen", "sind", "idiopathische", "Nekrosen", "intraabdominal", "gelegenen", "peritonealisierten", "Fettgewebes", ".", "Die", "Diagnose", "wird", "kaum", "je", "praeoperativ", "gestellt", "und", "die", "Patienten", "werden", "meist", "unter", "der", "Verdachtsdiagnose", "einer", "Appendicitis", "oder", "Cholecystitis", "operiert", ".", "Methoden", ":", "Wir", "berichten", "ueber", "eine", "32", "jaehrige", "Patientin", ",", "die", "uns", "aufgrund", "von", "Schmerzen", "im", "rechten", "Oberbauch", ",", "welche", "bereits", "2", "Tage", "andauerten", ",", "zugewiesen", "wurde", ".", "Die", "Klinik", "suggerierte", "eine", "akute", "Cholecystitis", ",", "Labor", "und", "Ultraschall", "waren", "indes", "unauffaellig", ".", "Wegen", "eines", "deutlich", "palpablen", "und", "stark", "druckdolenten", ",", "epigastrischen", "Tumors", "von", "2", "x", "3", "x", "3", "cm", "Groesse", "wurde", "eine", "Computertomographie", "(", "CT", ")", "durchgefuehrt", ",", "die", "einen", "gut", "abgrenzbaren", ",", "entzuendlich", "infiltrierten", "Anteil", "des", "auffaellig", "fetthaltigen", "Lig", ".", "teres", "hepatis", "nachwies", ".", "Mittels", "Laparoskopie", "wurde", "der", "mit", "dem", "Magenantrum", "verklebte", "nekrotische", "Fettzipfel", "reseziert", ".", "Die", "Patientin", "war", "24", "Std", ".", "postoperativ", "nahezu", "beschwerdefrei", "und", "verliess", "das", "Spital", "nach", "2", "Tagen", ".", "Die", "anschliessend", "histologisch", "bestaetigte", "haemorrhagische", "Fettgewebsnekrose", "erinnert", "an", "die", "Befunde", ",", "wie", "sie", "beim", "segmentalen", "Netzinfarkt", "und", "die", "Appendicitis", "epiploica", "beobachtet", "werden", "koennen", ".", "Schlussfolgerungen", ":", "Die", "Laparoskopie", "bietet", "neben", "der", "erweiterten", "Diagnostik", "die", "Moeglichkeit", "zur", "Therapie", ".", "Die", "Resektion", "fuehrt", "zu", "rascher", "Beschwerdefreiheit", "und", "verhindert", "Komplikationen", "wie", "die", "bakterielle", "Superinfektion", "mit", "Abscessbildung", "oder", "spontane", "intraabdominelle", "Blutungen", "." ]

[ "umlsterm" ]

age is a Person, > 18 y.o is a Value, American Society of Anesthesiologists Physical Status Classification is a Measurement, ASA is a Measurement, 1 - 2 is a Value

NCT03070847_inc_task0

Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Person, Measurement, Value

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators

[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]

[ "Measurement", "Value", "Person" ]

age is a Person, > 18 y.o is a Value, American Society of Anesthesiologists Physical Status Classification is a Measurement, ASA is a Measurement, 1 - 2 is a Value

NCT03070847_inc_task1

Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please typing these entity words according to sentence: age, > 18 y.o, American Society of Anesthesiologists Physical Status Classification, ASA, 1 - 2 Options: Person, Measurement, Value

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators

[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]

[ "Measurement", "Value", "Person" ]

age, > 18 y.o, American Society of Anesthesiologists Physical Status Classification, ASA, 1 - 2

NCT03070847_inc_task2

Sentence: age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators Instructions: please extract entity words from the input sentence

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

age > 18 y.o. American Society of Anesthesiologists Physical Status Classification (ASA) 1-2 signed informed consent form after reading the information about the study and talking with one of the investigators

[ "age", ">", "18", "y.o", ".", "\n", "American", "Society", "of", "Anesthesiologists", "Physical", "Status", "Classification", "(", "ASA", ")", "1", "-", "2", "\n", "signed", "informed", "consent", "form", "after", "reading", "the", "information", "about", "the", "study", "and", "talking", "with", "one", "of", "the", "investigators", "\n" ]

[ "Measurement", "Value", "Person" ]

1,5-diarylpyrrole nitrooxyalkyl ethers is a CHEMICAL, cyclooxygenase-2 is a GENE-Y, nitric oxide is a CHEMICAL, 3-substituted 1,5-diarylpyrroles is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, pyrrole is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, esters is a CHEMICAL, carbonates is a CHEMICAL, ethers is a CHEMICAL, COX-2 is a GENE-Y, NO is a CHEMICAL, nitrooxyalkyl ethers is a CHEMICAL, alcohols is a CHEMICAL, Nitrooxy is a CHEMICAL, NO is a CHEMICAL, COX-2 is a GENE-Y, interleukin-1β is a GENE-Y, IL-1β is a GENE-Y, ( 13)C is a CHEMICAL, nitrooxyalkyl ester and ether is a CHEMICAL, COX-2 is a GENE-Y

30108_task0

Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.

[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]

[ "CHEMICAL", "GENE-Y" ]

1,5-diarylpyrrole nitrooxyalkyl ethers is a CHEMICAL, cyclooxygenase-2 is a GENE-Y, nitric oxide is a CHEMICAL, 3-substituted 1,5-diarylpyrroles is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, pyrrole is a CHEMICAL, nitrooxyalkyl is a CHEMICAL, esters is a CHEMICAL, carbonates is a CHEMICAL, ethers is a CHEMICAL, COX-2 is a GENE-Y, NO is a CHEMICAL, nitrooxyalkyl ethers is a CHEMICAL, alcohols is a CHEMICAL, Nitrooxy is a CHEMICAL, NO is a CHEMICAL, COX-2 is a GENE-Y, interleukin-1β is a GENE-Y, IL-1β is a GENE-Y, ( 13)C is a CHEMICAL, nitrooxyalkyl ester and ether is a CHEMICAL, COX-2 is a GENE-Y

30108_task1

Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please typing these entity words according to sentence: 1,5-diarylpyrrole nitrooxyalkyl ethers, cyclooxygenase-2, nitric oxide, 3-substituted 1,5-diarylpyrroles, nitrooxyalkyl, pyrrole, nitrooxyalkyl, esters, carbonates, ethers, COX-2, NO, nitrooxyalkyl ethers, alcohols, Nitrooxy, NO, COX-2, interleukin-1β, IL-1β, ( 13)C, nitrooxyalkyl ester and ether, COX-2 Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.

[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]

[ "CHEMICAL", "GENE-Y" ]

1,5-diarylpyrrole nitrooxyalkyl ethers, cyclooxygenase-2, nitric oxide, 3-substituted 1,5-diarylpyrroles, nitrooxyalkyl, pyrrole, nitrooxyalkyl, esters, carbonates, ethers, COX-2, NO, nitrooxyalkyl ethers, alcohols, Nitrooxy, NO, COX-2, interleukin-1β, IL-1β, ( 13)C, nitrooxyalkyl ester and ether, COX-2

30108_task2

Sentence: Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors. A series of 3-substituted 1,5-diarylpyrroles bearing a nitrooxyalkyl side chain linked to different spacers were designed. New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as COX-2 selective inhibitors and NO donors were synthesized and are herein reported. By taking into account the metabolic conversion of nitrooxyalkyl ethers (9, 10) into corresponding alcohols, derivatives 17 and 18 were also studied. Nitrooxy derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective COX-2 inhibitors in in vitro experimental models. Further in vivo studies on compounds 9a,c and 17a highlighted good anti-inflammatory and antinociceptive activities. Compound 9c was able to inhibit glycosaminoglycan (GAG) release induced by interleukin-1β (IL-1β), showing cartilage protective properties. Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.

[ "Novel", "analgesic", "/", "anti", "-", "inflammatory", "agents", ":", "1,5-diarylpyrrole", "nitrooxyalkyl", "ethers", "and", "related", "compounds", "as", "cyclooxygenase-2", "inhibiting", "nitric", "oxide", "donors", ".", "\n", "A", "series", "of", "3-substituted", "1,5-diarylpyrroles", "bearing", "a", "nitrooxyalkyl", "side", "chain", "linked", "to", "different", "spacers", "were", "designed", ".", "New", "classes", "of", "pyrrole", "-", "derived", "nitrooxyalkyl", "inverse", "esters", ",", "carbonates", ",", "and", "ethers", "(", "7", "-", "10", ")", "as", "COX-2", "selective", "inhibitors", "and", "NO", "donors", "were", "synthesized", "and", "are", "herein", "reported", ".", "By", "taking", "into", "account", "the", "metabolic", "conversion", "of", "nitrooxyalkyl", "ethers", "(", "9", ",", "10", ")", "into", "corresponding", "alcohols", ",", "derivatives", "17", "and", "18", "were", "also", "studied", ".", "Nitrooxy", "derivatives", "showed", "NO", "-", "dependent", "vasorelaxing", "properties", ",", "while", "most", "of", "the", "compounds", "proved", "to", "be", "very", "potent", "and", "selective", "COX-2", "inhibitors", "in", "in", "vitro", "experimental", "models", ".", "Further", "in", "vivo", "studies", "on", "compounds", "9a", ",", "c", "and", "17a", "highlighted", "good", "anti", "-", "inflammatory", "and", "antinociceptive", "activities", ".", "Compound", "9c", "was", "able", "to", "inhibit", "glycosaminoglycan", "(", "GAG", ")", "release", "induced", "by", "interleukin-1β", "(", "IL-1β", ")", ",", "showing", "cartilage", "protective", "properties", ".", "Finally", ",", "molecular", "modeling", "and", "(", "1)H-", "and", "(", "13)C", "-", "NMR", "studies", "performed", "on", "compounds", "6c", ",", "d", ",", "9c", ",", "and", "10b", "allowed", "the", "right", "conformation", "of", "nitrooxyalkyl", "ester", "and", "ether", "side", "chain", "of", "these", "molecules", "within", "the", "COX-2", "active", "site", "to", "be", "assessed", "." ]

[ "CHEMICAL", "GENE-Y" ]

Hauttumoren is an umlsterm, Blutgefaesse is an umlsterm, Auge is an umlsterm, tumorspezifische is an umlsterm, Element is an umlsterm, Hauttumoren is an umlsterm, Diagnose is an umlsterm, Melanome is an umlsterm, Beurteilung is an umlsterm, Hauttumoren is an umlsterm

DerHautarzt.60470264.ger.abstr_task0

Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .

[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]

[ "umlsterm" ]

Hauttumoren is an umlsterm, Blutgefaesse is an umlsterm, Auge is an umlsterm, tumorspezifische is an umlsterm, Element is an umlsterm, Hauttumoren is an umlsterm, Diagnose is an umlsterm, Melanome is an umlsterm, Beurteilung is an umlsterm, Hauttumoren is an umlsterm

DerHautarzt.60470264.ger.abstr_task1

Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please typing these entity words according to sentence: Hauttumoren, Blutgefaesse, Auge, tumorspezifische, Element, Hauttumoren, Diagnose, Melanome, Beurteilung, Hauttumoren Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .

[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]

[ "umlsterm" ]

Hauttumoren, Blutgefaesse, Auge, tumorspezifische, Element, Hauttumoren, Diagnose, Melanome, Beurteilung, Hauttumoren

DerHautarzt.60470264.ger.abstr_task2

Sentence: Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die auflichtmikroskopische Suche nach vaskulaeren Strukturen in Hauttumoren ergab , dass Blutgefaesse viel haeufiger sichtbar waren als mit dem blossen Auge . Es wurden charakteristische z.T. sehr tumorspezifische Gefaessmuster , festgestellt und ihre Haeufigkeitsverteilung bestimmt . Das Vaskularisierungsmuster erwies sich als wichtiges Element zur auflichtmikroskopischen Charakterisierung von Hauttumoren , insbesondere zur Diagnose amelanotischer Melanome . Wir stellen ein diagnostisches Flussdiagramm fuer die systematische auflichtmikroskopische Beurteilung von Hauttumoren vor , welches sich u.a. als Grundlage fuer verbesserte bildanalytische Untersuchungen anbietet .

[ "Die", "auflichtmikroskopische", "Suche", "nach", "vaskulaeren", "Strukturen", "in", "Hauttumoren", "ergab", ",", "dass", "Blutgefaesse", "viel", "haeufiger", "sichtbar", "waren", "als", "mit", "dem", "blossen", "Auge", ".", "Es", "wurden", "charakteristische", "z.", "T.", "sehr", "tumorspezifische", "Gefaessmuster", ",", "festgestellt", "und", "ihre", "Haeufigkeitsverteilung", "bestimmt", ".", "Das", "Vaskularisierungsmuster", "erwies", "sich", "als", "wichtiges", "Element", "zur", "auflichtmikroskopischen", "Charakterisierung", "von", "Hauttumoren", ",", "insbesondere", "zur", "Diagnose", "amelanotischer", "Melanome", ".", "Wir", "stellen", "ein", "diagnostisches", "Flussdiagramm", "fuer", "die", "systematische", "auflichtmikroskopische", "Beurteilung", "von", "Hauttumoren", "vor", ",", "welches", "sich", "u.a", ".", "als", "Grundlage", "fuer", "verbesserte", "bildanalytische", "Untersuchungen", "anbietet", "." ]

[ "umlsterm" ]

Partial mole is a Condition, treatment is a Procedure, molar pregnancy is a Condition, evacuation or chemotherapy is a Scope, Women is a Person, hysterectomy is a Procedure, H Mole is a Condition

NCT01630954_exc_task0

Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition, Procedure

[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]

Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole

[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]

[ "Scope", "Condition", "Procedure", "Person" ]

Partial mole is a Condition, treatment is a Procedure, molar pregnancy is a Condition, evacuation or chemotherapy is a Scope, Women is a Person, hysterectomy is a Procedure, H Mole is a Condition

NCT01630954_exc_task1

Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please typing these entity words according to sentence: Partial mole, treatment, molar pregnancy, evacuation or chemotherapy, Women, hysterectomy, H Mole Options: Scope, Person, Condition, Procedure

[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]

Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole

[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]

[ "Scope", "Condition", "Procedure", "Person" ]

Partial mole, treatment, molar pregnancy, evacuation or chemotherapy, Women, hysterectomy, H Mole

NCT01630954_exc_task2

Sentence: Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole Instructions: please extract entity words from the input sentence

[ "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Person", "O", "B-Procedure", "O", "O", "O", "B-Condition", "I-Condition", "O" ]

Partial mole History of treatment for molar pregnancy like prior evacuation or chemotherapy Women requiring hysterectomy for treatment of H Mole

[ "Partial", "mole", "\n", "History", "of", "treatment", "for", "molar", "pregnancy", "like", "prior", "evacuation", "or", "chemotherapy", "\n", "Women", "requiring", "hysterectomy", "for", "treatment", "of", "H", "Mole", "\n" ]

[ "Scope", "Condition", "Procedure", "Person" ]

STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein

146_task0

Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.

[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]

[ "Protein" ]

STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein, STAT1 is a Protein

146_task1

Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please typing these entity words according to sentence: STAT1, STAT1, STAT1, STAT1, STAT1, STAT1, STAT1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.

[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]

[ "Protein" ]

STAT1, STAT1, STAT1, STAT1, STAT1, STAT1, STAT1

146_task2

Sentence: Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Fludarabine is a nucleoside analog used in the treatment of hematologic malignancies that can induce severe and prolonged immunosuppression. Although it can be incorporated into the DNA of dividing cells, fludarabine is also a potent inhibitor of cells with a low growth fraction, thus it must have other mechanisms of action. STAT1, which is activated in response to many lymphocyte-activating cytokines including the interferons, is essential for cell-mediated immunity, as the absence of this protein is associated with prominent defects in the ability to control viral infections. Here we show that fludarabine, but not the immunosuppressant cyclosporine A, inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes. Fludarabine caused a specific depletion of STAT1 protein (and mRNA) but not of other STATs. This loss of STAT1 was also seen in cells from patients treated with fludarabine in vivo. Brief exposure to fludarabine led to a sustained loss of STAT1, analogous to the prolonged period of immunosuppression induced by exposure to the drug in vivo. Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents.

[ "Fludarabine", "-", "induced", "immunosuppression", "is", "associated", "with", "inhibition", "of", "STAT1", "signaling", ".", "\n", "Fludarabine", "is", "a", "nucleoside", "analog", "used", "in", "the", "treatment", "of", "hematologic", "malignancies", "that", "can", "induce", "severe", "and", "prolonged", "immunosuppression", ".", "Although", "it", "can", "be", "incorporated", "into", "the", "DNA", "of", "dividing", "cells", ",", "fludarabine", "is", "also", "a", "potent", "inhibitor", "of", "cells", "with", "a", "low", "growth", "fraction", ",", "thus", "it", "must", "have", "other", "mechanisms", "of", "action", ".", "STAT1", ",", "which", "is", "activated", "in", "response", "to", "many", "lymphocyte", "-", "activating", "cytokines", "including", "the", "interferons", ",", "is", "essential", "for", "cell", "-", "mediated", "immunity", ",", "as", "the", "absence", "of", "this", "protein", "is", "associated", "with", "prominent", "defects", "in", "the", "ability", "to", "control", "viral", "infections", ".", "Here", "we", "show", "that", "fludarabine", ",", "but", "not", "the", "immunosuppressant", "cyclosporine", "A", ",", "inhibits", "the", "cytokine", "-", "induced", "activation", "of", "STAT1", "and", "STAT1-dependent", "gene", "transcription", "in", "normal", "resting", "or", "activated", "lymphocytes", ".", "Fludarabine", "caused", "a", "specific", "depletion", "of", "STAT1", "protein", "(", "and", "mRNA", ")", "but", "not", "of", "other", "STATs", ".", "This", "loss", "of", "STAT1", "was", "also", "seen", "in", "cells", "from", "patients", "treated", "with", "fludarabine", "in", "vivo", ".", "Brief", "exposure", "to", "fludarabine", "led", "to", "a", "sustained", "loss", "of", "STAT1", ",", "analogous", "to", "the", "prolonged", "period", "of", "immunosuppression", "induced", "by", "exposure", "to", "the", "drug", "in", "vivo", ".", "Thus", ",", "STAT1", "may", "be", "a", "useful", "target", "in", "the", "development", "of", "new", "immunosuppressive", "and", "antineoplastic", "agents", "." ]

[ "Protein" ]

P. aeruginosa is a Organism, P. aeruginosa is a Organism

35_task0

Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.

[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]

[ "Organism" ]

P. aeruginosa is a Organism, P. aeruginosa is a Organism

35_task1

Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please typing these entity words according to sentence: P. aeruginosa, P. aeruginosa Options: Organism

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.

[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]

[ "Organism" ]

P. aeruginosa, P. aeruginosa

35_task2

Sentence: Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Results The formation of biofilms has been proposed to be controlled in response to environmental signals [39]. Given that protein phosphorylation is a common modification system used in signal transduction that changes the function of proteins in response to environmental stimuli [38], we chose a phosphoproteomic approach for the detection and identification of regulatory pathways active following the transition to the surface attached mode of growth. Detection of differentially phosphorylated proteins over the course of biofilm formation While phosphoproteomic analyses have become widespread in studies of regulation, signaling, development, the characterization of bacterial species and host responses during pathogenesis [40]-[49], only a limited number of studies have demonstrated that bacterial phosphoproteomes are dynamic [44],[46],[48]. We therefore used a combination of 2D/PAGE and immunoblot analysis using commercially available anti-phospho Ser/Thr antibodies (see Suppl. Fig. S1A-B for an example) to probe for the presence of signal transduction events that occur over the course of biofilm formation. Immunoblots of whole cell extracts obtained from planktonic cells and biofilm cells representing five developmental stages (reversibly and irreversibly attached cells, maturation-1 and -2 and dispersion stage; following 8, 24, 72, 144, and 216 hr of growth, respectively, see [12],[50] for timing of biofilm stages) were thus analyzed for the presence of planktonic- and biofilm-specific phosphorylation events. The planktonic mode of growth coincided with 24 phosphorylated proteins that were not phosphorylated following the transition of P. aeruginosa to surface-associated mode of growth (Fig. 1A, stage-specific events). Additional stage-specific events were detected for biofilms differing in age. For instance, 8 hr and 24 hr old biofilms displayed 23 and 21 phosphorylation events, respectively, not detected at any other stage. Regardless of the biofilm developmental stage, 7 phosphorylation events were detected that were absent in planktonic cells (Fig. 1A, biofilm-specific events). In both modes of growth, 26 proteins were constitutively phosphorylated. In addition to biofilm stage-specific phosphorylation of proteins, protein phosphorylation events were detectable at more than one biofilm growth stage indicating that the transition to surface-associated growth coincides with distinct protein phosphorylation and dephosphorylation events. As shown in Fig. 1A, these phosphorylation events are subcategorized as occurring during the reversible and irreversible attachment, biofilm formation and maturation stage depending on when and for how long protein phosphorylation was detected. For instance, four proteins were phosphorylated both in planktonic and reversible attached cells (8 hr biofilms) but not at any other biofilm stage (Fig. 1A, reversible attachment) while 4 different proteins were phosphorylated only in planktonic cells and biofilm cells after 8 hr and 24 hr of growth under flowing conditions (Fig. 1A, irreversible attachment). Furthermore, evidence of proteins being dephosphorylated over the course of biofilm formation was detected. Multiple proteins were found to be dephosphorylated at either a single or at multiple stages over the course of biofilm formation and maturation (Fig. 1B). Moreover, the similarity of the biofilm phosphoproteome to the planktonic phosphorylation patterns decreased from 59% in 8-hr-old biofilms to 35% in 144-hr-old, mature biofilms. The reduced similarity in phosphorylation events between biofilms and planktonic cells was mainly due to biofilm specific phosphorylation events detected at one or more stages of development. Dispersion-stage biofilms (216-hr-old) shared 43% similarity with the phosphorylation patterns of planktonically-grown P. aeruginosa cells (not shown). The increase in similarity between the planktonic and the 216-hr-old biofilm phosphoproteomes is consistent with previous reports indicating that cells within dispersion-stage biofilms are returning to the planktonic mode of growth [12],[50]. Protein phosphorylation in bacteria is not restricted to serine and threonine amino acid residues; however, the analysis of phosphorylation events by immunoblotting is limited to the availability of anti-phospho Ser/Thr (and tyrosine) antibodies. We therefore also purified phosphorylated proteins using metal oxide affinity chromatography (MOAC, see Fig. S1), a gel-independent approach allowing for the enrichment of phosphoproteins independent of the phosphorylation site with an up to 100% specificity [51],[52], followed by cleavable isotope coded affinity tag (cICAT) labeling and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). This quantitative mass spectrometric approach was used to analyze protein phosphorylation patterns of biofilm cells grown to the reversible, irreversible, maturation-1 and maturation-2 biofilm stages (8-, 24-, 7-2, and 144-hr-old biofilms, respectively [12]) in comparison to those of planktonic cells. Similarly to the results obtained via immunoblot analysis, the changes in phosphorylation events over the course of biofilm development detected using LC-MS-MS analysis appeared to be stage-specific (two examples are shown in Suppl. Fig. S2), with the similarity to the planktonic patterns decreasing from 72% in 8 hr biofilms to 38% in 144 hr biofilms (Fig. 1C). The overall stage-specific (de)phosphorylation events as well as the differences in the phosphoproteome were similar to those detected by immunoblot analysis using anti-Ser/Thr antibodies. This is the first description of the dynamic changes of the phosphoproteome occurring during biofilm development. The combination of approaches used here has not been previously used to identify phosphorylated proteins in biofilms.

[ "Results", "\n", "The", "formation", "of", "biofilms", "has", "been", "proposed", "to", "be", "controlled", "in", "response", "to", "environmental", "signals", "[", "39", "]", ".", "Given", "that", "protein", "phosphorylation", "is", "a", "common", "modification", "system", "used", "in", "signal", "transduction", "that", "changes", "the", "function", "of", "proteins", "in", "response", "to", "environmental", "stimuli", "[", "38", "]", ",", "we", "chose", "a", "phosphoproteomic", "approach", "for", "the", "detection", "and", "identification", "of", "regulatory", "pathways", "active", "following", "the", "transition", "to", "the", "surface", "attached", "mode", "of", "growth", ".", "Detection", "of", "differentially", "phosphorylated", "proteins", "over", "the", "course", "of", "biofilm", "formation", "While", "phosphoproteomic", "analyses", "have", "become", "widespread", "in", "studies", "of", "regulation", ",", "signaling", ",", "development", ",", "the", "characterization", "of", "bacterial", "species", "and", "host", "responses", "during", "pathogenesis", "[", "40]-[49", "]", ",", "only", "a", "limited", "number", "of", "studies", "have", "demonstrated", "that", "bacterial", "phosphoproteomes", "are", "dynamic", "[", "44],[46],[48", "]", ".", "We", "therefore", "used", "a", "combination", "of", "2D", "/", "PAGE", "and", "immunoblot", "analysis", "using", "commercially", "available", "anti", "-", "phospho", "Ser", "/", "Thr", "antibodies", "(", "see", "Suppl", ".", "Fig", ".", "S1A", "-", "B", "for", "an", "example", ")", "to", "probe", "for", "the", "presence", "of", "signal", "transduction", "events", "that", "occur", "over", "the", "course", "of", "biofilm", "formation", ".", "Immunoblots", "of", "whole", "cell", "extracts", "obtained", "from", "planktonic", "cells", "and", "biofilm", "cells", "representing", "five", "developmental", "stages", "(", "reversibly", "and", "irreversibly", "attached", "cells", ",", "maturation-1", "and", "-2", "and", "dispersion", "stage", ";", "following", "8", ",", "24", ",", "72", ",", "144", ",", "and", "216", "hr", "of", "growth", ",", "respectively", ",", "see", "[", "12],[50", "]", "for", "timing", "of", "biofilm", "stages", ")", "were", "thus", "analyzed", "for", "the", "presence", "of", "planktonic-", "and", "biofilm", "-", "specific", "phosphorylation", "events", ".", "The", "planktonic", "mode", "of", "growth", "coincided", "with", "24", "phosphorylated", "proteins", "that", "were", "not", "phosphorylated", "following", "the", "transition", "of", "P.", "aeruginosa", "to", "surface", "-", "associated", "mode", "of", "growth", "(", "Fig", ".", "1A", ",", "stage", "-", "specific", "events", ")", ".", "Additional", "stage", "-", "specific", "events", "were", "detected", "for", "biofilms", "differing", "in", "age", ".", "For", "instance", ",", "8", "hr", "and", "24", "hr", "old", "biofilms", "displayed", "23", "and", "21", "phosphorylation", "events", ",", "respectively", ",", "not", "detected", "at", "any", "other", "stage", ".", "Regardless", "of", "the", "biofilm", "developmental", "stage", ",", "7", "phosphorylation", "events", "were", "detected", "that", "were", "absent", "in", "planktonic", "cells", "(", "Fig", ".", "1A", ",", "biofilm", "-", "specific", "events", ")", ".", "In", "both", "modes", "of", "growth", ",", "26", "proteins", "were", "constitutively", "phosphorylated", ".", "In", "addition", "to", "biofilm", "stage", "-", "specific", "phosphorylation", "of", "proteins", ",", "protein", "phosphorylation", "events", "were", "detectable", "at", "more", "than", "one", "biofilm", "growth", "stage", "indicating", "that", "the", "transition", "to", "surface", "-", "associated", "growth", "coincides", "with", "distinct", "protein", "phosphorylation", "and", "dephosphorylation", "events", ".", "As", "shown", "in", "Fig", ".", "1A", ",", "these", "phosphorylation", "events", "are", "subcategorized", "as", "occurring", "during", "the", "reversible", "and", "irreversible", "attachment", ",", "biofilm", "formation", "and", "maturation", "stage", "depending", "on", "when", "and", "for", "how", "long", "protein", "phosphorylation", "was", "detected", ".", "For", "instance", ",", "four", "proteins", "were", "phosphorylated", "both", "in", "planktonic", "and", "reversible", "attached", "cells", "(", "8", "hr", "biofilms", ")", "but", "not", "at", "any", "other", "biofilm", "stage", "(", "Fig", ".", "1A", ",", "reversible", "attachment", ")", "while", "4", "different", "proteins", "were", "phosphorylated", "only", "in", "planktonic", "cells", "and", "biofilm", "cells", "after", "8", "hr", "and", "24", "hr", "of", "growth", "under", "flowing", "conditions", "(", "Fig", ".", "1A", ",", "irreversible", "attachment", ")", ".", "Furthermore", ",", "evidence", "of", "proteins", "being", "dephosphorylated", "over", "the", "course", "of", "biofilm", "formation", "was", "detected", ".", "Multiple", "proteins", "were", "found", "to", "be", "dephosphorylated", "at", "either", "a", "single", "or", "at", "multiple", "stages", "over", "the", "course", "of", "biofilm", "formation", "and", "maturation", "(", "Fig", ".", "1B", ")", ".", "Moreover", ",", "the", "similarity", "of", "the", "biofilm", "phosphoproteome", "to", "the", "planktonic", "phosphorylation", "patterns", "decreased", "from", "59", "%", "in", "8-hr", "-", "old", "biofilms", "to", "35", "%", "in", "144-hr", "-", "old", ",", "mature", "biofilms", ".", "The", "reduced", "similarity", "in", "phosphorylation", "events", "between", "biofilms", "and", "planktonic", "cells", "was", "mainly", "due", "to", "biofilm", "specific", "phosphorylation", "events", "detected", "at", "one", "or", "more", "stages", "of", "development", ".", "Dispersion", "-", "stage", "biofilms", "(", "216-hr", "-", "old", ")", "shared", "43", "%", "similarity", "with", "the", "phosphorylation", "patterns", "of", "planktonically", "-", "grown", "P.", "aeruginosa", "cells", "(", "not", "shown", ")", ".", "The", "increase", "in", "similarity", "between", "the", "planktonic", "and", "the", "216-hr", "-", "old", "biofilm", "phosphoproteomes", "is", "consistent", "with", "previous", "reports", "indicating", "that", "cells", "within", "dispersion", "-", "stage", "biofilms", "are", "returning", "to", "the", "planktonic", "mode", "of", "growth", "[", "12],[50", "]", ".", "Protein", "phosphorylation", "in", "bacteria", "is", "not", "restricted", "to", "serine", "and", "threonine", "amino", "acid", "residues", ";", "however", ",", "the", "analysis", "of", "phosphorylation", "events", "by", "immunoblotting", "is", "limited", "to", "the", "availability", "of", "anti", "-", "phospho", "Ser", "/", "Thr", "(", "and", "tyrosine", ")", "antibodies", ".", "We", "therefore", "also", "purified", "phosphorylated", "proteins", "using", "metal", "oxide", "affinity", "chromatography", "(", "MOAC", ",", "see", "Fig", ".", "S1", ")", ",", "a", "gel", "-", "independent", "approach", "allowing", "for", "the", "enrichment", "of", "phosphoproteins", "independent", "of", "the", "phosphorylation", "site", "with", "an", "up", "to", "100", "%", "specificity", "[", "51],[52", "]", ",", "followed", "by", "cleavable", "isotope", "coded", "affinity", "tag", "(", "cICAT", ")", "labeling", "and", "analysis", "by", "liquid", "chromatography", "tandem", "mass", "spectrometry", "(", "LC", "-", "MS", "/", "MS", ")", ".", "This", "quantitative", "mass", "spectrometric", "approach", "was", "used", "to", "analyze", "protein", "phosphorylation", "patterns", "of", "biofilm", "cells", "grown", "to", "the", "reversible", ",", "irreversible", ",", "maturation-1", "and", "maturation-2", "biofilm", "stages", "(", "8-", ",", "24-", ",", "7", "-", "2", ",", "and", "144-hr", "-", "old", "biofilms", ",", "respectively", "[", "12", "]", ")", "in", "comparison", "to", "those", "of", "planktonic", "cells", ".", "Similarly", "to", "the", "results", "obtained", "via", "immunoblot", "analysis", ",", "the", "changes", "in", "phosphorylation", "events", "over", "the", "course", "of", "biofilm", "development", "detected", "using", "LC", "-", "MS", "-", "MS", "analysis", "appeared", "to", "be", "stage", "-", "specific", "(", "two", "examples", "are", "shown", "in", "Suppl", ".", "Fig", ".", "S2", ")", ",", "with", "the", "similarity", "to", "the", "planktonic", "patterns", "decreasing", "from", "72", "%", "in", "8", "hr", "biofilms", "to", "38", "%", "in", "144", "hr", "biofilms", "(", "Fig", ".", "1C", ")", ".", "The", "overall", "stage", "-", "specific", "(", "de)phosphorylation", "events", "as", "well", "as", "the", "differences", "in", "the", "phosphoproteome", "were", "similar", "to", "those", "detected", "by", "immunoblot", "analysis", "using", "anti", "-", "Ser", "/", "Thr", "antibodies", ".", "This", "is", "the", "first", "description", "of", "the", "dynamic", "changes", "of", "the", "phosphoproteome", "occurring", "during", "biofilm", "development", ".", "The", "combination", "of", "approaches", "used", "here", "has", "not", "been", "previously", "used", "to", "identify", "phosphorylated", "proteins", "in", "biofilms", ".", "\n" ]

[ "Organism" ]

klinische Forschung is an umlsterm, Entscheidungsfindung is an umlsterm, Chirurgie is an umlsterm, Industrieunterstuetzung is an umlsterm, Deutschland is an umlsterm, Oesophagus is an umlsterm, Pankreas is an umlsterm, Darmerkrankungen is an umlsterm

DerChirurg.00710626.ger.abstr_task0

Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .

[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]

[ "umlsterm" ]

klinische Forschung is an umlsterm, Entscheidungsfindung is an umlsterm, Chirurgie is an umlsterm, Industrieunterstuetzung is an umlsterm, Deutschland is an umlsterm, Oesophagus is an umlsterm, Pankreas is an umlsterm, Darmerkrankungen is an umlsterm

DerChirurg.00710626.ger.abstr_task1

Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please typing these entity words according to sentence: klinische Forschung, Entscheidungsfindung, Chirurgie, Industrieunterstuetzung, Deutschland, Oesophagus, Pankreas, Darmerkrankungen Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .

[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]

[ "umlsterm" ]

klinische Forschung, Entscheidungsfindung, Chirurgie, Industrieunterstuetzung, Deutschland, Oesophagus, Pankreas, Darmerkrankungen

DerChirurg.00710626.ger.abstr_task2

Sentence: Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Qualitativ hochwertige klinische Forschung bietet die Chance , einen unmittelbaren Einfluss auf die medizinische Entscheidungsfindung zu nehmen . Um eine Bestandsaufnahme der aktuellen Situation in der klinischen gastroenterologischen Chirurgie aufzuzeigen , wurde im November 1999 eine Umfrage an 171 chirurgischen Kliniken mit visceralchirurgischem Schwerpunkt durchgefuehrt . Von den 93 antwortenden Kliniken fuehrten 45,2 % insgesamt 91 klinische Studien durch . Nur 8,8 % dieser Studien wurden als prospektiv-randomisierte Multicenterstudien beschrieben , 60 % waren reine Singlecenterstudien . Die Studienfinanzierung erfolgte in 60 Faellen aus dem klinikeigenen Budget , in 27 Faellen durch Industrieunterstuetzung und in 4 Faellen durch unabhaengige Institutionen , wie die Deutsche Forschungsgemeinschaft oder das BMBF . Von den Studien wurden 7,7 % durch freigestellte Mitarbeiter betreut , in 92,3 % war dies zusaetzlich zur klinischen Routine erforderlich . Die Mehrzahl der klinischen Studien in Deutschland befasst sich mit Erkrankungen des Oesophagus , des Pankreas oder Chronisch Entzuendlichen Darmerkrankungen . Zwischen den alten und neuen Bundeslaendern zeigen sich keine wesentlichen Unterschiede in der Entwicklung und Durchfuehrung klinischer Studien .

[ "Zusammenfassung", ".", "Qualitativ", "hochwertige", "klinische", "Forschung", "bietet", "die", "Chance", ",", "einen", "unmittelbaren", "Einfluss", "auf", "die", "medizinische", "Entscheidungsfindung", "zu", "nehmen", ".", "Um", "eine", "Bestandsaufnahme", "der", "aktuellen", "Situation", "in", "der", "klinischen", "gastroenterologischen", "Chirurgie", "aufzuzeigen", ",", "wurde", "im", "November", "1999", "eine", "Umfrage", "an", "171", "chirurgischen", "Kliniken", "mit", "visceralchirurgischem", "Schwerpunkt", "durchgefuehrt", ".", "Von", "den", "93", "antwortenden", "Kliniken", "fuehrten", "45,2", "%", "insgesamt", "91", "klinische", "Studien", "durch", ".", "Nur", "8,8", "%", "dieser", "Studien", "wurden", "als", "prospektiv", "-", "randomisierte", "Multicenterstudien", "beschrieben", ",", "60", "%", "waren", "reine", "Singlecenterstudien", ".", "Die", "Studienfinanzierung", "erfolgte", "in", "60", "Faellen", "aus", "dem", "klinikeigenen", "Budget", ",", "in", "27", "Faellen", "durch", "Industrieunterstuetzung", "und", "in", "4", "Faellen", "durch", "unabhaengige", "Institutionen", ",", "wie", "die", "Deutsche", "Forschungsgemeinschaft", "oder", "das", "BMBF", ".", "Von", "den", "Studien", "wurden", "7,7", "%", "durch", "freigestellte", "Mitarbeiter", "betreut", ",", "in", "92,3", "%", "war", "dies", "zusaetzlich", "zur", "klinischen", "Routine", "erforderlich", ".", "Die", "Mehrzahl", "der", "klinischen", "Studien", "in", "Deutschland", "befasst", "sich", "mit", "Erkrankungen", "des", "Oesophagus", ",", "des", "Pankreas", "oder", "Chronisch", "Entzuendlichen", "Darmerkrankungen", ".", "Zwischen", "den", "alten", "und", "neuen", "Bundeslaendern", "zeigen", "sich", "keine", "wesentlichen", "Unterschiede", "in", "der", "Entwicklung", "und", "Durchfuehrung", "klinischer", "Studien", "." ]

[ "umlsterm" ]

muscle actin is a Individual_protein, profilin is a Individual_protein

607_task0

Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]

Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.

[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]

[ "Individual_protein" ]

muscle actin is a Individual_protein, profilin is a Individual_protein

607_task1

Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please typing these entity words according to sentence: muscle actin, profilin Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]

Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.

[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]

[ "Individual_protein" ]

muscle actin, profilin

607_task2

Sentence: Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "B-Individual_protein", "O", "O" ]

Pyrenyliodoacetamide labeling of cysteine 374 of muscle actin reduces the affinity for profilin 10-fold.

[ "Pyrenyliodoacetamide", "labeling", "of", "cysteine", "374", "of", "muscle", "actin", "reduces", "the", "affinity", "for", "profilin", "10-fold", "." ]

[ "Individual_protein" ]

therapy is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, platelet is an umlsterm, coronary artery disease is an umlsterm, antiplatelet drugs is an umlsterm, anticoagulation is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, aspirin is an umlsterm, drug is an umlsterm, choice is an umlsterm, treatment is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, contrast is an umlsterm, anticoagulation is an umlsterm, patients is an umlsterm, risk is an umlsterm, thrombosis is an umlsterm, urokinase is an umlsterm, therapy is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, angina pectoris is an umlsterm, leads is an umlsterm, symptoms is an umlsterm, platelet membrane glycoprotein is an umlsterm, clinical trials is an umlsterm, weight is an umlsterm, heparins is an umlsterm, syndromes is an umlsterm, future is an umlsterm

ZfuerKardiologie.8087s145.eng.abstr_task0

Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .

[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]

[ "umlsterm" ]

therapy is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, platelet is an umlsterm, coronary artery disease is an umlsterm, antiplatelet drugs is an umlsterm, anticoagulation is an umlsterm, treatment is an umlsterm, syndromes is an umlsterm, aspirin is an umlsterm, drug is an umlsterm, choice is an umlsterm, treatment is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, contrast is an umlsterm, anticoagulation is an umlsterm, patients is an umlsterm, risk is an umlsterm, thrombosis is an umlsterm, urokinase is an umlsterm, therapy is an umlsterm, patients is an umlsterm, coronary artery disease is an umlsterm, angina pectoris is an umlsterm, leads is an umlsterm, symptoms is an umlsterm, platelet membrane glycoprotein is an umlsterm, clinical trials is an umlsterm, weight is an umlsterm, heparins is an umlsterm, syndromes is an umlsterm, future is an umlsterm

ZfuerKardiologie.8087s145.eng.abstr_task1

Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please typing these entity words according to sentence: therapy, treatment, syndromes, platelet, coronary artery disease, antiplatelet drugs, anticoagulation, treatment, syndromes, aspirin, drug, choice, treatment, patients, coronary artery disease, contrast, anticoagulation, patients, risk, thrombosis, urokinase, therapy, patients, coronary artery disease, angina pectoris, leads, symptoms, platelet membrane glycoprotein, clinical trials, weight, heparins, syndromes, future Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .

[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]

[ "umlsterm" ]

therapy, treatment, syndromes, platelet, coronary artery disease, antiplatelet drugs, anticoagulation, treatment, syndromes, aspirin, drug, choice, treatment, patients, coronary artery disease, contrast, anticoagulation, patients, risk, thrombosis, urokinase, therapy, patients, coronary artery disease, angina pectoris, leads, symptoms, platelet membrane glycoprotein, clinical trials, weight, heparins, syndromes, future

ZfuerKardiologie.8087s145.eng.abstr_task2

Sentence: Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Antithrombotic therapy is a basic part in the treatment of acute as well as chronic coronary syndromes . The rationale is an enhanced platelet activity with predomination of procoagulatory mechanisms in coronary artery disease . The current status of antiplatelet drugs , anticoagulation , and chronic thrombolysis used in the treatment of chronic coronary syndromes is discussed . It is concluded that low-dose aspirin is the current drug of choice for long term oral treatment in patients with stable chronic coronary artery disease . In contrast , oral anticoagulation with coumadin should be considered in patients with higher risk for atrial or ventricular thrombosis . The impact of long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris leads to a marked improvement of clinical symptoms . Oral blockade of platelet membrane glycoprotein IIb/IIIa receptor and clinical trials regarding antiischemic effects of low-molecular weight heparins in chronic coronary syndromes are expected for the future .

[ "Antithrombotic", "therapy", "is", "a", "basic", "part", "in", "the", "treatment", "of", "acute", "as", "well", "as", "chronic", "coronary", "syndromes", ".", "The", "rationale", "is", "an", "enhanced", "platelet", "activity", "with", "predomination", "of", "procoagulatory", "mechanisms", "in", "coronary", "artery", "disease", ".", "The", "current", "status", "of", "antiplatelet", "drugs", ",", "anticoagulation", ",", "and", "chronic", "thrombolysis", "used", "in", "the", "treatment", "of", "chronic", "coronary", "syndromes", "is", "discussed", ".", "It", "is", "concluded", "that", "low", "-", "dose", "aspirin", "is", "the", "current", "drug", "of", "choice", "for", "long", "term", "oral", "treatment", "in", "patients", "with", "stable", "chronic", "coronary", "artery", "disease", ".", "In", "contrast", ",", "oral", "anticoagulation", "with", "coumadin", "should", "be", "considered", "in", "patients", "with", "higher", "risk", "for", "atrial", "or", "ventricular", "thrombosis", ".", "The", "impact", "of", "long", "-", "term", "intermittent", "urokinase", "therapy", "in", "patients", "with", "end", "-", "stage", "coronary", "artery", "disease", "and", "refractory", "angina", "pectoris", "leads", "to", "a", "marked", "improvement", "of", "clinical", "symptoms", ".", "Oral", "blockade", "of", "platelet", "membrane", "glycoprotein", "IIb", "/", "IIIa", "receptor", "and", "clinical", "trials", "regarding", "antiischemic", "effects", "of", "low", "-", "molecular", "weight", "heparins", "in", "chronic", "coronary", "syndromes", "are", "expected", "for", "the", "future", "." ]

[ "umlsterm" ]

objective is an umlsterm, stent is an umlsterm, Stent is an umlsterm, technology is an umlsterm, Polymers is an umlsterm, high temperature is an umlsterm, pressure is an umlsterm, derivatives is an umlsterm, lactic acid is an umlsterm, glycolic acid is an umlsterm, hydroxyethylene - methacrylate is an umlsterm, HEMA is an umlsterm, cell adhesion is an umlsterm, Methacrylates is an umlsterm, protein is an umlsterm, cell adhesion is an umlsterm, degradation is an umlsterm, polymers is an umlsterm, cell adhesion is an umlsterm, HEMA is an umlsterm, grafting is an umlsterm, stent is an umlsterm, HEMA is an umlsterm, stents is an umlsterm, female is an umlsterm, sheep is an umlsterm, blood is an umlsterm, urine analysis is an umlsterm, ultrasound is an umlsterm, autopsy is an umlsterm, findings is an umlsterm, Histopathological is an umlsterm, analysis is an umlsterm, epithelium is an umlsterm, stent is an umlsterm, regeneration is an umlsterm

DerUrologeA.00390557.eng.abstr_task0

Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .

[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]

[ "umlsterm" ]

objective is an umlsterm, stent is an umlsterm, Stent is an umlsterm, technology is an umlsterm, Polymers is an umlsterm, high temperature is an umlsterm, pressure is an umlsterm, derivatives is an umlsterm, lactic acid is an umlsterm, glycolic acid is an umlsterm, hydroxyethylene - methacrylate is an umlsterm, HEMA is an umlsterm, cell adhesion is an umlsterm, Methacrylates is an umlsterm, protein is an umlsterm, cell adhesion is an umlsterm, degradation is an umlsterm, polymers is an umlsterm, cell adhesion is an umlsterm, HEMA is an umlsterm, grafting is an umlsterm, stent is an umlsterm, HEMA is an umlsterm, stents is an umlsterm, female is an umlsterm, sheep is an umlsterm, blood is an umlsterm, urine analysis is an umlsterm, ultrasound is an umlsterm, autopsy is an umlsterm, findings is an umlsterm, Histopathological is an umlsterm, analysis is an umlsterm, epithelium is an umlsterm, stent is an umlsterm, regeneration is an umlsterm

DerUrologeA.00390557.eng.abstr_task1

Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please typing these entity words according to sentence: objective, stent, Stent, technology, Polymers, high temperature, pressure, derivatives, lactic acid, glycolic acid, hydroxyethylene - methacrylate, HEMA, cell adhesion, Methacrylates, protein, cell adhesion, degradation, polymers, cell adhesion, HEMA, grafting, stent, HEMA, stents, female, sheep, blood, urine analysis, ultrasound, autopsy, findings, Histopathological, analysis, epithelium, stent, regeneration Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .

[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]

[ "umlsterm" ]

objective, stent, Stent, technology, Polymers, high temperature, pressure, derivatives, lactic acid, glycolic acid, hydroxyethylene - methacrylate, HEMA, cell adhesion, Methacrylates, protein, cell adhesion, degradation, polymers, cell adhesion, HEMA, grafting, stent, HEMA, stents, female, sheep, blood, urine analysis, ultrasound, autopsy, findings, Histopathological, analysis, epithelium, stent, regeneration

DerUrologeA.00390557.eng.abstr_task2

Sentence: With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the objective of developing a biodegradable ureteric stent , various polylactides were analyzed and grafted with a clinically adapted surface . Stent moulding was performed by CESP technology ( Controlled Expansion of Saturated Polymers ) , which is not based on high temperature but gas-loading under high pressure which induces a foamy bulk structure . The hydrolytically biodegradable , synthetic homo- and copolymers poly ( D , L-lactide ) ( PDLLA ) , poly ( D , L-lactide-co-trimethylene-carbonate ) ( PDLLA-co-TMC ) , poly ( D , L-lactide-co-glycolide ) ( PDLLA-co-Gly ) as derivatives of lactic acid or glycolic acid and surface modifications with hydroxyethylene-methacrylate ( HEMA ) and oligoethyleneoxidemonomethacrylate ( OEOMA ) were analyzed with regard to cytotoxicity and cell adhesion . Methacrylates have minimized protein and cell adhesion and degradation of non-toxic products . All polymers exhibited a high degree of biocompatibility and cell adhesion was markedly reduced following HEMA grafting . A 3 cm and 7 Charrière prototype of the stent was moulded from PDLLA-co-TMC by CESP-technology , and grafted with HEMA by means of plasma-induced polymerization . Finally , the stents were implanted into female sheep , following unilateral ureterotomy . Regular blood and urine analysis as well as ultrasound and the final autopsy revealed no pathological findings . Histopathological analysis exhibited a regular epithelium without any changes being determined by contact to the stent , and a good regeneration of all layers in the area of anastomosis .

[ "With", "the", "objective", "of", "developing", "a", "biodegradable", "ureteric", "stent", ",", "various", "polylactides", "were", "analyzed", "and", "grafted", "with", "a", "clinically", "adapted", "surface", ".", "Stent", "moulding", "was", "performed", "by", "CESP", "technology", "(", "Controlled", "Expansion", "of", "Saturated", "Polymers", ")", ",", "which", "is", "not", "based", "on", "high", "temperature", "but", "gas", "-", "loading", "under", "high", "pressure", "which", "induces", "a", "foamy", "bulk", "structure", ".", "The", "hydrolytically", "biodegradable", ",", "synthetic", "homo-", "and", "copolymers", "poly", "(", "D", ",", "L", "-", "lactide", ")", "(", "PDLLA", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "trimethylene", "-", "carbonate", ")", "(", "PDLLA", "-", "co", "-", "TMC", ")", ",", "poly", "(", "D", ",", "L", "-", "lactide", "-", "co", "-", "glycolide", ")", "(", "PDLLA", "-", "co", "-", "Gly", ")", "as", "derivatives", "of", "lactic", "acid", "or", "glycolic", "acid", "and", "surface", "modifications", "with", "hydroxyethylene", "-", "methacrylate", "(", "HEMA", ")", "and", "oligoethyleneoxidemonomethacrylate", "(", "OEOMA", ")", "were", "analyzed", "with", "regard", "to", "cytotoxicity", "and", "cell", "adhesion", ".", "Methacrylates", "have", "minimized", "protein", "and", "cell", "adhesion", "and", "degradation", "of", "non", "-", "toxic", "products", ".", "All", "polymers", "exhibited", "a", "high", "degree", "of", "biocompatibility", "and", "cell", "adhesion", "was", "markedly", "reduced", "following", "HEMA", "grafting", ".", "A", "3", "cm", "and", "7", "Charrière", "prototype", "of", "the", "stent", "was", "moulded", "from", "PDLLA", "-", "co", "-", "TMC", "by", "CESP", "-", "technology", ",", "and", "grafted", "with", "HEMA", "by", "means", "of", "plasma", "-", "induced", "polymerization", ".", "Finally", ",", "the", "stents", "were", "implanted", "into", "female", "sheep", ",", "following", "unilateral", "ureterotomy", ".", "Regular", "blood", "and", "urine", "analysis", "as", "well", "as", "ultrasound", "and", "the", "final", "autopsy", "revealed", "no", "pathological", "findings", ".", "Histopathological", "analysis", "exhibited", "a", "regular", "epithelium", "without", "any", "changes", "being", "determined", "by", "contact", "to", "the", "stent", ",", "and", "a", "good", "regeneration", "of", "all", "layers", "in", "the", "area", "of", "anastomosis", "." ]

[ "umlsterm" ]

IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, CD3 is a Protein, CD28 is a Protein, MEK is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, IL-10 is a Protein, MEK is a Protein, p38 MAPK is a Protein, GSK-3beta is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein

39_task0

Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.

[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]

[ "Protein" ]

IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, CD3 is a Protein, CD28 is a Protein, MEK is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein, IL-10 is a Protein, MEK is a Protein, p38 MAPK is a Protein, GSK-3beta is a Protein, IL-10 is a Protein, ERK1 is a Protein, ERK2 is a Protein, IL-10 is a Protein

39_task1

Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please typing these entity words according to sentence: IL-10, ERK1, ERK2, IL-10, ERK1, ERK2, CD3, CD28, MEK, ERK1, ERK2, IL-10, IL-10, MEK, p38 MAPK, GSK-3beta, IL-10, ERK1, ERK2, IL-10 Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.

[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]

[ "Protein" ]

IL-10, ERK1, ERK2, IL-10, ERK1, ERK2, CD3, CD28, MEK, ERK1, ERK2, IL-10, IL-10, MEK, p38 MAPK, GSK-3beta, IL-10, ERK1, ERK2, IL-10

39_task2

Sentence: IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.

[ "IL-10", "Production", "by", "Th2", "and", "Th17", "Cells", "Also", "Requires", "ERK1", "and", "ERK2", "Activation", "\n", "To", "address", "whether", "IL-10", "production", "by", "Th2", "and", "Th17", "cells", "was", "also", "dependent", "on", "ERK1", "and", "ERK2", "activation", ",", "we", "differentiated", "these", "cells", "with", "anti", "-", "CD3", "and", "anti", "-", "CD28", "in", "the", "absence", "of", "APCs", "(", "Shoemaker", "et", "al", ".", ",", "2006", ";", "Veldhoen", "et", "al", ".", ",", "2009", ";", "Veldhoen", "et", "al", ".", ",", "2006", ")", ",", "in", "the", "presence", "or", "absence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", ".", "We", "showed", "that", "ERK1", "and", "ERK2", "activation", "is", "a", "common", "pathway", "required", "for", "induction", "of", "IL-10", "in", "different", "Th", "cell", "subsets", "because", "IL-10", "production", "by", "both", "Th2", "and", "Th17", "cells", "was", "markedly", "inhibited", "in", "the", "presence", "of", "the", "MEK", "inhibitor", "(", "PD184352", ")", "(", "Figure", "5D", "and", "Figure", "S5B", ")", ".", "In", "contrast", ",", "inhibitors", "of", "p38", "MAPK", "or", "of", "GSK-3beta", "activation", "did", "not", "affect", "the", "expression", "of", "IL-10", "by", "these", "subsets", "(", "Figure", "S5B", ")", ".", "Activation", "of", "the", "ERK1", "and", "ERK2", "signaling", "pathway", "is", "therefore", "a", "common", "requirement", "for", "the", "induction", "of", "IL-10", "production", "by", "Th1", ",", "Th2", ",", "and", "Th17", "cells", "." ]

[ "Protein" ]

SULT1E1 is a protein, beta - estradiol is a compound

DS.d1448_task0

Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]

SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.

[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]

[ "compound", "protein" ]

SULT1E1 is a protein, beta - estradiol is a compound

DS.d1448_task1

Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please typing these entity words according to sentence: SULT1E1, beta - estradiol Options: compound, protein

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]

SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.

[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]

[ "compound", "protein" ]

SULT1E1, beta - estradiol

DS.d1448_task2

Sentence: SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations. Instructions: please extract entity words from the input sentence

[ "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O" ]

SULT1E1 is responsible for the sulfation and inactivation of beta-estradiol (E2) at physiological concentrations.

[ "SULT1E1", "is", "responsible", "for", "the", "sulfation", "and", "inactivation", "of", "beta", "-", "estradiol", "(", "E2", ")", "at", "physiological", "concentrations", "." ]

[ "compound", "protein" ]

motorischen Endplatte is an umlsterm, Parese is an umlsterm, Behandlung is an umlsterm, Kiefergelenkluxationen is an umlsterm, Mundoeffnung is an umlsterm, Luxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Patienten is an umlsterm, Kiefergelenkluxationen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Luxationen is an umlsterm, Erstbehandlung is an umlsterm, Luxation is an umlsterm, Behandlungen is an umlsterm, Luxationen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, Patienten is an umlsterm, Mundoeffnung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, kieferoeffnenden is an umlsterm, Therapie is an umlsterm, Kiefergelenkluxationen is an umlsterm

MundKieferGesichtschirurgie.8002s125.ger.abstr_task0

Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .

[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]

[ "umlsterm" ]

motorischen Endplatte is an umlsterm, Parese is an umlsterm, Behandlung is an umlsterm, Kiefergelenkluxationen is an umlsterm, Mundoeffnung is an umlsterm, Luxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Kiefergelenkluxationen is an umlsterm, Patienten is an umlsterm, Kiefergelenkluxationen is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Luxationen is an umlsterm, Erstbehandlung is an umlsterm, Luxation is an umlsterm, Behandlungen is an umlsterm, Luxationen is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, Patienten is an umlsterm, Mundoeffnung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Rezidiven is an umlsterm, kieferoeffnenden is an umlsterm, Therapie is an umlsterm, Kiefergelenkluxationen is an umlsterm

MundKieferGesichtschirurgie.8002s125.ger.abstr_task1

Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please typing these entity words according to sentence: motorischen Endplatte, Parese, Behandlung, Kiefergelenkluxationen, Mundoeffnung, Luxationen, Kiefergelenkluxationen, Kiefergelenkluxationen, Patienten, Kiefergelenkluxationen, Behandlung, Patienten, Luxationen, Erstbehandlung, Luxation, Behandlungen, Luxationen, Patienten, Behandlung, Rezidiven, Patienten, Mundoeffnung, Patienten, Patienten, Behandlung, Rezidiven, kieferoeffnenden, Therapie, Kiefergelenkluxationen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .

[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]

[ "umlsterm" ]

motorischen Endplatte, Parese, Behandlung, Kiefergelenkluxationen, Mundoeffnung, Luxationen, Kiefergelenkluxationen, Kiefergelenkluxationen, Patienten, Kiefergelenkluxationen, Behandlung, Patienten, Luxationen, Erstbehandlung, Luxation, Behandlungen, Luxationen, Patienten, Behandlung, Rezidiven, Patienten, Mundoeffnung, Patienten, Patienten, Behandlung, Rezidiven, kieferoeffnenden, Therapie, Kiefergelenkluxationen

MundKieferGesichtschirurgie.8002s125.ger.abstr_task2

Sentence: Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Botulinumtoxin A fuehrt ueber eine Hemmung der Azetylcholinfreisetzung an der motorischen Endplatte zu einer 2-4 Monate andauernden Parese der quergestreiften Muskulatur . Seit 1995 werden Botulinumtoxininjektionen in der Behandlung rezidivierender Kiefergelenkluxationen eingesetzt . Die chemische Denervierung des M. pterygoideus lateralis bewirkt eine eingeschraenkte Mundoeffnung und kann hierdurch Luxationen verhindern . Kiefergelenkluxationen , die infolge eines erhoehten Tonus der protrahierenden Kaumuskulatur auftreten , wurden kuerzlich als neurogene Kiefergelenkluxationen definiert . In einer klinischen Studie untersuchten wir die Wirksamkeit von Botulinumtoxininjektionen in den M. pterygoideus lateralis bei 5 Patienten mit rezidivierenden neurogenen Kiefergelenkluxationen . In den 3 Monaten vor der ersten Behandlung traten bei den Patienten insgesamt 19 Luxationen auf . Im Zeitraum von 3 Monaten nach der Erstbehandlung kam es nur bei 1 Patientin zu einer einzigen Luxation . Wir fuehrten insgesamt 25 Behandlungen durch . Im 6-36 Monate andauernden Beobachtungszeitraum kam es zu 5 Luxationen . Zwei Patienten sind mittlerweile auch ueber 1 Jahr nach der letzten Behandlung frei von Rezidiven . Als Nebenwirkung der Schwaechung des M. pterygoideus lateralis kam es bei allen Patienten zu einer eingeschraenkten Mundoeffnung , die sich im Verlauf von 3-4 Monaten vollstaendig zurueckbildete . Alle anderen Nebenwirkungen waren fuer die Patienten ebenfalls akzeptabel und spaetestens nach 3 Wochen vollstaendig reversibel . Bei beiden Patienten , die auch ohne weitere Behandlung frei von Rezidiven sind , hat sich durch den Spontanverlauf der neurologischen Grunderkrankung die Tonuserhoehung der kieferoeffnenden Muskulatur zurueckgebildet . Unsere Ergebnisse zeigen , dass Botulinumtoxininjektionen eine nebenwirkungsarme Behandlungsalternative in der Therapie rezidivierender neurogener Kiefergelenkluxationen darstellen .

[ "Botulinumtoxin", "A", "fuehrt", "ueber", "eine", "Hemmung", "der", "Azetylcholinfreisetzung", "an", "der", "motorischen", "Endplatte", "zu", "einer", "2", "-", "4", "Monate", "andauernden", "Parese", "der", "quergestreiften", "Muskulatur", ".", "Seit", "1995", "werden", "Botulinumtoxininjektionen", "in", "der", "Behandlung", "rezidivierender", "Kiefergelenkluxationen", "eingesetzt", ".", "Die", "chemische", "Denervierung", "des", "M.", "pterygoideus", "lateralis", "bewirkt", "eine", "eingeschraenkte", "Mundoeffnung", "und", "kann", "hierdurch", "Luxationen", "verhindern", ".", "Kiefergelenkluxationen", ",", "die", "infolge", "eines", "erhoehten", "Tonus", "der", "protrahierenden", "Kaumuskulatur", "auftreten", ",", "wurden", "kuerzlich", "als", "neurogene", "Kiefergelenkluxationen", "definiert", ".", "In", "einer", "klinischen", "Studie", "untersuchten", "wir", "die", "Wirksamkeit", "von", "Botulinumtoxininjektionen", "in", "den", "M.", "pterygoideus", "lateralis", "bei", "5", "Patienten", "mit", "rezidivierenden", "neurogenen", "Kiefergelenkluxationen", ".", "In", "den", "3", "Monaten", "vor", "der", "ersten", "Behandlung", "traten", "bei", "den", "Patienten", "insgesamt", "19", "Luxationen", "auf", ".", "Im", "Zeitraum", "von", "3", "Monaten", "nach", "der", "Erstbehandlung", "kam", "es", "nur", "bei", "1", "Patientin", "zu", "einer", "einzigen", "Luxation", ".", "Wir", "fuehrten", "insgesamt", "25", "Behandlungen", "durch", ".", "Im", "6", "-", "36", "Monate", "andauernden", "Beobachtungszeitraum", "kam", "es", "zu", "5", "Luxationen", ".", "Zwei", "Patienten", "sind", "mittlerweile", "auch", "ueber", "1", "Jahr", "nach", "der", "letzten", "Behandlung", "frei", "von", "Rezidiven", ".", "Als", "Nebenwirkung", "der", "Schwaechung", "des", "M.", "pterygoideus", "lateralis", "kam", "es", "bei", "allen", "Patienten", "zu", "einer", "eingeschraenkten", "Mundoeffnung", ",", "die", "sich", "im", "Verlauf", "von", "3", "-", "4", "Monaten", "vollstaendig", "zurueckbildete", ".", "Alle", "anderen", "Nebenwirkungen", "waren", "fuer", "die", "Patienten", "ebenfalls", "akzeptabel", "und", "spaetestens", "nach", "3", "Wochen", "vollstaendig", "reversibel", ".", "Bei", "beiden", "Patienten", ",", "die", "auch", "ohne", "weitere", "Behandlung", "frei", "von", "Rezidiven", "sind", ",", "hat", "sich", "durch", "den", "Spontanverlauf", "der", "neurologischen", "Grunderkrankung", "die", "Tonuserhoehung", "der", "kieferoeffnenden", "Muskulatur", "zurueckgebildet", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "Botulinumtoxininjektionen", "eine", "nebenwirkungsarme", "Behandlungsalternative", "in", "der", "Therapie", "rezidivierender", "neurogener", "Kiefergelenkluxationen", "darstellen", "." ]

[ "umlsterm" ]

Aminoglutethimide is a DRUG, Aminoglutethimide is a DRUG, corticosteroids is a GROUP, Amphotericin B is a DRUG, corticosteroids is a GROUP, amphotericin B is a DRUG, diuretics is a GROUP, amphotericin B is a DRUG, hydrocortisone is a DRUG, Antibiotics is a GROUP, Macrolide antibiotics is a GROUP, corticosteroid is a GROUP, Anticholinesterases is a GROUP, anticholinesterase agents is a GROUP, corticosteroids is a GROUP, anticholinesterase agents is a GROUP, corticosteroid is a GROUP, Anticoagulants is a GROUP, corticosteroids is a GROUP, warfarin is a DRUG, warfarin is a DRUG, Antidiabetics is a GROUP, corticosteroids is a GROUP, antidiabetic agents is a GROUP, isoniazid is a DRUG, Cholestyramine is a DRUG, Cholestyramine is a DRUG, corticosteroids is a GROUP, Cyclosporine is a DRUG, cyclosporine is a DRUG, corticosteroids is a GROUP, indomethacin is a DRUG, Digitalis glycosides is a GROUP, digitalis glycosides is a GROUP, Ephedrine is a DRUG, Ephedrine is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, Estrogens is a GROUP, contraceptives is a GROUP, Estrogens is a GROUP, corticosteroids is a GROUP, barbiturates is a GROUP, phenytoin is a DRUG, carbamazepine is a DRUG, rifampin is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, macrolide antibiotics is a GROUP, erythromycin is a DRUG, corticosteroids is a GROUP, Dexamethasone is a DRUG, indinavir is a DRUG, erythromycin is a DRUG, Ketoconazole is a DRUG, Ketoconazole is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, corticosteroid is a DRUG, Nonsteroidal anti - inflammatory agents is a GROUP, NSAIDS is a GROUP, aspirin is a BRAND, nonsteroidal antiinflammatory agents is a GROUP, corticosteroids is a GROUP, Aspirin is a BRAND, corticosteroids is a GROUP, salicylates is a GROUP, corticosteroids is a GROUP, Phenytoin is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, Corticosteroids is a GROUP, Thalidomide is a DRUG, thalidomide is a DRUG, Vaccines is a GROUP, corticosteroid is a GROUP, live is a GROUP, inactivated vaccines is a GROUP, Corticosteroids is a GROUP, live attenuated vaccines is a GROUP, vaccines is a GROUP, corticosteroid is a GROUP

Dexamethasone_ddi_task0

Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, BRAND, DRUG

[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]

Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]

[ "GROUP", "DRUG", "BRAND" ]

Aminoglutethimide is a DRUG, Aminoglutethimide is a DRUG, corticosteroids is a GROUP, Amphotericin B is a DRUG, corticosteroids is a GROUP, amphotericin B is a DRUG, diuretics is a GROUP, amphotericin B is a DRUG, hydrocortisone is a DRUG, Antibiotics is a GROUP, Macrolide antibiotics is a GROUP, corticosteroid is a GROUP, Anticholinesterases is a GROUP, anticholinesterase agents is a GROUP, corticosteroids is a GROUP, anticholinesterase agents is a GROUP, corticosteroid is a GROUP, Anticoagulants is a GROUP, corticosteroids is a GROUP, warfarin is a DRUG, warfarin is a DRUG, Antidiabetics is a GROUP, corticosteroids is a GROUP, antidiabetic agents is a GROUP, isoniazid is a DRUG, Cholestyramine is a DRUG, Cholestyramine is a DRUG, corticosteroids is a GROUP, Cyclosporine is a DRUG, cyclosporine is a DRUG, corticosteroids is a GROUP, indomethacin is a DRUG, Digitalis glycosides is a GROUP, digitalis glycosides is a GROUP, Ephedrine is a DRUG, Ephedrine is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, Estrogens is a GROUP, contraceptives is a GROUP, Estrogens is a GROUP, corticosteroids is a GROUP, barbiturates is a GROUP, phenytoin is a DRUG, carbamazepine is a DRUG, rifampin is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, macrolide antibiotics is a GROUP, erythromycin is a DRUG, corticosteroids is a GROUP, Dexamethasone is a DRUG, indinavir is a DRUG, erythromycin is a DRUG, Ketoconazole is a DRUG, Ketoconazole is a DRUG, corticosteroids is a GROUP, corticosteroid is a GROUP, ketoconazole is a DRUG, corticosteroid is a DRUG, Nonsteroidal anti - inflammatory agents is a GROUP, NSAIDS is a GROUP, aspirin is a BRAND, nonsteroidal antiinflammatory agents is a GROUP, corticosteroids is a GROUP, Aspirin is a BRAND, corticosteroids is a GROUP, salicylates is a GROUP, corticosteroids is a GROUP, Phenytoin is a DRUG, phenytoin is a DRUG, dexamethasone is a DRUG, Corticosteroids is a GROUP, Thalidomide is a DRUG, thalidomide is a DRUG, Vaccines is a GROUP, corticosteroid is a GROUP, live is a GROUP, inactivated vaccines is a GROUP, Corticosteroids is a GROUP, live attenuated vaccines is a GROUP, vaccines is a GROUP, corticosteroid is a GROUP

Dexamethasone_ddi_task1

Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please typing these entity words according to sentence: Aminoglutethimide, Aminoglutethimide, corticosteroids, Amphotericin B, corticosteroids, amphotericin B, diuretics, amphotericin B, hydrocortisone, Antibiotics, Macrolide antibiotics, corticosteroid, Anticholinesterases, anticholinesterase agents, corticosteroids, anticholinesterase agents, corticosteroid, Anticoagulants, corticosteroids, warfarin, warfarin, Antidiabetics, corticosteroids, antidiabetic agents, isoniazid, Cholestyramine, Cholestyramine, corticosteroids, Cyclosporine, cyclosporine, corticosteroids, indomethacin, Digitalis glycosides, digitalis glycosides, Ephedrine, Ephedrine, corticosteroids, corticosteroid, Estrogens, contraceptives, Estrogens, corticosteroids, barbiturates, phenytoin, carbamazepine, rifampin, corticosteroids, corticosteroid, ketoconazole, macrolide antibiotics, erythromycin, corticosteroids, Dexamethasone, indinavir, erythromycin, Ketoconazole, Ketoconazole, corticosteroids, corticosteroid, ketoconazole, corticosteroid, Nonsteroidal anti - inflammatory agents, NSAIDS, aspirin, nonsteroidal antiinflammatory agents, corticosteroids, Aspirin, corticosteroids, salicylates, corticosteroids, Phenytoin, phenytoin, dexamethasone, Corticosteroids, Thalidomide, thalidomide, Vaccines, corticosteroid, live, inactivated vaccines, Corticosteroids, live attenuated vaccines, vaccines, corticosteroid Options: GROUP, BRAND, DRUG

[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]

Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]

[ "GROUP", "DRUG", "BRAND" ]

Aminoglutethimide, Aminoglutethimide, corticosteroids, Amphotericin B, corticosteroids, amphotericin B, diuretics, amphotericin B, hydrocortisone, Antibiotics, Macrolide antibiotics, corticosteroid, Anticholinesterases, anticholinesterase agents, corticosteroids, anticholinesterase agents, corticosteroid, Anticoagulants, corticosteroids, warfarin, warfarin, Antidiabetics, corticosteroids, antidiabetic agents, isoniazid, Cholestyramine, Cholestyramine, corticosteroids, Cyclosporine, cyclosporine, corticosteroids, indomethacin, Digitalis glycosides, digitalis glycosides, Ephedrine, Ephedrine, corticosteroids, corticosteroid, Estrogens, contraceptives, Estrogens, corticosteroids, barbiturates, phenytoin, carbamazepine, rifampin, corticosteroids, corticosteroid, ketoconazole, macrolide antibiotics, erythromycin, corticosteroids, Dexamethasone, indinavir, erythromycin, Ketoconazole, Ketoconazole, corticosteroids, corticosteroid, ketoconazole, corticosteroid, Nonsteroidal anti - inflammatory agents, NSAIDS, aspirin, nonsteroidal antiinflammatory agents, corticosteroids, Aspirin, corticosteroids, salicylates, corticosteroids, Phenytoin, phenytoin, dexamethasone, Corticosteroids, Thalidomide, thalidomide, Vaccines, corticosteroid, live, inactivated vaccines, Corticosteroids, live attenuated vaccines, vaccines, corticosteroid

Dexamethasone_ddi_task2

Sentence: Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible. Instructions: please extract entity words from the input sentence

[ "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O" ]

Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids. Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use. Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients. Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage. Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration. Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal. Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids. Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control. Skin tests: Corticosteroids may suppress reactions to skin tests. Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use. Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

[ "Aminoglutethimide", ":", "Aminoglutethimide", "may", "diminish", "adrenal", "suppression", "by", "corticosteroids", ".", "Amphotericin", "B", "injection", "and", "potassium", "-", "depleting", "agents", ":", "When", "corticosteroids", "are", "administered", "concomitantly", "with", "potassium", "-", "depleting", "agents", "(", "e.g", ".", ",", "amphotericin", "B", ",", "diuretics", ")", ",", "patients", "should", "be", "observed", "closely", "for", "development", "of", "hypokalemia", ".", "In", "addition", ",", "there", "have", "been", "cases", "reported", "in", "which", "concomitant", "use", "of", "amphotericin", "B", "and", "hydrocortisone", "was", "followed", "by", "cardiac", "enlargement", "and", "congestive", "heart", "failure", ".", "Antibiotics", ":", "Macrolide", "antibiotics", "have", "been", "reported", "to", "cause", "a", "significant", "decrease", "in", "corticosteroid", "clearance", ".", "Anticholinesterases", ":", "Concomitant", "use", "of", "anticholinesterase", "agents", "and", "corticosteroids", "may", "produce", "severe", "weakness", "in", "patients", "with", "myasthenia", "gravis", ".", "If", "possible", ",", "anticholinesterase", "agents", "should", "be", "withdrawn", "at", "least", "24", "hours", "before", "initiating", "corticosteroid", "therapy", ".", "Anticoagulants", ",", "oral", ":", "Co", "-", "administration", "of", "corticosteroids", "and", "warfarin", "usually", "results", "in", "inhibition", "of", "response", "to", "warfarin", ",", "although", "there", "have", "been", "some", "conflicting", "reports", ".", "Therefore", ",", "coagulation", "indices", "should", "be", "monitored", "frequently", "to", "maintain", "the", "desired", "anticoagulant", "effect", ".", "Antidiabetics", ":", "Because", "corticosteroids", "may", "increase", "blood", "glucose", "concentrations", ",", "dosage", "adjustments", "of", "antidiabetic", "agents", "may", "be", "required", ".", "Antitubercular", "drugs", ":", "Serum", "concentrations", "of", "isoniazid", "may", "be", "decreased", ".", "Cholestyramine", ":", "Cholestyramine", "may", "increase", "the", "clearance", "of", "corticosteroids", ".", "Cyclosporine", ":", "Increased", "activity", "of", "both", "cyclosporine", "and", "corticosteroids", "may", "occur", "when", "the", "two", "are", "used", "concurrently", ".", "Convulsions", "have", "been", "reported", "with", "this", "concurrent", "use", ".", "Dexamethasone", "suppression", "test", "(", "DST", "):", "False", "-", "negative", "results", "in", "the", "dexamethasone", "suppression", "test", "(", "DST", ")", "in", "patients", "being", "treated", "with", "indomethacin", "have", "been", "reported", ".", "Thus", ",", "results", "of", "the", "DST", "should", "be", "interpreted", "with", "caution", "in", "these", "patients", ".", "Digitalis", "glycosides", ":", "Patients", "on", "digitalis", "glycosides", "may", "be", "at", "increased", "risk", "of", "arrhythmias", "due", "to", "hypokalemia", ".", "Ephedrine", ":", "Ephedrine", "may", "enhance", "the", "metabolic", "clearance", "of", "corticosteroids", ",", "resulting", "in", "decreased", "blood", "levels", "and", "lessened", "physiologic", "activity", ",", "thus", "requiring", "an", "increase", "in", "corticosteroid", "dosage", ".", "Estrogens", ",", "including", "oral", "contraceptives", ":", "Estrogens", "may", "decrease", "the", "hepatic", "metabolism", "of", "certain", "corticosteroids", ",", "thereby", "increasing", "their", "effect", ".", "Hepatic", "Enzyme", "Inducers", ",", "Inhibitors", "and", "Substrates", ":", "Drugs", "which", "induce", "cytochrome", "P450", "3A4", "(", "CYP", "3A4", ")", "enzyme", "activity", "(", "e.g", ".", ",", "barbiturates", ",", "phenytoin", ",", "carbamazepine", ",", "rifampin", ")", "may", "enhance", "the", "metabolism", "of", "corticosteroids", "and", "require", "that", "the", "dosage", "of", "the", "corticosteroid", "be", "increased", ".", "Drugs", "which", "inhibit", "CYP", "3A4", "(", "e.g", ".", ",", "ketoconazole", ",", "macrolide", "antibiotics", "such", "as", "erythromycin", ")", "have", "the", "potential", "to", "result", "in", "increased", "plasma", "concentrations", "of", "corticosteroids", ".", "Dexamethasone", "is", "a", "moderate", "inducer", "of", "CYP", "3A4", ".", "Co", "-", "administration", "with", "other", "drugs", "that", "are", "metabolized", "by", "CYP", "3A4", "(", "e.g", ".", ",", "indinavir", ",", "erythromycin", ")", "may", "increase", "their", "clearance", ",", "resulting", "in", "decreased", "plasma", "concentration", ".", "Ketoconazole", ":", "Ketoconazole", "has", "been", "reported", "to", "decrease", "the", "metabolism", "of", "certain", "corticosteroids", "by", "up", "to", "60", "%", ",", "leading", "to", "increased", "risk", "of", "corticosteroid", "side", "effects", ".", "In", "addition", ",", "ketoconazole", "alone", "can", "inhibit", "adrenal", "corticosteroid", "synthesis", "and", "may", "cause", "adrenal", "insufficiency", "during", "corticosteroid", "withdrawal", ".", "Nonsteroidal", "anti", "-", "inflammatory", "agents", "(", "NSAIDS", "):", "Concomitant", "use", "of", "aspirin", "(", "or", "other", "nonsteroidal", "antiinflammatory", "agents", ")", "and", "corticosteroids", "increases", "the", "risk", "of", "gastrointestinal", "side", "effects", ".", "Aspirin", "should", "be", "used", "cautiously", "in", "conjunction", "with", "corticosteroids", "in", "hypoprothrombinemia", ".", "The", "clearance", "of", "salicylates", "may", "be", "increased", "with", "concurrent", "use", "of", "corticosteroids", ".", "Phenytoin", ":", "In", "post", "-", "marketing", "experience", ",", "there", "have", "been", "reports", "of", "both", "increases", "and", "decreases", "in", "phenytoin", "levels", "with", "dexamethasone", "co", "-", "administration", ",", "leading", "to", "alterations", "in", "seizure", "control", ".", "Skin", "tests", ":", "Corticosteroids", "may", "suppress", "reactions", "to", "skin", "tests", ".", "Thalidomide", ":", "Co", "-", "administration", "with", "thalidomide", "should", "be", "employed", "cautiously", ",", "as", "toxic", "epidermal", "necrolysis", "has", "been", "reported", "with", "concomitant", "use", ".", "Vaccines", ":", "Patients", "on", "corticosteroid", "therapy", "may", "exhibit", "a", "diminished", "response", "to", "toxoids", "and", "live", "or", "inactivated", "vaccines", "due", "to", "inhibition", "of", "antibody", "response", ".", "Corticosteroids", "may", "also", "potentiate", "the", "replication", "of", "some", "organisms", "contained", "in", "live", "attenuated", "vaccines", ".", "Routine", "administration", "of", "vaccines", "or", "toxoids", "should", "be", "deferred", "until", "corticosteroid", "therapy", "is", "discontinued", "if", "possible", "." ]

[ "GROUP", "DRUG", "BRAND" ]

DOSTINEX is a BRAND, phenothiazines is a GROUP, butyrophenones is a GROUP, thioxanthines is a GROUP, metoclopramide is a DRUG

Cabergoline_ddi_task0

Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG, BRAND

[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]

DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.

[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]

[ "GROUP", "DRUG", "BRAND" ]

DOSTINEX is a BRAND, phenothiazines is a GROUP, butyrophenones is a GROUP, thioxanthines is a GROUP, metoclopramide is a DRUG

Cabergoline_ddi_task1

Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please typing these entity words according to sentence: DOSTINEX, phenothiazines, butyrophenones, thioxanthines, metoclopramide Options: GROUP, DRUG, BRAND

[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]

DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.

[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]

[ "GROUP", "DRUG", "BRAND" ]

DOSTINEX, phenothiazines, butyrophenones, thioxanthines, metoclopramide

Cabergoline_ddi_task2

Sentence: DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide. Instructions: please extract entity words from the input sentence

[ "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "B-DRUG", "O" ]

DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.

[ "DOSTINEX", "should", "not", "be", "administered", "concurrently", "with", "D2-antagonists", ",", "such", "as", "phenothiazines", ",", "butyrophenones", ",", "thioxanthines", ",", "or", "metoclopramide", "." ]

[ "GROUP", "DRUG", "BRAND" ]

diagnostic is an umlsterm, axes is an umlsterm, axis is an umlsterm, psychiatric diagnoses is an umlsterm, Guidelines is an umlsterm, Diagnostic is an umlsterm, Criteria is an umlsterm, Research is an umlsterm, Axis is an umlsterm, Diagnostic is an umlsterm, Scale is an umlsterm, DDS is an umlsterm, axis is an umlsterm, lifestyle is an umlsterm, axis is an umlsterm, axis is an umlsterm, Assessment is an umlsterm, Scale is an umlsterm, case histories is an umlsterm, axis is an umlsterm, axis is an umlsterm, axis is an umlsterm, assessment is an umlsterm, axis is an umlsterm, variation is an umlsterm, axis is an umlsterm, value is an umlsterm

DerNervenarzt.70680231.eng.abstr_task0

Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .

[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]

[ "umlsterm" ]

diagnostic is an umlsterm, axes is an umlsterm, axis is an umlsterm, psychiatric diagnoses is an umlsterm, Guidelines is an umlsterm, Diagnostic is an umlsterm, Criteria is an umlsterm, Research is an umlsterm, Axis is an umlsterm, Diagnostic is an umlsterm, Scale is an umlsterm, DDS is an umlsterm, axis is an umlsterm, lifestyle is an umlsterm, axis is an umlsterm, axis is an umlsterm, Assessment is an umlsterm, Scale is an umlsterm, case histories is an umlsterm, axis is an umlsterm, axis is an umlsterm, axis is an umlsterm, assessment is an umlsterm, axis is an umlsterm, variation is an umlsterm, axis is an umlsterm, value is an umlsterm

DerNervenarzt.70680231.eng.abstr_task1

Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please typing these entity words according to sentence: diagnostic, axes, axis, psychiatric diagnoses, Guidelines, Diagnostic, Criteria, Research, Axis, Diagnostic, Scale, DDS, axis, lifestyle, axis, axis, Assessment, Scale, case histories, axis, axis, axis, assessment, axis, variation, axis, value Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .

[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]

[ "umlsterm" ]

diagnostic, axes, axis, psychiatric diagnoses, Guidelines, Diagnostic, Criteria, Research, Axis, Diagnostic, Scale, DDS, axis, lifestyle, axis, axis, Assessment, Scale, case histories, axis, axis, axis, assessment, axis, variation, axis, value

DerNervenarzt.70680231.eng.abstr_task2

Sentence: With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

With the introduction of operationalized diagnostic systems the multiaxial approach became a more important issue . The proposed multiaxial system of ICD-10 consists of three axes : on axis I psychiatric diagnoses are made according to the ICD-10 Clinical Guidelines or Diagnostic Criteria for Research . Axis II ( Disability Diagnostic Scale , DDS ) deals with impairment of psychosocial functioning . On axis III environmental/circumstantial and personal lifestyle management factors are rated . As part of the WHO international field trial , applicability and inter-rater reliability of the system were examined in seven German-speaking centers . In addition axis II was compared with the corresponding axis of DSM-III-R ( Global Assessment of Functioning Scale ) . 45 German clinicians rated 12 case histories written in English ( provided by WHO ) with 488 ratings altogether . Diagnoses on axis I with an average percentage agreement of 65.6 % and a mean K of 0.50 showed a moderate inter-rater reliability . For axis II the intraclass coefficient was 0.62 , and that for the corresponding DSM-III axis was 0.65 : both these axes thus also had a moderate inter-rater reliability . There was a close correlation between the subscales and the global assessment of axis II there was . Wide variation was found in the psychosocial circumstances on axis III , the mean K value being 0.16. In the discussion proposals for the revision process for the multiaxial ICD-10 system are made .

[ "With", "the", "introduction", "of", "operationalized", "diagnostic", "systems", "the", "multiaxial", "approach", "became", "a", "more", "important", "issue", ".", "The", "proposed", "multiaxial", "system", "of", "ICD-10", "consists", "of", "three", "axes", ":", "on", "axis", "I", "psychiatric", "diagnoses", "are", "made", "according", "to", "the", "ICD-10", "Clinical", "Guidelines", "or", "Diagnostic", "Criteria", "for", "Research", ".", "Axis", "II", "(", "Disability", "Diagnostic", "Scale", ",", "DDS", ")", "deals", "with", "impairment", "of", "psychosocial", "functioning", ".", "On", "axis", "III", "environmental", "/", "circumstantial", "and", "personal", "lifestyle", "management", "factors", "are", "rated", ".", "As", "part", "of", "the", "WHO", "international", "field", "trial", ",", "applicability", "and", "inter", "-", "rater", "reliability", "of", "the", "system", "were", "examined", "in", "seven", "German", "-", "speaking", "centers", ".", "In", "addition", "axis", "II", "was", "compared", "with", "the", "corresponding", "axis", "of", "DSM", "-", "III", "-", "R", "(", "Global", "Assessment", "of", "Functioning", "Scale", ")", ".", "45", "German", "clinicians", "rated", "12", "case", "histories", "written", "in", "English", "(", "provided", "by", "WHO", ")", "with", "488", "ratings", "altogether", ".", "Diagnoses", "on", "axis", "I", "with", "an", "average", "percentage", "agreement", "of", "65.6", "%", "and", "a", "mean", "K", "of", "0.50", "showed", "a", "moderate", "inter", "-", "rater", "reliability", ".", "For", "axis", "II", "the", "intraclass", "coefficient", "was", "0.62", ",", "and", "that", "for", "the", "corresponding", "DSM", "-", "III", "axis", "was", "0.65", ":", "both", "these", "axes", "thus", "also", "had", "a", "moderate", "inter", "-", "rater", "reliability", ".", "There", "was", "a", "close", "correlation", "between", "the", "subscales", "and", "the", "global", "assessment", "of", "axis", "II", "there", "was", ".", "Wide", "variation", "was", "found", "in", "the", "psychosocial", "circumstances", "on", "axis", "III", ",", "the", "mean", "K", "value", "being", "0.16", ".", "In", "the", "discussion", "proposals", "for", "the", "revision", "process", "for", "the", "multiaxial", "ICD-10", "system", "are", "made", "." ]

[ "umlsterm" ]

serum is a Organism_substance

PMID-2607031_task0

Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.

[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]

[ "Organism_substance" ]

serum is a Organism_substance

PMID-2607031_task1

Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please typing these entity words according to sentence: serum Options: Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.

[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]

[ "Organism_substance" ]

serum

PMID-2607031_task2

Sentence: Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening method for insecticidal activity using first instars of black blow fly (Diptera: Calliphoridae). A bioassay method suitable for rapid mass screening of fermentation and synthetic organic compounds for insecticidal activity is described. The test, which uses first instars of susceptible black blow fly, Phormia regina (Meigen), in a bovine serum medium, detects insecticidal activity with reproducible results. It is capable of selecting the most active compound in structure-activity relationships by minimum effective dose concentration studies. The bioassay system is easy to operate and requires only a minute quantity of chemical compound.

[ "Screening", "method", "for", "insecticidal", "activity", "using", "first", "instars", "of", "black", "blow", "fly", "(", "Diptera", ":", "Calliphoridae", ")", ".", "\n", "A", "bioassay", "method", "suitable", "for", "rapid", "mass", "screening", "of", "fermentation", "and", "synthetic", "organic", "compounds", "for", "insecticidal", "activity", "is", "described", ".", "The", "test", ",", "which", "uses", "first", "instars", "of", "susceptible", "black", "blow", "fly", ",", "Phormia", "regina", "(", "Meigen", ")", ",", "in", "a", "bovine", "serum", "medium", ",", "detects", "insecticidal", "activity", "with", "reproducible", "results", ".", "It", "is", "capable", "of", "selecting", "the", "most", "active", "compound", "in", "structure", "-", "activity", "relationships", "by", "minimum", "effective", "dose", "concentration", "studies", ".", "The", "bioassay", "system", "is", "easy", "to", "operate", "and", "requires", "only", "a", "minute", "quantity", "of", "chemical", "compound", ".", "\n" ]

[ "Organism_substance" ]

perfusion is an umlsterm, shock is an umlsterm, mucosa is an umlsterm, oxygen is an umlsterm, vessels is an umlsterm, mucosa is an umlsterm, tip is an umlsterm, risk is an umlsterm, ischemia is an umlsterm, dysfunction is an umlsterm, bacteria is an umlsterm, toxins is an umlsterm, leukocytes is an umlsterm, cytokine is an umlsterm, syndrome is an umlsterm, role is an umlsterm, shock is an umlsterm, dysfunction is an umlsterm

DerAnaesthesist.00490446.eng.abstr_task0

Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .

[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]

[ "umlsterm" ]

perfusion is an umlsterm, shock is an umlsterm, mucosa is an umlsterm, oxygen is an umlsterm, vessels is an umlsterm, mucosa is an umlsterm, tip is an umlsterm, risk is an umlsterm, ischemia is an umlsterm, dysfunction is an umlsterm, bacteria is an umlsterm, toxins is an umlsterm, leukocytes is an umlsterm, cytokine is an umlsterm, syndrome is an umlsterm, role is an umlsterm, shock is an umlsterm, dysfunction is an umlsterm

DerAnaesthesist.00490446.eng.abstr_task1

Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please typing these entity words according to sentence: perfusion, shock, mucosa, oxygen, vessels, mucosa, tip, risk, ischemia, dysfunction, bacteria, toxins, leukocytes, cytokine, syndrome, role, shock, dysfunction Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .

[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]

[ "umlsterm" ]

perfusion, shock, mucosa, oxygen, vessels, mucosa, tip, risk, ischemia, dysfunction, bacteria, toxins, leukocytes, cytokine, syndrome, role, shock, dysfunction

DerAnaesthesist.00490446.eng.abstr_task2

Sentence: The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

The splanchnic perfusion is reduced early in the course of any shock . The mucosa of the gut suffers most as it experiences a high oxygen demand even in the steady state . The specific arrangement of the micro vessels within the villus of the mucosa exposes the tip of the villus at the highest risk for ischemia , particularly in low flow states . As a consequence the integrity of the mucosal layer is compromised and dysfunction of the mucosal barrier may allow bacteria and toxins to translocate from the gut lumen . Activation of leukocytes and stimulation of cytokine synthesis may comprise a sustained inflammatory response syndrome . So far there is a good body of evidence that the splanchnic region may play an important role in the pathophysiological sequence from shock to organ dysfunction .

[ "The", "splanchnic", "perfusion", "is", "reduced", "early", "in", "the", "course", "of", "any", "shock", ".", "The", "mucosa", "of", "the", "gut", "suffers", "most", "as", "it", "experiences", "a", "high", "oxygen", "demand", "even", "in", "the", "steady", "state", ".", "The", "specific", "arrangement", "of", "the", "micro", "vessels", "within", "the", "villus", "of", "the", "mucosa", "exposes", "the", "tip", "of", "the", "villus", "at", "the", "highest", "risk", "for", "ischemia", ",", "particularly", "in", "low", "flow", "states", ".", "As", "a", "consequence", "the", "integrity", "of", "the", "mucosal", "layer", "is", "compromised", "and", "dysfunction", "of", "the", "mucosal", "barrier", "may", "allow", "bacteria", "and", "toxins", "to", "translocate", "from", "the", "gut", "lumen", ".", "Activation", "of", "leukocytes", "and", "stimulation", "of", "cytokine", "synthesis", "may", "comprise", "a", "sustained", "inflammatory", "response", "syndrome", ".", "So", "far", "there", "is", "a", "good", "body", "of", "evidence", "that", "the", "splanchnic", "region", "may", "play", "an", "important", "role", "in", "the", "pathophysiological", "sequence", "from", "shock", "to", "organ", "dysfunction", "." ]

[ "umlsterm" ]

p53 is a protein, bioflavonoid is a compound, apigenin is a compound, RNA - binding protein is a protein

DS.d696_task0

Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]

Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.

[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]

[ "protein", "compound" ]

p53 is a protein, bioflavonoid is a compound, apigenin is a compound, RNA - binding protein is a protein

DS.d696_task1

Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please typing these entity words according to sentence: p53, bioflavonoid, apigenin, RNA - binding protein Options: compound, protein

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]

Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.

[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]

[ "protein", "compound" ]

p53, bioflavonoid, apigenin, RNA - binding protein

DS.d696_task2

Sentence: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "B-compound", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O" ]

Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNA-binding protein HuR.

[ "Enhancement", "of", "p53", "expression", "in", "keratinocytes", "by", "the", "bioflavonoid", "apigenin", "is", "associated", "with", "RNA", "-", "binding", "protein", "HuR." ]

[ "protein", "compound" ]

Hand is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Schweden is an umlsterm, Genereal is an umlsterm, Wisconsin is an umlsterm, USA is an umlsterm, Schmerz is an umlsterm, Biopsieergebnisse is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Biopsiepositionen is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Ohnmacht is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Patientenaufklaerung is an umlsterm, Biopsie is an umlsterm, Biopsiepositionen is an umlsterm, Patienten is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Biopsieposition is an umlsterm

DerRadiologe.70370629.ger.abstr_task0

Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .

[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]

[ "umlsterm" ]

Hand is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Schweden is an umlsterm, Genereal is an umlsterm, Wisconsin is an umlsterm, USA is an umlsterm, Schmerz is an umlsterm, Biopsieergebnisse is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Biopsiepositionen is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Ohnmacht is an umlsterm, Spezifitaet is an umlsterm, Biopsiepositionen is an umlsterm, Patientenaufklaerung is an umlsterm, Biopsie is an umlsterm, Biopsiepositionen is an umlsterm, Patienten is an umlsterm, Brustbiopsie is an umlsterm, Biopsie is an umlsterm, Biopsieposition is an umlsterm

DerRadiologe.70370629.ger.abstr_task1

Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please typing these entity words according to sentence: Hand, Brustbiopsie, Biopsie, Schweden, Genereal, Wisconsin, USA, Schmerz, Biopsieergebnisse, Spezifitaet, Biopsiepositionen, Biopsiepositionen, Biopsie, Biopsie, Ohnmacht, Spezifitaet, Biopsiepositionen, Patientenaufklaerung, Biopsie, Biopsiepositionen, Patienten, Brustbiopsie, Biopsie, Biopsieposition Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .

[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]

[ "umlsterm" ]

Hand, Brustbiopsie, Biopsie, Schweden, Genereal, Wisconsin, USA, Schmerz, Biopsieergebnisse, Spezifitaet, Biopsiepositionen, Biopsiepositionen, Biopsie, Biopsie, Ohnmacht, Spezifitaet, Biopsiepositionen, Patientenaufklaerung, Biopsie, Biopsiepositionen, Patienten, Brustbiopsie, Biopsie, Biopsieposition

DerRadiologe.70370629.ger.abstr_task2

Sentence: An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

An Hand einer prospektiv randomisierten Studie sollen in diesem Beitrag die sitzende und die liegende Brustbiopsie verglichen werden . Die Ergebnisse dieser Studie wurden teilweise bereits publiziert [ 11 ] . Insgesamt wurden 103 Patientinnen stereotaktisch gezielt biopsiert . In 51 Faellen wurde die Biopsie in liegender Position ( TRC-Mammotest , Schweden ) , in 52 Faellen in sitzender Position ( Stereotix 2 ; Genereal Electric Medical Systems Milwaukee , Wisconsin , USA ) , durchgefuehrt . Mit Hilfe von prae- und postbioptischen Frageboegen wurden die allgemeine Unruhe/Angst , Schmerz sowie subjektive Erfahrungen aller Patientinnen bestimmt . Zusaetzlich wurden etwaige vasovagale Reaktionen nach ihrem Ausmass ( 0-2 ) bewertet . Saemtliche Biopsieergebnisse wurden operativ verifiziert und die Spezifitaet und Sensitivitaet beider Biopsiepositionen ermittelt und verglichen . Es konnte kein statisch signifikanter Unterschied zwischen beiden Biopsiepositionen bezueglich der allgemeinen Toleranz festgestellt werden . Signifikant mehr Patientinnen ( p = 0,04 ) der liegenden Position wuerden vor einer neuerlichen Biopsie Medikation zur Beruhigung wuenschen . Insgesamt 3 Patientinnen ( liegend : n = 1 ; sitzend : n = 2 ) fielen waehrend der Biopsie in Ohnmacht . Kein statistisch signifikanter Unterschied fand sich bezueglich Sensitivitaet ( 95 % ) und Spezifitaet ( 100 % ) zwischen beiden Biopsiepositionen . Besonderes Augenmerk sollte auf eine " intensive " Patientenaufklaerung und Betreuung vor der Biopsie gerichtet werden . Beide Biopsiepositionen werden von den Patienten gleich gut toleriert . Allgemeine vasovagale Reaktionen stellen kein grosses Problem der Brustbiopsie dar . Der Erfolg bzw das Ergebnis der Biopsie ist unabhaengig von der Biopsieposition .

[ "An", "Hand", "einer", "prospektiv", "randomisierten", "Studie", "sollen", "in", "diesem", "Beitrag", "die", "sitzende", "und", "die", "liegende", "Brustbiopsie", "verglichen", "werden", ".", "Die", "Ergebnisse", "dieser", "Studie", "wurden", "teilweise", "bereits", "publiziert", "[", "11", "]", ".", "Insgesamt", "wurden", "103", "Patientinnen", "stereotaktisch", "gezielt", "biopsiert", ".", "In", "51", "Faellen", "wurde", "die", "Biopsie", "in", "liegender", "Position", "(", "TRC", "-", "Mammotest", ",", "Schweden", ")", ",", "in", "52", "Faellen", "in", "sitzender", "Position", "(", "Stereotix", "2", ";", "Genereal", "Electric", "Medical", "Systems", "Milwaukee", ",", "Wisconsin", ",", "USA", ")", ",", "durchgefuehrt", ".", "Mit", "Hilfe", "von", "prae-", "und", "postbioptischen", "Frageboegen", "wurden", "die", "allgemeine", "Unruhe", "/", "Angst", ",", "Schmerz", "sowie", "subjektive", "Erfahrungen", "aller", "Patientinnen", "bestimmt", ".", "Zusaetzlich", "wurden", "etwaige", "vasovagale", "Reaktionen", "nach", "ihrem", "Ausmass", "(", "0", "-", "2", ")", "bewertet", ".", "Saemtliche", "Biopsieergebnisse", "wurden", "operativ", "verifiziert", "und", "die", "Spezifitaet", "und", "Sensitivitaet", "beider", "Biopsiepositionen", "ermittelt", "und", "verglichen", ".", "Es", "konnte", "kein", "statisch", "signifikanter", "Unterschied", "zwischen", "beiden", "Biopsiepositionen", "bezueglich", "der", "allgemeinen", "Toleranz", "festgestellt", "werden", ".", "Signifikant", "mehr", "Patientinnen", "(", "p", "=", "0,04", ")", "der", "liegenden", "Position", "wuerden", "vor", "einer", "neuerlichen", "Biopsie", "Medikation", "zur", "Beruhigung", "wuenschen", ".", "Insgesamt", "3", "Patientinnen", "(", "liegend", ":", "n", "=", "1", ";", "sitzend", ":", "n", "=", "2", ")", "fielen", "waehrend", "der", "Biopsie", "in", "Ohnmacht", ".", "Kein", "statistisch", "signifikanter", "Unterschied", "fand", "sich", "bezueglich", "Sensitivitaet", "(", "95", "%", ")", "und", "Spezifitaet", "(", "100", "%", ")", "zwischen", "beiden", "Biopsiepositionen", ".", "Besonderes", "Augenmerk", "sollte", "auf", "eine", "\"", "intensive", "\"", "Patientenaufklaerung", "und", "Betreuung", "vor", "der", "Biopsie", "gerichtet", "werden", ".", "Beide", "Biopsiepositionen", "werden", "von", "den", "Patienten", "gleich", "gut", "toleriert", ".", "Allgemeine", "vasovagale", "Reaktionen", "stellen", "kein", "grosses", "Problem", "der", "Brustbiopsie", "dar", ".", "Der", "Erfolg", "bzw", "das", "Ergebnis", "der", "Biopsie", "ist", "unabhaengig", "von", "der", "Biopsieposition", "." ]

[ "umlsterm" ]

Antikonvulsiva is an umlsterm, Schmerzen is an umlsterm, Kopfschmerzsyndromen is an umlsterm, Schmerzen is an umlsterm

DerSchmerz.70110411.ger.abstr_task0

Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .

[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]

[ "umlsterm" ]

Antikonvulsiva is an umlsterm, Schmerzen is an umlsterm, Kopfschmerzsyndromen is an umlsterm, Schmerzen is an umlsterm

DerSchmerz.70110411.ger.abstr_task1

Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please typing these entity words according to sentence: Antikonvulsiva, Schmerzen, Kopfschmerzsyndromen, Schmerzen Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .

[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]

[ "umlsterm" ]

Antikonvulsiva, Schmerzen, Kopfschmerzsyndromen, Schmerzen

DerSchmerz.70110411.ger.abstr_task2

Sentence: Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Antikonvulsiva haben bei chronisch neuropathischen Schmerzen sowie bestimmten Kopfschmerzsyndromen eine vielfach belegte gute analgetische Wirkung . Auch bei Schmerzen nichtneurogener Ursache kann ein Einsatz erwogen werden , insbesondere wenn Nichtopioid- und Opioidanalgetika nicht ausreichen .

[ "Antikonvulsiva", "haben", "bei", "chronisch", "neuropathischen", "Schmerzen", "sowie", "bestimmten", "Kopfschmerzsyndromen", "eine", "vielfach", "belegte", "gute", "analgetische", "Wirkung", ".", "Auch", "bei", "Schmerzen", "nichtneurogener", "Ursache", "kann", "ein", "Einsatz", "erwogen", "werden", ",", "insbesondere", "wenn", "Nichtopioid-", "und", "Opioidanalgetika", "nicht", "ausreichen", "." ]

[ "umlsterm" ]

JA is an intervention, SP is an intervention, young children with autism is a participant

1258_task0

Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, participant

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]

These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .

[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]

[ "participant", "intervention" ]

JA is an intervention, SP is an intervention, young children with autism is a participant

1258_task1

Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please typing these entity words according to sentence: JA, SP, young children with autism Options: intervention, participant

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]

These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .

[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]

[ "participant", "intervention" ]

JA, SP, young children with autism

1258_task2

Sentence: These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "B-intervention", "O", "O", "B-participant", "I-participant", "I-participant", "I-participant", "O" ]

These findings suggest clinically significant benefits of actively treating JA and SP skills in young children with autism .

[ "These", "findings", "suggest", "clinically", "significant", "benefits", "of", "actively", "treating", "JA", "and", "SP", "skills", "in", "young", "children", "with", "autism", "." ]

[ "participant", "intervention" ]

Hydroxy - Methyl - Peroxy is a CHEMICAL

23641685_task0

Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]

Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.

[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]

[ "CHEMICAL" ]

Hydroxy - Methyl - Peroxy is a CHEMICAL

23641685_task1

Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please typing these entity words according to sentence: Hydroxy - Methyl - Peroxy Options: CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]

Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.

[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]

[ "CHEMICAL" ]

Hydroxy - Methyl - Peroxy

23641685_task2

Sentence: Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O" ]

Cavity Ringdown Spectroscopy of the Hydroxy-Methyl-Peroxy Radical.

[ "Cavity", "Ringdown", "Spectroscopy", "of", "the", "Hydroxy", "-", "Methyl", "-", "Peroxy", "Radical", "." ]

[ "CHEMICAL" ]

AML1 is a Protein, CBF beta is a Protein, c - Myb is a Protein, MZF-1 is a Protein

766_task0

Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.

[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]

[ "Protein" ]

AML1 is a Protein, CBF beta is a Protein, c - Myb is a Protein, MZF-1 is a Protein

766_task1

Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please typing these entity words according to sentence: AML1, CBF beta, c - Myb, MZF-1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.

[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]

[ "Protein" ]

AML1, CBF beta, c - Myb, MZF-1

766_task2

Sentence: Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in transcription factor genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that transcription factors are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, transcription factors from several families are active, including AML1/CBF beta, C/EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis.

[ "Transcriptional", "regulation", "during", "myelopoiesis", ".", "\n", "The", "coordinated", "production", "of", "all", "blood", "cells", "from", "a", "common", "stem", "cell", "is", "a", "highly", "regulated", "process", "involving", "successive", "stages", "of", "commitment", "and", "differentiation", ".", "From", "analyses", "of", "mice", "deficient", "in", "transcription", "factor", "genes", "and", "from", "the", "characterizations", "of", "chromosome", "breakpoints", "in", "human", "leukemias", ",", "it", "has", "become", "evident", "that", "transcription", "factors", "are", "important", "regulators", "of", "hematopoiesis", ".", "During", "myelopoiesis", ",", "which", "includes", "the", "development", "of", "granulocytic", "and", "monocytic", "lineages", ",", "transcription", "factors", "from", "several", "families", "are", "active", ",", "including", "AML1", "/", "CBF", "beta", ",", "C", "/", "EBP", ",", "Ets", ",", "c", "-", "Myb", ",", "HOX", ",", "and", "MZF-1", ".", "Few", "of", "these", "factors", "are", "expressed", "exclusively", "in", "myeloid", "cells", ";", "instead", "it", "appears", "that", "they", "cooperatively", "regulate", "transcription", "of", "myeloid", "-", "specific", "genes", ".", "Here", "we", "discuss", "recent", "advances", "in", "transcriptional", "regulation", "during", "myelopoiesis", "." ]

[ "Protein" ]

methylmalonate semialdehyde dehydrogenase is a GENE-Y

1898092_task0

Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.

[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

methylmalonate semialdehyde dehydrogenase is a GENE-Y

1898092_task1

Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please typing these entity words according to sentence: methylmalonate semialdehyde dehydrogenase Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.

[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

methylmalonate semialdehyde dehydrogenase

1898092_task2

Sentence: The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

The effect of ligand binding on the proteolytic pattern of methylmalonate semialdehyde dehydrogenase.

[ "The", "effect", "of", "ligand", "binding", "on", "the", "proteolytic", "pattern", "of", "methylmalonate", "semialdehyde", "dehydrogenase", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

interleukin-4 receptor alpha chain is a protein_subunit, p47phox is an other_organic_compound, phagocyte NADPH oxidase is a protein_molecule, B cells is a cell_type

38652_task0

Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, cell_type, protein_molecule, protein_subunit

[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.

[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]

[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]

interleukin-4 receptor alpha chain is a protein_subunit, p47phox is an other_organic_compound, phagocyte NADPH oxidase is a protein_molecule, B cells is a cell_type

38652_task1

Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please typing these entity words according to sentence: interleukin-4 receptor alpha chain, p47phox, phagocyte NADPH oxidase, B cells Options: other_organic_compound, cell_type, protein_molecule, protein_subunit

[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.

[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]

[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]

interleukin-4 receptor alpha chain, p47phox, phagocyte NADPH oxidase, B cells

38652_task2

Sentence: Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein_subunit", "I-protein_subunit", "I-protein_subunit", "I-protein_subunit", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Association of the interleukin-4 receptor alpha chain with p47phox, an activator of the phagocyte NADPH oxidase in B cells.

[ "Association", "of", "the", "interleukin-4", "receptor", "alpha", "chain", "with", "p47phox", ",", "an", "activator", "of", "the", "phagocyte", "NADPH", "oxidase", "in", "B", "cells", "." ]

[ "protein_subunit", "multi_cell", "protein_domain_or_region", "protein_molecule", "other_name", "cell_type", "other_organic_compound", "cell_line", "protein_family_or_group" ]

Chromosomale is an umlsterm, Spontanaborten is an umlsterm, Paraffin - eingebetteten is an umlsterm, Gewebe is an umlsterm, Aborte is an umlsterm, Metaphasen is an umlsterm, Zentromer - spezifischen is an umlsterm, DNA - Sonden is an umlsterm, Chromosomen is an umlsterm, Kernsuspensionen is an umlsterm, Chromosomenaberrationen is an umlsterm, Kernsuspensionen is an umlsterm, Paraffin - eingebettetem is an umlsterm, Abortmaterial is an umlsterm, genetischen Beratung is an umlsterm, Eltern is an umlsterm

DerPathologe.80190120.ger.abstr_task0

Sentence: Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant .

[ "Chromosomale", "Aberrationen", "sind", "eine", "wichtige", "Ursache", "von", "Spontanaborten", ".", "Zum", "Nachweis", "genetischer", "Stoerungen", "im", "Paraffin", "-", "eingebetteten", "Gewebe", "wurden", "26", "Aborte", "mit", "bekanntem", "zytogenetischem", "Befund", "an", "Metaphasen", "(", "konventionelle", "Zytogenetik", "/", "KZG", ";", "25", "numerische", "und", "eine", "strukturelle", "Aberration", ")", "retrospektiv", "mit", "der", "sog", ".", "Interphasezytogenetik", "(", "IZG", ")", "mit", "Zentromer", "-", "spezifischen", "DNA", "-", "Sonden", "(", "fuer", "#", "X", ",", "#", "Y", ",", "#", "10", "#", "18", "und", "#", "13/#21", ")", ",", "analysiert", ".", "Durch", "Zuordnung", "der", "IZG", "-", "Signalverteilungen", "(", "Chromosomen", "#", "X", ",", "#", "Y", "und", "#", "18", ")", "zu", "den", "KZG", "-", "Befunden", "wurden", "Grenzwerte", "fuer", "die", "IZG", "-", "Diagnose", "von", "Aneusomien", "ermittelt", "(", "fuer", "Zugewinn", ">", "=", "15", "%", "Kerne", "mit", "+1", "Signal", ";", "fuer", "Deletion", ">", "=", "40", "%", "der", "Kerne", "mit", "-1", "Signal", ")", ".", "Die", "Ergebnisse", "in", "Schnittpraeparaten", "(", "6", "µm", "dick", ")", "und", "parallel", "untersuchten", "Kernsuspensionen", "korrelierten", "statistisch", "hoch", "signifikant", "(", "p", "0,0001", ")", ".", "KZG-", "und", "IZG", "-", "Diagnosen", "stimmten", "in", "18", "von", "20", "auswertbaren", "Faellen", "ueberein", "(", "90", "%", ";", "kein", "falsch", "-", "positiver", "Befund", ")", ".", "Korrelationen", "zwischen", "zytogenetischen", "und", "histomorphologischen", "Befunden", "fanden", "sich", "nicht", ".", "Mit", "der", "IZG", "lassen", "sich", "numerische", "Chromosomenaberrationen", "an", "Schnitten", "und", "Kernsuspensionen", "von", "Paraffin", "-", "eingebettetem", "Abortmaterial", "zuverlaessig", "nachweisen", ",", "was", "die", "Moeglichkeit", "zur", "genetischen", "Beratung", "der", "Eltern", "eroeffnet", ".", "Die", "ermittelten", "Grenzwerte", "fuer", "den", "Nachweis", "von", "Aneusomien", "sind", "auch", "fuer", "tumorzytogenetische", "Untersuchungen", "mit", "der", "IZG", "-", "Technik", "relevant", "." ]

[ "umlsterm" ]

Chromosomale is an umlsterm, Spontanaborten is an umlsterm, Paraffin - eingebetteten is an umlsterm, Gewebe is an umlsterm, Aborte is an umlsterm, Metaphasen is an umlsterm, Zentromer - spezifischen is an umlsterm, DNA - Sonden is an umlsterm, Chromosomen is an umlsterm, Kernsuspensionen is an umlsterm, Chromosomenaberrationen is an umlsterm, Kernsuspensionen is an umlsterm, Paraffin - eingebettetem is an umlsterm, Abortmaterial is an umlsterm, genetischen Beratung is an umlsterm, Eltern is an umlsterm

DerPathologe.80190120.ger.abstr_task1

Sentence: Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant . Instructions: please typing these entity words according to sentence: Chromosomale, Spontanaborten, Paraffin - eingebetteten, Gewebe, Aborte, Metaphasen, Zentromer - spezifischen, DNA - Sonden, Chromosomen, Kernsuspensionen, Chromosomenaberrationen, Kernsuspensionen, Paraffin - eingebettetem, Abortmaterial, genetischen Beratung, Eltern Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Chromosomale Aberrationen sind eine wichtige Ursache von Spontanaborten . Zum Nachweis genetischer Stoerungen im Paraffin-eingebetteten Gewebe wurden 26 Aborte mit bekanntem zytogenetischem Befund an Metaphasen ( konventionelle Zytogenetik/KZG ; 25 numerische und eine strukturelle Aberration ) retrospektiv mit der sog . Interphasezytogenetik ( IZG ) mit Zentromer-spezifischen DNA-Sonden ( fuer #X, #Y, #10 #18 und #13/#21 ) , analysiert . Durch Zuordnung der IZG-Signalverteilungen ( Chromosomen #X, #Y und #18 ) zu den KZG-Befunden wurden Grenzwerte fuer die IZG-Diagnose von Aneusomien ermittelt ( fuer Zugewinn > =15% Kerne mit +1 Signal ; fuer Deletion > =40% der Kerne mit -1 Signal ) . Die Ergebnisse in Schnittpraeparaten ( 6 µm dick ) und parallel untersuchten Kernsuspensionen korrelierten statistisch hoch signifikant ( p 0,0001 ) . KZG- und IZG-Diagnosen stimmten in 18 von 20 auswertbaren Faellen ueberein ( 90% ; kein falsch-positiver Befund ) . Korrelationen zwischen zytogenetischen und histomorphologischen Befunden fanden sich nicht . Mit der IZG lassen sich numerische Chromosomenaberrationen an Schnitten und Kernsuspensionen von Paraffin-eingebettetem Abortmaterial zuverlaessig nachweisen , was die Moeglichkeit zur genetischen Beratung der Eltern eroeffnet . Die ermittelten Grenzwerte fuer den Nachweis von Aneusomien sind auch fuer tumorzytogenetische Untersuchungen mit der IZG-Technik relevant .

[ "Chromosomale", "Aberrationen", "sind", "eine", "wichtige", "Ursache", "von", "Spontanaborten", ".", "Zum", "Nachweis", "genetischer", "Stoerungen", "im", "Paraffin", "-", "eingebetteten", "Gewebe", "wurden", "26", "Aborte", "mit", "bekanntem", "zytogenetischem", "Befund", "an", "Metaphasen", "(", "konventionelle", "Zytogenetik", "/", "KZG", ";", "25", "numerische", "und", "eine", "strukturelle", "Aberration", ")", "retrospektiv", "mit", "der", "sog", ".", "Interphasezytogenetik", "(", "IZG", ")", "mit", "Zentromer", "-", "spezifischen", "DNA", "-", "Sonden", "(", "fuer", "#", "X", ",", "#", "Y", ",", "#", "10", "#", "18", "und", "#", "13/#21", ")", ",", "analysiert", ".", "Durch", "Zuordnung", "der", "IZG", "-", "Signalverteilungen", "(", "Chromosomen", "#", "X", ",", "#", "Y", "und", "#", "18", ")", "zu", "den", "KZG", "-", "Befunden", "wurden", "Grenzwerte", "fuer", "die", "IZG", "-", "Diagnose", "von", "Aneusomien", "ermittelt", "(", "fuer", "Zugewinn", ">", "=", "15", "%", "Kerne", "mit", "+1", "Signal", ";", "fuer", "Deletion", ">", "=", "40", "%", "der", "Kerne", "mit", "-1", "Signal", ")", ".", "Die", "Ergebnisse", "in", "Schnittpraeparaten", "(", "6", "µm", "dick", ")", "und", "parallel", "untersuchten", "Kernsuspensionen", "korrelierten", "statistisch", "hoch", "signifikant", "(", "p", "0,0001", ")", ".", "KZG-", "und", "IZG", "-", "Diagnosen", "stimmten", "in", "18", "von", "20", "auswertbaren", "Faellen", "ueberein", "(", "90", "%", ";", "kein", "falsch", "-", "positiver", "Befund", ")", ".", "Korrelationen", "zwischen", "zytogenetischen", "und", "histomorphologischen", "Befunden", "fanden", "sich", "nicht", ".", "Mit", "der", "IZG", "lassen", "sich", "numerische", "Chromosomenaberrationen", "an", "Schnitten", "und", "Kernsuspensionen", "von", "Paraffin", "-", "eingebettetem", "Abortmaterial", "zuverlaessig", "nachweisen", ",", "was", "die", "Moeglichkeit", "zur", "genetischen", "Beratung", "der", "Eltern", "eroeffnet", ".", "Die", "ermittelten", "Grenzwerte", "fuer", "den", "Nachweis", "von", "Aneusomien", "sind", "auch", "fuer", "tumorzytogenetische", "Untersuchungen", "mit", "der", "IZG", "-", "Technik", "relevant", "." ]

[ "umlsterm" ]